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Cover  picture: Center: 3D representation (including molecular orbital total charge density energy surface) 
of the minimized energy structure of compound 201 as calculated by CambridgeSoft Chem3D (Mechanics 
calculations). Left top: NOE relations in compound 94a, indicating all-cis conformation. Right top: Diene-
controlled asymmetric HDA reaction furnishing key compound 94. Left bottom: Mechanism of SeO2-
mediated allylic oxidation. Right bottom: Catalytic asymmetric HDA reaction affording compound 183. 
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„In this house, we OBEY the laws of thermodynamics!“ 
 
-  Homer Simpson  - 
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Abbreviations 
 
 
AD    asymmetric dihydroxylation 
ax.    axial 
BINOL    1,1´-binaphth-2,2´-ol 
borsm    based on recovered starting material 
Cp    cyclopentadienyl 
CRM1/crm1   chromosome region maintenance 
DET    diethyl tartrate 
DMP    Dess-Martin periodinane 
eq.    equatorial or equivalent 
GAP    GTPase-activating protein 
GDP    guanosine diphosphate 
GI50    concentration at which cell growth is inhibited 50% 
GTP    guanosine triphosphate 
HDA    hetero Diels-Alder 
HIV    human immunodeficiency virus 
HMDS    hexamethyldisilazane, hexamethyldisilazide 
HPV    human papilloma virus 
HOMO    highest occupied molecular orbital 
IC50    concentration at which cell growth is inhibited 50% 
LC50    concentration at which letality is 50% 
LMB    leptomycin B 
MDM2    murine double minute 2 
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NES    nuclear export sequence 
NLS    nuclear localization sequence 
NPC    nuclear pore complex 
RanBP    Ran-binding protein 
RCC    regulator of chromosome condensation 
SAR    structure-activity relationships 
TGI concentration at which tumor growth is completely 
inhibited 
THP    tetrahydropyran, -yl 
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1 Introduction 
 
1.1 General introduction 
 
Natural products play a key role in modern drug development. According to a recent 
survey, up to 40% of al current trade drugs are natural products, or compounds derived or 
otherwise inspired by them.1-6 Considering the fact that these compounds constitute less 
than 1% of all screened compounds, it is clear that their success rate in terms of the 
probability to find activity is much higher than for fully synthetic compounds. This is 
hardly surprising, since natural products are in essence already optimized structures being 
the result of millions of years of evolution. The fact that many biologically active natural 
products with a certain native target also bind to human proteins can be rationalized by the 
occurence of a limited number of protein folding types in nature.7,8 These are conserved 
amino acid sequences in proteins that fold in a particular manner, quite independent of the 
rest of the protein. Through recombination and mutation of folding sequences, new proteins 
evolve. This theory provides a strong argument not only for natural products research, but 
for synthesis of derivatives and analogues of natural products as well. 
Another argument for natural products as starting points for drug development is the 
observation that they commonly fit Lipinski’s rule of five,9* an important tool to estimate 
bioavailability on the basis of structure, equally well as current trade drugs.10 
 
* Based on an analysis of orally available drugs, Lipinski and co-workers postulated the now famous “rule 
of five”. The rule states that, in order to be orally available, drug-like compounds should have: (a) not more  
than 5 hydrogen bond donors (-OH and –NH groups); (b) not more than 10 hydrogen bond acceptors 
(notably O and N); (c) a molecular weight under 500, and (d) a log P value under 5.
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Synthetic drugs are often rich in five- and six-membered nitrogen-containing aromatic 
heterocycles and therefore relatively rigid. These substructures are much less common in 
natural products, which are often more or less flexible structures in dynamic equilibria. 
Some of nature’s strategies to limit conformational freedom in principally linear 
compounds like polyketides are e.g. formation of medium and large rings (macrocycles)11 
or formation of tetrahydropyran (THP) and -furan rings. In some cases, the stereochemistry 
of methyl substituents on a linear polyketide chain may govern the overall conformation of 
the molecule through 1,3-allylic strain or syn-pentane interactions.12 All of the above 
structural elements impose a preferred conformation on the molecule, but still leave it quite 
flexible. This is in accordance with the currently accepted “hand-and-glove” model for 
receptor-substrate binding rather than the earlier “key-and-lock” model.13 
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Figure 1.1. THP-containing biologically active natural products. 
 
Tetrahydropyran (THP) rings are common structural motifs in biologically active natural 
products,14 including laulimalide (1), bryostatins I (2a) and II (2b), phorboxazoles A (3a) 
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and B (3b), and ambruticin (4, see Fig. 1.1). Such compounds are mainly of polyketide 
origin and the THP rings result from cyclization through two oxygen functionalities in a 
1,5-relationship. 
 
1.2 Ratjadone and the leptomycin family 
 
A THP-containing polyketide natural product with exceptionally high biological activity is 
ratjadone (5, Fig. 1.2). It was isolated from the myxobacterium Sorangium cellulosum 
present in a soil sample collected in Cala Ratjada (Mallorca, Spain) by Höfle and 
Reichenbach and co-workers in 1995.15,16 It was originally selected for its modest 
antifungal activity against Mucor hiemalis, Phytophthora drechsleri, Ceratocystis ulmi, and 
Monilia brunnea, but was soon shown to possess very strong cytotoxic properties, with IC50 
values in the picomolar range for a variety of mammalian cell lines.15,16 
 
O
OH
OH
O O5: Ratjadone  
Figure 1.2. Ratjadone. 
 
Ratjadone is a member of a group of structurally similar compounds generally referred to as 
the leptomycin family, after its most prominent representative, leptomycin B (6). Other 
members include callystatin A,17,18 the kasuza- and anguinomycins, leptolstatin,19 and the 
leptofuranins20,21 (Fig. 1.3).  Recently, Höfle and co-workers isolated several other 
ratjadones from another strain of Sorangium cellulosum and named these ratjadones B-D 
(Fig. 1.3), while renaming the original ratjadone to ratjadone A.22 For the sake of 
simplicity, ratjadone A will be referred to in this thesis as ratjadone. 
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Figure 1.3. Members of the leptomycin family, including the ratjadones. 
 
1.2.1 Inhibition of nuclear export of proteins 
 
Leptomycin B (LMB, 6) was demonstrated to inhibit the function of the crm1 gene, which 
was shown to be required for maintaining correct chromosome structure in the fission yeast 
Schizosaccharomyces pombe.23 Later, the corresponding CRM1 protein was found to have 
a much broader function, namely nuclear export of proteins, many of which are essential 
for cell growth. As a result, the cell cycle is arrested in the G1 phase upon exposure to 
LMB (6). There are two main routes for the export of proteins from the cell nucleus to the 
cytosol. The first involves proteins carrying nuclear localization sequences (NLS), rich in 
basic amino acids, and this route is responsible for a major part of subcellular distribution 
of proteins. The second route concerns proteins carrying nuclear export sequences (NES) 
rich in leucine. CRM1/exportin 1 was shown to be a receptor for NES in both higher and 
lower eukaryotes. 
Nuclear export of NES-carrying proteins by CRM1 is regulated by the GTPase Ran (see 
Fig. 1.4), which exists primarily in the GTP-bound state in the nucleus due to the high 
GTP/GDP ratio and the action of the nucleotide exchange factor RCC1.24 CRM1, RanGTP 
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and a NES-carrying cargo protein associate to form a complex, which is transported from 
the nucleus to the cytoplasm through the nuclear pore complex (NPC). There, the complex 
is rapidly dissociated by the action of RanBP1 and RanBP2.25 In addition, the cytoplasmic 
protein RanGAP stimulates the GTPase activity of Ran and thus converts it to its GDP-
bound state, preventing reassociation of the complex.26 The cargo protein is released into 
the cytoplasm and CRM1 and RanGDP are shuttled back to the nucleus. 
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RanGAP
P
NES PNES P
NES
CRM1
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RanBP2 NPC
NPC = nuclear pore complex
NucleusCytoplasm
= protein export
= recycling of carrier
   proteins and cofactors
 
Figure 1.4. RanGTP-dependent nuclear export of proteins by CRM1. 
 
It has been suggested that leptomycin B inhibits the CRM1 protein of S. pombe by covalent 
bonding through Michael addition of Cys529 to the α,β-unsaturated lactone moiety.27 
Cys529 lies in the “central conserved region”, which is thought to be involved in NES 
binding.28 This hypothesis is supported by the fact that Saccharomyces cerevisiae (whose 
wild-type CRM1 protein contains a serine residue instead of cysteine), and a Cys529Ser 
mutant of S. pombe, are insensitive to leptomycin B. Serine residue hydroxyl groups 
typically do not react with α,β-unsaturated carbonyl compounds under physiological 
conditions. Indirect evidence was supplied by the strongly decreased activity of a 
leptomycin B derivative that is a nitromethane Michael adduct of the natural product and 
therefore not a Michael acceptor anymore.27 Also, a synthetic octadecapeptide representing 
amino acid residues 513-530 of human CRM1 was shown to form an adduct with LMB by 
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mass spectrometry. A similar octadecapeptide, in which only the Cys residue was 
substituted by a Ser residue, did not display such adduct formation in the mass 
spectrometric analysis.27 Recently, ratjadone and some of its minor natural derivatives were 
also shown to inhibit nuclear export, and covalent binding to S. pombe CRM1 protein 
through Michael addition was proven.22 
Thus, the extremely high activity of the members of the leptomycin family can be related to 
covalent binding of the CRM1 cysteine residue to the α,β-unsaturated lactone in a Michael-
type addition. Interestingly, LMB does not react with cysteine-containing compounds such 
as L-cysteine or glutathione under physiological conditions.27 Therefore, Kudo et al. 
propose that the molecule initially binds to the CRM1 protein in a non-covalent manner, 
thereby facilitating Michael addition of the cysteine residue thiol group to the α,β-
unsaturated lactone by proximity effects.27 
 
Because of this dramatic and selective activity, leptomycin B (which is available by 
fermentation) has become an important tool in cell biology, and possible therapeutic 
applications of these compounds have also been suggested.29 A possible basis for such an 
application is the effect of CRM1 on the activity of the p53 tumor suppressor protein. The 
p53 protein marks an important checkpoint in the cell cycle, as it screens the DNA for 
aberrations and abnormal proliferation.29 Detection of such an abnormality leads to a 
cascade of cellular events and eventually to apoptosis. Inactivation of p53 is an important 
criterium for the development of cancer. Indeed, in more than half of all human tumors, the 
P53 gene is mutated. In the majority of cancers in which the P53 gene is not mutated, p53 
activity is compromised in a different manner, such as downregulation of transcription or 
translation, or through excessive export of p53 from the cell nucleus, where the majority of 
cellular events concerning the cell cycle take place, to the cytosol.29 In addition, 
degradation of p53 takes place in the cytoplasm, e.g. under the influence of the MDM2 
oncoprotein or the HPV (human papilloma virus, an oncovirus) E6 protein.30 Since the p53 
protein carries an NES sequence,31 regulation of CRM1 would be expected to influence the 
activity of p53 in the cell nucleus. Indeed, it has been demonstrated that p53 activity in the 
cell nucleus increases considerably upon treatment with leptomycin B.30 Accumulation of 
p53 in the nucleus frequently results in apoptosis rather than growth arrest in cancer cells, 
especially in comparison with many other tissues.29 It has been suggested that non-
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genotoxic activation of p53 (such as that caused by treatment with leptomycin family 
members) may be particularly effective, whilst avoiding typical side effects caused by 
current cancer therapeutics.29 
The obvious drawback to pharmaceutical application of compounds of the leptomycin 
family is their inherent cytotoxicity. A wide variety of other essential cellular processes are 
also compromised as a consequence of inhibition of CRM1. Therapeutic effects may, 
however, occur at subtoxic concentrations. Additionally, there may be a selectivity towards 
cancer cells. However, preliminary clinical trials with leptomycin B were halted due to 
secondary effects and problems with pharmacokinetic studies.29 Nevertheless, the use of 
these compounds has been suggested for topical application for the treatment of tumors.29 
Other protein substrates for CRM1 that are of clinical interest include the HIV-1 Rev 
protein32 and the influenza ribonucleoprotein complex,33 as well as other viral proteins.34 
 
1.2.2 Williams' synthesis of (-)-ratjadone  
 
Ratjadone has been the object of several total synthesis efforts, which will be discussed in 
the coming sections. In 2001, Williams et al. reported the total synthesis of the unnatural 
isomer (-)-ratjadone (5a).35 The synthesis strategy involves an aldol-based reacion sequence 
to THP fragment 12, followed by connection to linear C3-C14 fragment 13 and subsequent 
elaboration to (-)-ratjadone 5a.  
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Figure 1.5. Retrosynthesis of Williams’ total synthesis of (-)-ratjadone 5a. 
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The forward synthesis commenced with conversion of known Evans’ aldol product 14 to 
aldehyde 15 by TBDPS protection, reductive cleavage of the chiral auxiliary and 
subsequent Swern oxidation (Scheme 1.1). Brown asymmetric allylation using 
B−allyldiisocampheyl-borane followed by PMB protection then furnished 16. The terminal 
olefin was converted to an aldehyde by selective Sharpless dihydroxylation and subsequent 
in situ vicinal diol cleavage. Wittig reaction followed by DIBAL-H reduction afforded an 
allylic alcohol, which was was subjected to Sharpless asymmetric epoxidation to give 
epoxide 17. After protection of the primary alcohol as a pivaloate, TBDPS cleavage 
followed by treatment with acid triggered intramolecular epoxide opening to give 18. 
Cleavage of the PMB protective group was then followed by double TBS protection. 
Reductive cleavage of the pivaloate followed by Dess-Martin oxidation36 finally furnished 
THP building block 12. 
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Scheme 1.1. (a) TBDPSCl, imidazole, CH2Cl2; (b) LiBH4, Et2O, H2O, 84% over two steps; (c) (COCl)2, 
DMSO, Et3N, CH2Cl2, 98%; (d) B-allyldiisocampheylborane, Et2O, -78°C, 91%; (e) PMB 
trichloroacetimidate, CSA, CH2Cl2, 67%; (f) AD-mix α, tBuOH, H2O, then NaIO4, aq. THF, quant.; (g) 
MeOC(O)CH=PPh3, CH2Cl2, 88%; (h) DIBAL-H, CH2Cl2, -78°C, 96%; (i) (+)-DET, Ti(OiPr)4, 4Å sieves, 
tBuOOH, CH2Cl2, 98%; (j) PivCl, py, CH2Cl2, 95%; (k) TBAF, THF, 40°C, 82%; (l) CSA, CH2Cl2, 90 %; 
(m) CAN, CH3CN, H2O, quant.; (n) TBSCl, imidazole, DMAP, DMF, 91%; (o) DIBAL-H, CH2Cl2, -78°C, 
99%; (p) DMP, NaHCO3, CH2Cl2, 93%. 
 
Synthesis of linear fragment 13 started with alkylation of known Evans' amide 1937 to give 
20 in a 11:1 mixture of isomers favoring the desired 2’S isomer. Reductive cleavage of the 
auxiliary followed by Swern oxidation38 afforded 21. Still-Gennari reaction39 and 
subsequent DIBAL-H reduction then furnished allylic alcohol 23, which was subject to 
Swern oxidation,38 giving an aldehyde that was converted to alkyne 24 using the Corey-
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Fuchs40 procedure. Wipf hydrozirconation followed by transmetallation to the organozinc 
reagent41 and subsequent reaction with 3-phenylthiopropionaldehyde produced 25 as a 
mixture of diastereomers. After Dess-Martin oxidation36, a Terashima reduction42,43 
introduced the desired S-configuration in 25 (5:1 mixture of diastereomers). Then, the 
thioether was converted to the sulfone and the free alcohol was protected as a pivaloate. 
Cleavage of the TBDPS ether and conversion of the resulting alcohol to the corresponding 
bromide then completed the synthesis of linear fragment 13. 
 
OPiv
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Br
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O
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R
TBDPSO
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R
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OH
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Scheme 1.2. (a) NaHMDS, THF, -78°C, then MeI, 81%, (2’S:2’R = 11:1); (b) LiBH4, MeOH, Et2O, 87%; 
(c) (COCl)2, DMSO, Et3N, CH2Cl2, 94%; (d) (CF3CH2O)2P(O)CHMeCO2Et, KHMDS, 18-crown-6, THF, 
99%; (e) DIBAL-H, Et2O, -78°C, 98% (f) (COCl)2, DMSO, Et3N, CH2Cl2; (g) CBr4, PPh3, CH2Cl2; (h) 
nBuLi, THF, -78°C, 85% over three steps; (i) Cp2Zr(H)Cl, CH2Cl2, 23°C, then Me2Zn, -65°C, then 
3-phenylthiopropionaldehyde, -65→0°C, 92%; (j) DMP, NaHCO3, CH2Cl2, 84%; (k) LiAlH4 (2.0 eq.), (-)-
N-Me-ephedrine (2.0 eq.), N-ethylaniline (4.0 eq.), Et2O, -78°C, 98%; (l) (NH4)6Mo7O24, H2O2, aq. EtOH, 
0°C, 90%; (m) PivCl, py, DMAP, CH2Cl2, quant.; (n) TBAF, THF, quant.; (o) MsCl, collidine, CH2Cl2, 
then LiBr, THF, 82%. 
 
The two main fragments 12 and 13 were now coupled by conversion of bromide 13 to the 
corresponding tributylphosphonium salt and Wittig reaction with 12. Exchange of the 
pivaloate protective group for TES was followed by α-deprotonation of the sulfone and 
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subsequent reaction with ethylene oxide, installing the final two atoms of the (-)-ratjadone 
carbon skeleton. After Dess-Martin oxidation36 of the primary alcohol, acidic cleavage of 
the TES ether afforded a lactol, which was then oxidized to the corresponding lactone. 
Basic elimination of the sulfone and cleavage of the TBS protective groups under mild 
conditions finally afforded (-)-ratjadone 5a. 
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Scheme 1.3. (a) PBu3, then 12, toluene, then KOtBu/THF, 0°C, 72%; (b) DIBAL-H, CH2Cl2, -78°C, 89%; 
(c) TESCl, py, CH2Cl2, 94%; (d) nBuLi, THF, HMPA, then ethylene oxide, 78%; (e) DMP, NaHCO3, 
CH2Cl2; (f) PPTS, EtOH, 0°C; (g) TPAP, NMO, 4Å sieves, CH2Cl2, 86% over three steps; (h) DBU, 
toluene, 87%; (i) HF•py, py, THF, 76%. 
 
1.2.3 Kalesse' synthesis of (+)-ratjadone 
 
Shortly before Williams published his synthesis, Kalesse and co-workers reported their 
total synthesis of the natural isomer (+)-ratjadone (5). Kalesse used a much more elegant 
and convergent strategy (see retrosynthesis in Fig. 1.6) that employs a Heck coupling and a 
Wittig reaction to connect A (THP ring, 28), B (chain, 29), and C (lactone, 30) 
fragments.44,45 THP fragment 28 was constructed in a fashion similar to Williams’ 
synthesis, but more efficiently. The synthesis of aldehyde 31 was achieved in analogy to the 
corresponding enantiomeric, PMB-protected aldehyde in the Williams’ synthesis. A 
vinyloguous Mukaiyama aldol reaction46 then afforded ester 32 in a single step, whereas a 
multistep procedure was required for the comparable transformation in the 
Williams’synthesis. 
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Figure 1.6. Retrosynthetic analysis of Kalesse’s total synthesis of (+)-ratjadone 
 
A more efficient and simpler protective group strategy in the following transformation 
reduces the number of steps in comparison with the Williams’ synthesis. Construction of 
aldehyde ent-12 from Evans’ aldol ent-14 required only 11 reaction steps in the Kalesse 
synthesis, compared to 17 steps for the enantiomeric species in the Williams’ synthesis 
(Scheme 1.4).  
O
OR
OR
X
ent-12: R = TBS, X = O
37: R = TBS, X = CH2
28: R = H, X = CH2
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OH
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Scheme 1.4. (a) MeONHMe•HCl, AlMe3, CH2Cl2, -20→25°C; (b) TBSOTf, 2,6-lutidine, CH2Cl2, -78°C; 
(c) DIBAL-H, THF, -78°C, 83% over three steps; (d) B(C6F5)3, CH2Cl2/Et2O 9:1, -78°C, dr > 19:1, 80%; (e) 
DIBAL-H, THF, -78°C; (f) mCPBA, NaHCO3, CH2Cl2, 0°C, 85% over two steps; (g) (i) TBAF, THF, 88%; 
(ii) amberlyst-15, THF, 93%; (h) TBSOTf, CH2Cl2, -78°C, 87%; (i) HCl, CHCl3, 97%; (j) DMP, CH2Cl2, 
0°C, 92%; (k) Tebbe reagent, THF, 0°C, 95%; (l) TBAF, THF, quant. 
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Treatment of aldehyde ent-12 with Tebbe reagent furnished the required alkene 37, and its 
unprotected form 28 was available by standard desilylation. 
The B fragment 29 was constructed in a relatively short sequence from known alkyne 38, 
which is available in five steps from commercial Roche ester [methyl (S)-3-hydroxy-2-
methyl-propionate].47 Carbometallation using the Cp2ZrCl2/AlMe3 combination according 
to the Negishi protocol afforded vinylic iodide 39. Dess-Martin oxidation and subsequent 
Still-Gennari reaction provided ester 40, and DIBAL-H reduction followed by a two-step 
conversion of the resulting alcohol 41 to the corresponding tributylphosphonium bromide 
furnished B fragment 29. The strength of this part of the synthesis is that protective groups 
are not required. 
 
I
X38
I
OMe
40
OH
I
39 OH
O
41: X = OH
42: X = Br
29: X = PBu3Br
e
f
a b,c d
 
Scheme 1.5. (a) Cp2ZrCl2, AlMe3, I2, CH2Cl2, THF, -15→25°C, 83%; (b) DMP, CH2Cl2, 0°C, 81%; (c) 
(CF3CH2O)2P(O)CHMeCO2Et, KHMDS, 18-crown-6, THF, -78°C, 85%; (d) DIBAL-H, CH2Cl2, -78°C, 
77%; (e) CBr4, PPh3, CH3CN; (f) PBu3, CH3CN, 87% over two steps. 
 
The carbon skeleton of the C fragment 30 was constructed in a single step by a Ti(OiPr)4-
catalyzed hetero Diels-Alder reaction between 1-methoxy-1,3-butadiene and ethyl 
glyoxylate.48 The ester function of 43 was then reduced and the equatorial methyl acetal 
was converted to the more stable axial isopropyl acetal 44. Subsequent Swern oxidation 
afforded the required aldehyde 30. 
 
O
O OiPr
30
HO
O OiPr
44
EtO
O OMe
43
O
EtO
O OMe
O
a b,c d
 
Scheme 1.6. (a) Ti(OiPr)4, (+)-BINOL, 4Å mol. sieves, CH2Cl2, 65%; (b) LiAlH4, Et2O, 0°C; (c) PPTS, 
iPrOH; (d) (COCl)2, DMSO, Et3N, CH2Cl2, 77% over three steps. 
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The B and C fragments were efficiently connected by a Wittig reaction to give 45. Heck 
reaction (which was shown to be the most efficient palladium-catalyzed cross-coupling 
reaction in preliminary studies) of 45 with alkene 37 afforded the desired coupling product 
27 in 45% yield. However, when unprotected alkene 28 was used, the coupling reaction 
proceeded in 80% yield. Subsequent reprotection of the two free hydroxyl groups furnished 
27. After hydrolysis of the isopropyl acetal and oxidation of 48 to the lactone, the synthesis 
of (+)-ratjadone 5 was completed by mild hydrolysis of the TBS ethers. 
 
I
O OiPr4529
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O
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O
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30
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Scheme 1.7. (a) KOtBu, toluene, 0°C, 76%; (b) Pd(OAc)2, Bu4NBr, Cs2CO3, Et3N, DMF, 80% with 28, 
45% with 37; (c) PPTS, H2O/acetone, 83%; (d) TBSOTf, 2,6-lutidine, CH2Cl2, 0°C, 83%; (e) MnO2, 
CH2Cl2, py, 77%; (f) HF•py, THF, py, 76%. 
 
In conclusion, Kalesse’s total synthesis of (+)-ratjadone features the efficient asymmetric 
synthesis of three fragments that are connected by two efficient coupling reactions. The 
specific planning of the synthesis limits the requirement for protective groups. This in turn 
reduces the number of steps and increases efficiency.  
 
1.2.4 SAR studies of ratjadone 
 
In a later study, Kalesse et al. published limited SAR data based on the biological 
evaluation of a small library of synthetic ratjadone analogues.49 These compounds were 
mainly diastereomers, which were derived from connection of both enantiomers of 
Chapter 1 
 
 26
fragments 28, 29, and 30 in analogy to the total synthesis described above. The structures 
and activities of the tested compounds are shown in Table 1.1. 
 
Table 1.1: Growth inhibition and LC50 values for compounds 5 and 50-54 against different cell lines 
(values in ng ml-1) 
 
O
OH
OH
O O
5
O
OH
OH
O O
50
O
OH
OH
O O
51
O
OH
OH
O O
52
O
OH
OH
O O
53
O
OH
O O
54
5
1016
 
Cell line HM02 Cell line HEPG2 Cell line MCF7 Compound 
GI50 TGI* LC50 GI50 TGI* LC50 GI50 TGI* LC50
5 0.36 2.3 90 0.8 >100 >100 1.1 >100 >100 
50 <5.0 24 250 13 >500 >500 16 >500 >500 
51 17.0 >100 >100 85 >100 >100 25 >100 >100 
52 >100 >100 >100 >100 >100 >100 >100 >100 >100 
53 70 >100 >100 >100 >100 >100 75 >100 >100 
54 5.0 140 >500 58 >500 >500 100 >500 >500 
* TGI: concentration at which a complete inhibition of cell growth was observed. 
 
This study shows that the stereochemistry at C10 is very important (10R:10S = 1:200), and 
it was suggested that it has a major influence on the overall conformation of the molecule 
by minimization of allylic and homoallylic strain. Indeed, such factors often govern 
conformation of open-chain compounds.12 This suggestion was confirmed by modelling 
studies. The configuration at C5, which is extremely important in callystatin A (5R:5S = 
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1:350),50 does not have such a pronounced influence in ratjadone (5R:5S = 1:20). Also, the 
absolute stereochemistry of the THP ring is relatively unimportant. Indeed, omission of all 
THP substituents only leads to minor loss of activity. This is somewhat surprising, since the 
presence of hydroxy and keto functionalities at the correct positions in the left-hand side of 
callystatin A are of major importance for the activity.51 It should, however, be noted that 
although activity may be retained in this compound, the pharmalogical profile might differ 
significantly from natural ratjadone. 
In addition, the fact that compounds lacking a complete lactone functionality show a 
complete loss of tumor growth inhibition demonstrates that the α,β-unsaturated lactone is 
crucial for the biological activity. Finally, replacement of the hydroxyl group at C16 by a 
keto function results in a major loss of biological activity, indicating that this functionality 
is important for receptor binding. 
 
1.3 Aim of the project 
 
We recognized a linear terpenoid-like structure in the polyene chain of ratjadone and 
decided to employ our experience in the application of bifunctional terpenoid building 
blocks in total synthesis to construct ratjadone analogues with terpenoid-derived polyene 
spacers. 
We considered two different approaches to such compounds. Initially, the use of a one-
carbon elongated farnesol derivative as a C5-C17 fragment was explored. Preliminary 
studies following this strategy showed that it had some complications mainly due to 
difficulties in synthesis and instability of aldehydes of type 56, limiting efficiency and 
flexibility.  
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Figure 1.7. Retrosynthetic analysis of ratjadone analogues based on C1-elongated farnesol derivatives 
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In an alternative approach, bifunctional derivatives of geraniol and nerol (59) were 
considered as C7-C14 fragments and connected to preconstructed C1-C6 (60) and C15-C24 
(58) fragments.  
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Figure 1.8. Retrosynthetic analysis of ratjadone analogues based on geraniol/nerol derivatives. Numbering 
is based on ratjadone numbering. 
 
This strategy is similar to the convergent total synthesis strategy of Kalesse, and combines 
three building blocks of comparable size, i.e. A (THP ring, 58), B (chain, 59), and C 
(lactone, 60) fragments. The possibility for diversity enhancement is increased, since not 
only the THP fragment can be varied, but also the polyene chain, by varying source 
(geraniol vs. nerol) and orientation of the bifunctional terpene derivative (Fig. 1.9). 
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Figure 1.9. Different ratjadone mimics, varying in terpene source (geraniol (left) vs. nerol (right)) and 
orientation (→ vs. ←). 
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Kalesse et al. suggested a 3D structure in which the C1-C9 and C11-C24 moieties are 
perpendicular, imposed by C10 stereochemistry (due to allylic strain and syn-pentane 
interactions, Fig. 1.10) to rationalize the extreme difference in activity between natural (+)-
ratjadone and its 10S isomer.49 We calculated the minimum energy conformations for 
compounds 61-64 (with the same THP ring as natural ratjadone) and found that compound 
61 in the low energy region adopts a very similar conformation as the natural product. It 
was therefore decided that the target ratjadone analogues should have a geraniol-derived 
terpenoid fragment in the same orientation as in 61 (Fig. 1.9). 
CH3
CH3
CH3
H H
HH
Minimized allylic strain
Minimized
syn-pentane
interactions  
 
Figure 1.10. Twisted conformation of ratjadone chain governed by allylic strain and syn-pentane 
interactions suggested by Kalesse.49,52 
 
Altogether, the route suggested in Fig. 1.8 can be deemed the most promising route with 
respect to accessability and variability. In combination with versatile new and existing 
routes to each of the components, this strategy should provide access to a wide variety of 
ratjadone analogues. 
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2 Synthesis of the ratjadone analogue A fragment 
 
2.1 Retrosynthesis 
 
The C15-C24 polyketide domain, or the A fragment, represents the greatest challenge from 
a synthetic point of view, containing five stereocenters and a six-membered ring. The ideal 
building block would be aldehyde ent-12, also featured in Kalesse´s total synthesis of 
ratjadone (Fig. 2.1).1,2  
O
OTBS
OTBS
O
ent-12  
 
Figure 2.1. THP fragment building block ent-12. 
 
In this synthesis, the required linear precursor was synthesized by sequential Evans 
asymmetric aldol and vinylogous Mukaiyama aldol reactions3 followed by epoxidation, and 
then cyclized by intramolecular epoxide opening. Although this is an effective and elegant 
route for total synthesis, it requires the use of an expensive chiral auxiliary [(R)-4-
benzyloxazolidin-2-one] and is limited with respect to variation of the substituents on the 
ring. For our study towards ratjadone analogues, a method was required that would provide 
rapid access to structurally varied THPs. However, few general synthetic methods to 
substituted THPs are known. Two methods that have been employed for the synthesis of 
complex THP systems are the hetero Diels-Alder reaction and Prins-type cyclizations. The 
former is a Lewis acid-mediated formal [4+2] cycloaddition, and the latter is a cationic 
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cyclization of a species derived from a hemiacetal of a homoallylic alcohol and an aldehyde 
(see Fig 2.2).  
OHR1 O R2+ OR1 R2
H X
OR1 R2
X
Lewis acid
HX
65 66  
Figure 2.2. Prins cyclization 
 
Recently, the Prins cyclization and related reactions have attracted significant attention 
from the synthetic community.4-13 The original Prins cyclization involved a reaction 
between an aldehyde and a homoallylic alcohol, but recently variations involving e.g. 
preconstructed hemiacetal acetates have been described.6,13 Such reactions have been 
successfully employed in the total and partial synthesis of natural products. An important 
advantage of this methodology is the possibility to construct tetrahydropyrans from readily 
available starting materials, namely simple aldehydes and homoallylic alcohols, which are 
available in enantiomerically pure form by Brown allylation (or crotylation). In some cases, 
yields and diastereoselectivities of Prins(-type) cyclizations are somewhat disappointing, 
although cases have been described where both yield and diastereoselectivity are 
excellent.6,13 A major drawback of this type of reaction is the formation of side products, 
probably arising from an oxonia-Cope-type rearrangement,6,12 especially when substituents 
at the 2- or 6-position stabilize the cationic intermediate. 
 
RO O
OBn
RO O
OBn
RO O
OBn
OAc
OAc
O
OH
67 68 69
a
 
 
Scheme 2.1. Rychnovsky's synthesis of a pentasubstituted tetrahydropyran towards phorboxazoles. (a) cat. 
BF3•Et2O, AcOH, 52%. 
 
Rychnovsky and co-workers described the synthesis of the C22-C26 THP segment of the 
phorboxazoles (cf. Fig. 1.1) by a stereoselective Prins cyclization of hemiacetal acetate 67 
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(Scheme 2.1).13 The resulting THP 69 shows significant similarity to the desired THP 
fragment for ratjadone analogs. 
In order to construct such a fragment, cyclization precursor 70 would be required (Scheme 
2.2). Hemiacetal acetate 70 would be available through asymmetric crotylation of 
crotonaldehyde and subsequent esterification with known (R)-(2O,3O-
isopropylidene)glyceric acid, followed by DIBAL-H reduction and subsequent acetylation 
in analogy to Rychnovsky´s synthesis.13 
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Scheme 2.2. Hypothetical Prins-type cyclization of hemiacetal acetate 70; divergent reaction pathways 
leading to a tetrahydropyran (a) and tetrahydrofuran (b) product. 
 
However, the important difference with the phorboxazole fragment lies in the presence of 
the propenyl substituent. Here, in addition to the THP Prins cyclization path (a) leading to 
72, an alternative cationic cyclization (b) to form THF compound 73 is possible. Such 
THF-forming Prins cyclizations are well-known reactions. Also, the propenyl substituent 
makes the cationic intermediate prone to oxonia-Cope-type rearrangements.6,11 Therefore, 
this route was considered unlikely to be successful and was abandoned. 
During the preparation of this manuscript, Cossey and Funk described the construction of 
THP fragment 28 (an intermediate in Kalesse's total synthesis of ratjadone) via a Prins-type 
cyclization of enecarbamate 76 (Scheme 2.3).14 This strategy is based on an alternative 
bond construction, and employs a variation of the Prins cyclization that had not been 
previously described in literature. Obviously, this route provides very fast and efficient 
access to 28. 
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Scheme 2.3. (a) tBuLi, -78°C→-50°C, 1.1 h, then 75, BF3•Et2O, -78°C, 3 h, 62%; (b) CH3CH=CHCHO, 
InCl3, CH2Cl2, 84%; (c) Al(iBu)3, hexanes, -30°C, 1.5 h, 95% (ax./eq. = 48:52); (d) TBAF, THF, 100%. 
 
Another excellent method for the construction of multiply substituted THPs is the hetero 
Diels-Alder (HDA) reaction. The HDA reaction is formally analoguous to the well-known 
Diels-Alder reaction, with the difference that one (or more) of the carbon atoms of either 
the diene or the dienophile is substituted by a heteroatom. Many variations of the HDA 
reaction have been described.15 The version that is relevant to this study is the Lewis acid-
catalyzed reaction between an electron-rich diene (often activated by oxygen substituents) 
and an aldehyde (see example Scheme 2.4). In the early 1980s, Danishefsky and co-
workers first demonstrated the synthetic potential of this reaction.16-18 This work mainly 
concerned reactions between Danishefsky’s diene [1-methoxy-3-(trimethylsilyloxy)buta-
diene, 78] (or derivatives) and aromatic aldehydes. 
 
MeO
OTMS
O
+
MeO
OTMS
O
O
O
a
78 79 80  
Scheme 2.4. (a) various Lewis acids. 
 
The possibility to construct a substituted THP system (typically a dihydro-γ-pyrone) by 
forming a carbon-carbon and a carbon-oxygen bond in a single step contributed to the 
popularity of the HDA reaction. Up to three stereocenters can be formed in the reaction (as 
well as a fourth one after desilylation, and a fifth one by induction), and different groups 
have pursued development of a catalytic asymmetric version. Danishefsky and co-workers 
reported the first example.19 More recently, several other chiral Lewis acid catalysts were 
developed, including aluminum20,21 and boron22,23 complexes (Fig. 2.3). 
Synthesis of the ratjadone analogue A fragment 
 
 39
 
OiPr
OiPr
O
O
O B
O
CO2H
R
O
81
O
O
Al Me
SiPh3
SiPh3
(S)-82  
Figure 2.3. Aluminum- and boron-based asymmetric HDA catalysts 
 
Most of these, however, require doubly activated dienes such as Danishefsky’s diene 78 as 
substrate, which limits their applicability substantially. Only Jacobsen’s recently developed 
Cr(III) catalysts 83a and 83b (Scheme 2.5) accept monoactivated dienes as substrates.24 
The applicablity of these catalysts was demonstrated by the catalytic asymmetric 
construction of di- or tetrahydropyran building blocks in the total synthesis of natural 
products.25-27 Catalysts 83a and 83b were also shown to induce high stereoselectivities in 
inverse electron demand HDA reactions.28,29  
O-N
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83a: X- = Cl-
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Scheme 2.5. (a) (i) Mol. Sieves 4 Å, 83a or b (0.5-3 mol%); (ii) AcOH, TBAF, THF, 97% (>99% ee, >95% 
de). 
 
Paterson and Lockhurst recently demonstrated that this catalyst may also be applied in more 
complex systems, using a catalytic asymmetric HDA reaction for the construction of a 
phorboxazole A fragment.30 However, applicability still seems to be limited, depending on 
the nature of the aldehyde and steric bulk of either of the substrates. 
Especially α,β-unsaturated aldehydes lack reactivity and typically require doubly activated 
dienes as reaction partners.17 Their incorporation is highly desirable, since the resulting 
exocyclic vinyl group provides the THP-building block with a handle for metathetic 
connection or macrocyclization procedures. Unfortunately, to the best of our knowledge, no 
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diastereo- or enantioselective HDA reaction of α,β-unsaturated aldehydes with 
monoactivated dienes has been described so far. 
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Scheme 2.6. Cink and Forsyth´s synthesis towards phorboxazole A31; (a) BF3•Et2O, Et2O, -78°C; (b) 
TBAF, TsOH, THF, 60% over two steps; Synthesis of medium-sized ring ethers by Mujica et al.32: (c) 
BF3•Et2O, Et2O, -25°C, 82%; (d) TBAF, THF, 98%. 
 
Another means of controlling the stereochemical outcome of the HDA reaction is the use of 
enantiomerically pure starting materials. After a first observation by Danishefsky,18 several 
examples of asymmetric HDA reactions with enantiomerically pure chiral aldehydes have 
been described (Scheme 2.6).31,32 Martin et al. have demonstrated a synergistic effect 
between a chiral aldehyde and a chiral diene (Scheme 2.7).33 
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Scheme 2.7. (a) BF3•Et2O, Et2O, -15°C, 74%. 
 
Hu et al. described an asymmetric HDA reaction using a chiral diene and a chiral Co(II) 
salen catalyst.34 Similary, Jacobsen and co-workers reported match/mismatch effects when 
using chiral aldehydes and catalysts 83a and 83b (or enantiomers).35 
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We considered the use of an HDA reaction for the construction of the ratjadone THP 
fragment and analogues, envisioning ketone 94 as a precursor for building block ent-12. 
There are two possible retrosynthetic disconnections to form ketone 94 by HDA reaction (a 
and b, Fig. 2.4). 
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Figure 2.4. Possible retrosynthetic routes to 94 using HDA reactions 
 
Since aldehyde 87 is known to induce stereochemistry in similar HDA reactions,18,31,32 
route b was initially considered promising. Preliminary studies soon showed that 
silyloxytriene 96 is unable to react as a diene in HDA reactions, presumably due to 
delocalization of electrons in the conjugated system. Therefore, route a was explored 
further.  
Unfortunately, α,β-unsaturated aldehydes are notoriously bad dienophiles in HDA 
reactions. Also, no previous examples of diene-controlled asymmetric HDA reactions were 
found in literature. A synergistic effect between a chiral aldehyde and a chiral diene has 
been described. However, the similar reaction using a chiral aldehyde as the sole source of 
chirality produced a similar result, which makes the contribution to stereochemical 
induction by the chiral diene unclear.33 
Also, it was difficult to predict which of the two expected all-cis diastereomers would 
dominate in such a diene-controlled HDA reaction. Since Kalesse and co-workers reported 
that absolute stereochemistry of the substituents in this fragment only has limited impact on 
the biological activity,36 and because this project is diversity- rather than target-oriented, we 
decided to further pursue this route in order to construct various THP fragments for 
ratjadone analogues. 
 
Chapter 2 
 
 42
2.2 Synthesis of THP fragments of ratjadone analogues 
 
We started with the construction of silyloxydiene 95. The chirality is derived from aldehyde 
87, which can be prepared in two straightforward steps from inexpensive mannitol. 
Efficient large-scale procedures to 87 have been described.37,38 The other required 
component is ylide 97, available by α´-alkylation of (triphenylphosphoranylidene)-acetone 
(98).39 Wittig reaction between aldehyde 87 and ylide 97 affords the required enone 99.  
Subsequent treatment with TBSOTf in the presence of Et3N readily yields diene 95 without 
loss of enantiomeric purity. 
PPh3
O
O
OO
O
O
O
OTBS
O
O99 95
97 87
+ a b
 
 
Scheme 2.8. (a) CH2Cl2, rt, 42%; (b) TBSOTf, Et3N, Et2O, 0°C, 88%. 
 
The subsequent hetero Diels-Alder reaction between diene 95 and crotonaldehyde (Scheme 
2.9) was performed according to the conditions described by Mujica et al.32  
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O
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Scheme 2.9. (a) CH3CH=CHCHO (1.5 eq.), BF3•Et2O (1.5 eq.), Et2O, -30°C, 97%; (b) AcOH (2.5 eq), 
TBAF (1.5 eq.), THF, 87%. 
 
With some minor modifications (1.0 eq. diene, 1.5 eq. aldehyde, 1.5 eq. BF3•Et2O, 1.5 h at 
-30°C), the reaction proceeded in excellent yield (97%,) in a 4:1 mixture of diastereomers, 
which was obtained without further purification.  
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Thus, the complete skeleton of the desired building block including introduction of four 
chiral centers was achieved in only three steps from known, easily available compounds. 
The crude diastereomeric mixture was then desilylated by treatment with TBAF in the 
presence of AcOH to prevent partial epimerization at C3. The resulting isomers 94a and 
94b were readily separated by flash chromatography (94a:94b = 4:1). Both diastereomers 
were assigned the all-cis configuration of the ring substituents based on 1H NMR coupling 
constants. 
O
O
O
O
94a
O
O
O
O
94b  
 
Figure 2.5. Two all-cis diastereomers 94a and 94b. 
 
Since X-ray analysis to unambiguously assign the absolute configuration was not possible 
because the compounds are oils, it was decided to further convert the main isomer 94a. If it 
would have the desired (2S,3R,6S) configuration, the reaction sequence described below 
(Scheme 2.10) would afford triol 101a, a known compound from Kalesse´s total synthesis 
of (+)-ratjadone.2 This transformation required selective reduction of the ketone function to 
the axial alcohol. Cink and Forsyth described a similar case, where reduction with 
K−Selectride® was most successful.31 Thus, the ketone function of 94a was reduced with 
K−Selectride® to give a 1:4 mixture of axial alcohol 102a and equatorial alcohol 102b (in 
quantitative yield), which were easily separated by flash chromatography. Other reduction 
methods were investigated (see below), but none led to a higher yield of axial alcohol 102a. 
The relative stereochemistries of alcohols 102a and 102b were assigned by 1H NMR shifts 
and coupling constants, and further confirmed for 102a by NOESY. Subsequent removal of 
the isopropylidene group furnished triol 101b, which was shown to be not identical to 101a 
by comparison of 1H NMR spectra.2 
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Scheme 2.10. (a) K-Selectride, THF, -78°C (100%, eq.:ax. = 80:20); (b) PPTS, acetone/H2O 1:1, 58%. 
 
A rationale for the observed diastereoselectivity of the HDA reaction leading to 94 may be 
provided by considering the approach of the aldehyde dienophile to diene 95. Figure 2.6 
shows a Newman projection of the C3-C2 bond in 95, suggesting that the dienophile is 
more likely to approach the diene from the sterically less hindered top face. A (pseudo-) 
concerted, disrotatory reaction mechanism would then preferentially lead to 94a. 
 
H
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OTBS
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23
 
 
Figure 2.6. Sterically more favorable approach of the dienophile to diene 95. 
 
In contrast to the K-Selectride® reduction of 94a, the reduction of ketone 103 (lacking the 
methyl substituent at the 3-position of the THP ring, synthesis v.i.) with K-Selectride® 
primarily afforded the axial alcohol 105a, whereas reduction of a similar compound with an 
ethyl α-substituent (104a) under the same conditions furnished exclusively the equatorial 
alcohol .  
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Compound R 
= 
Ratio 
ax.:eq. 
103a H 89:11 
94a Me 20:80 
 
O
O
O
O O
R
OH
O
O
O
OH
O
O
103a (R = H)
94a (R = Me)
105b (R = H)
102b (R = Me)
equatorial
+
105a (R = H)
102a (R = Me)
axial
a
R R
104a Et <5:>95 
 
Scheme 2.11. (a) K-Selectride®, THF. 
 
Cr(II) amino acid complexes have been successfully employed in the diastereoselective 
reduction of ketones.40-42 In cooperation with Dr. K. Micskei of Debrecen University, 
Hungary, reduction of ketones 103a, 94a, and 104a (with an ethyl substituent in 3-position, 
synthesis v.i.) with Cr(II) amino acid complexes were investigated.† Complexes of Cr(II) 
with several achiral (IDA, NTA and EDTA) and chiral (L-valine, L-histidine) amino acids 
were tested (Table 2.1).‡  
 
The results in Table 2.1 clearly demonstrate that reductions of THP-4-ones with Cr(II) 
amino acid complexes depend strongly on α-substitution of the ketone. In the absence of 
α−substituents (ketone 103a), most of the employed complexes successfully reduced the 
ketone to the corresponding alcohols. With ketone 94a, which carries a methyl substituent 
in 3-position, only the Cr(II) NTA complex was successful, possibly indicating that a 
delicate balance between reactivity and limited steric hindrance is required here. Ketone 
104a, with an ethyl substituent, was not reduced by any of the complexes. 
                                                 
† This part of the work was performed in Dr. Micskei's laboratory at Debrecen University. This short 
research visit was financed by a DAAD/PPP Ungarn program. 
‡ Typical procedure: A mixture of H2O (15 ml) and DMF (15 ml) was degassed by bubbling Ar through the 
solution for at least 30 min. Cr(OAc)2•H2O (10 eq. with respect to the ketone) was added, followed by an 
amino acid (10 (IDA, NTA, EDTA) or 20 (L-Val, L-His) eq.) and an appropriate amount of 2N aq. NaOH. 
Ar was bubbled through the mixture continuously. When all Cr(II) was in solution, the ketone (~50 mg) 
was added. The reaction vessel was closed under Ar overpressure and the mixture was stirred overnight. 
The mixture was diluted with Et2O and washed five times with H2O and once with brine, dried (Na2SO4), 
filtered and concentrated in vacuo. The crude product was analyzed by 1H NMR to determine the ax./eq. 
ratio. 
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Table 2.1. Reduction of THP-4-ones with Cr(II) amino acid complexes 
O
O
O
O
O
R
OH
O
O
O
OH
O
O
103a (R = H)
94a (R = Me)
104a (R = Et)
105b (R = H)
102b (R = Me)
106b (R = Et)
equatorial
+
105a (R = H)
102a (R = Me)
106a (R = Et)
axial
CrCl2 
. 2H2O
Amino acid
R R
DMF/H2O 1:1
 
Ratio ax./eq. (conversion, %) Amino acid pH 
103a (R = H) 94a (R = Me) 104a (R = Et) 
IDA 6.0 47:61 n.r.a n.r. 
NTA 4.6 46:51 39:55 n.r. 
EDTA 5.0 40:54 n.r. n.r. 
L-Valc 9.5 38:59 n.t.b n.t. 
L-Hisc 9.3 38:61 n.t. n.t. 
a n.r.: No reaction; b n.t.: Not tested; c two amino acids coordinated to each Cr(II) ion. 
 
The most remarkable observation made during these reductions is the fact that the observed 
diastereoselectivity is relatively independent of both the amino acid and the ketone; it is 
typically 40:60 (ax./eq.). Indeed, for ketone 94a, this means an increase of the ax./eq. ratio 
with respect to the K-Selectride® reduction. However, since the isolated yield was not 
quantitative and the reaction is somewhat more difficult to perform than K-Selectride® or 
NaBH4 reduction, this method was not further exploited. 
 
Thus, the main product does not have the same absolute stereochemistry as the 
corresponding ratjadone fragment when the (S)-isomer of diene 95 is used, nor is selective 
reduction of the ketone to the required axial alcohol efficient. We attempted to improve the 
diastereomeric ratio by subjecting diene 95 and crotonaldehyde to a catalytic asymmetric 
HDA reaction using Jacobsen´s HDA catalyst 83a.24 Unfortunately, no reaction was 
observed, not even at higher temperature and longer reaction time. This may be caused 
either by poor reactivity of the α,β-unsaturated aldehyde or mismatch effects of the chiral 
diene and the catalyst, as was also described by Jacobsen and co-workers.35 
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Scheme 2.12. (a) crotonaldehyde, mol. sieves 4 Å, 83a (3 mol%), no reaction. 
 
However, the described route provides rapid and efficient access to highly functionalized 
THP ring systems with defined stereochemistry. Thus, it is suitable for the construction of 
A ring analogues of ratjadone, but not immediately useful for the original ratjadone 
A fragment, which is not mandatory for activity anyway.36 
Reduction of ketone 94a with NaBH4 afforded exclusively equatorial alcohol 102b in 
quantitative yield. Because of the excellent availability of this compound, it was used for 
further synthetic studies. The isopropylidene group was efficiently removed by treatment 
with 1.0 eq. of PPTS in MeOH. Other methods (Zn(NO3)2•4H2O, CH3CN; PPTS, 
acetone/H2O) were also successful but required long reaction times (> 7 d).  
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Scheme 2.13. (a) NaBH4, MeOH, 100%; (b) PPTS, MeOH, 88%; (c) TBSOTf, 2,6-lutidine, CH2Cl2, -78°C, 
99%; (d) HCl, CHCl3, 91%; (e) Dess-Martin periodinane, CH2Cl2, 84%. 
 
Subsequent transformation to aldehyde 108 was achieved in analogy to Kalesse´s total 
synthesis of (+)-ratjadone.1,2 Triple TBS protection followed by selective cleavage of the 
primary TBS ether (HCl, CHCl3) furnished alcohol 107. Dess-Martin oxidation43 resulted in 
adequately protected aldehyde 108. 
 
Attempts were also made to construct the original A ring building block ent-12 from 94b. 
Ketone 94b was smoothly converted to the corresponding equatorial alcohol 109. Then, the 
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C4 stereocenter had to be inverted. In a first study, Mitsunobu inversion44 was accompanied 
by β-elimination, as well as the formation of a third, unidentified product. The desired 
inversion product 110 was obtained in a modest 33% yield, and was still contaminated with 
large quantities of diisopropyl hydrazinedicarboxylate. With a larger amount of 110 in 
hand, aldehyde ent-12 would be available in analogy to 108. Unfortunately, repetition of 
the Mitsunobu reaction on preparative scale failed. 
 
O
O
O
O
94b
O
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O
109
O
OAc
O
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a b
 
 
Scheme 2.14. (a) NaBH4, MeOH, quant.; (b) DIAD, Ph3P, AcOH, THF, 33%. 
 
In order to investigate the scope and exploit the efficiency of the described HDA 
methodology, a number of derivatives of ketone 94 were synthesized. 
β-Keto ylides 111-113 were obtained by alkylation of ylide 98 with the appropriate alkyl 
iodides after deprotonation with n-BuLi (Table 2.2).39 Enones 114-117 were obtained by 
Wittig reaction of aldehyde 87 with ylides 98, 97, 111, and 112, respectively, as 
summarized in Table 2.1. In all cases, only the E-enone was isolated, the Z-product was 
either absent or present as a minor impurity that was easily removed by flash 
chromatography. This in contrast to a literature report, where 114 was formed in a 3:1 E/Z 
ratio.34 Yields of this step varied and were sometimes mediocre. This is probably caused by 
difficulties in the purification of the β-keto ylides. Enones 99 and 114-116 were smoothly 
converted to the corresponding TBS enol ethers 95 and 117-119. 
 
Hu et al. reported that treatment of 117 with BF3•Et2O resulted in decomposition.34 
Whereas we found this to be true at room temperature, BF3•Et2O-mediated decomposition 
of silyloxydienes 95 and 117-119 was not observed at temperatures below -20°C.  Thus, 
dienes 95 and 117-119 were subjected to BF3•Et2O-mediated HDA reaction with 
crotonaldehyde or cinnamaldehyde between -20°C and -35°C. The resulting dihydropyrans 
were desilylated to give tetrahyropyran-4-ones (Table 2.3). 
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Table 2.2. Synthesis of silyloxydienes 
PPh3
O
R1
THF
O
OO
CH2Cl2
O
R1
O
O Et2O
TBSOTf
Et3N
OTBS
R1
O
O
O
PPh3
114 R = H
  99 R = Me
115 R = Et
116 R = iPr
n-BuLi
R1I
98
97, 111-113
117 R = H
  95 R = Me
118 R = Et
119 R = iPr
 
Entry Ylide R1 = Ylide yield 
(%) 
Enone Enone 
yield (%) 
Diene Diene 
yield (%) 
1 98 H --- 114 80 117 95 
2 97 Me 94 99 42 95 88 
3 111 Et 88 115 43 118 93 
4 112 iPr 100 116 54 119 46 
5 113 iBu 95 --- --- --- --- 
 
 
Table 2.3: HDA reactions and desilylation 
 
OTBS
R1
O
O
Et2O O
R1
R2
OTBS
O
O
AcOH
TBAF
THF O
R1
R2
O
O
O
R2CHO
BF3
.Et2O
95, 
117-119 120-126 103-104,127-131  
 
Entry Diene R1 = R2 = HDA product THP-4-one Yield (% over two 
steps) 
1 117 H CH3CH=CH 120 103 78 
2 117 H PhCH=CH 121 127 85 
3 95 Me PhCH=CH 122 128 85 
4 118 Et CH3CH=CH 123 104 84 
5 118 Et PhCH=CH 124 129 72 
6 119 iPr CH3CH=CH 125 130 77 
7 119 iPr PhCH=CH 126 131 69 
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Yields (Table 2.3) and diasteromeric ratios (Table 2.4) of the HDA products range from 
good to excellent. The isolated tetrahydropyran-4-ones 103, 104, and 127-131 were 
typically mixtures of the two isomers that have all-cis configuration of the ring substituents, 
as was the case for 94. This was confirmed by NOE spectroscopy for 131a and based on 
analogy of 1H NMR coupling constants for the other tetrahydropyran-4-ones. 
Diastereomeric ratios are summarized in Table 2.4. 
 
In case of 131, a minor amount (~5%) of a third isomer (131c, thought to be a compound 
with a trans relationship of the 2- and 6-substituents) could also be isolated. Its 1H NMR 
spectrum displays many similarities with 131a and 131b, but the proton at 6-position shows 
a significant downfield shift with respect to the two major compounds. Third isomeric 
products were also observed for 103 and 127, but these were inseparable from 103b and 
127b, respectively. Amounts of these isomers never exceeded 5%. 
 
Table 2.4: Diastereoselectivity of diene-controlled asymmetric HDA reactions 
 
HDA product Entry R1 = R2 = 
Nr. Ratio a:b 
1 H CH3CH=CH 103 2:1 
2 H PhCH=CH 127 1.6:1 
3 Me CH3CH=CH 94 4:1 
4 Me PhCH=CH 128 10:1 
5 Et CH3CH=CH 104 7:1 
6 Et PhCH=CH 129 8:1 
7 iPr CH3CH=CH 130 7:1 
 
 
 
O
R1
R2
O
O
O
a
O
R1
R2
O
O
O
b  
8 iPr PhCH=CH 131 4:1 
 
HDA reaction of diene 117 with ethyl glyoxylate under various conditions, including 
Co(II) salen catalysis, has been reported to afford not only both cis diastereomers, but both 
trans isomers as well.34 These results suggest that the products arise from a tandem 
Mukaiyama-Michael-type addition, rather than a (pseudo-)concerted [4+2] cycloaddition. 
The HDA reactions described in this study employ α,β-unsaturated aldehydes (which are 
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typically less reactive than ethyl glyoxylate), and generally afford only the all-cis isomers. 
Thus, these reactions presumably proceed through a more selective (pseudo-)concerted 
[4+2] cycloaddition mechanism. 
 
Further evidence for the exclusive formation of the all-cis products was supplied by HDA 
reaction of achiral dienes 132 and 133 (i.e. with an isopropyl group instead of the 
dimethyldioxolane substituent) with crotonaldehyde or cinnamaldehyde (Scheme 2.15). 
Here, only one pair of (enantiomeric) diastereomers of the desilylated HDA products 
134-136 was formed. The all-cis configuration was confirmed by NOE spectroscopy for 
135 and based on analogy of 1H NMR coupling constants for the other tetrahydropyran-4-
ones 134 and 136. Dienes 132 and 133 were derived from ketones 137 and 138, which were 
obtained by Wittig reaction of ylides 111 and 113 with isobutyraldehyde. 
 
OTBS
R1
O
R1
R2
O
b,c
134: R1 = Et, R2 = CH3CH=CH
135: R1 = Et, R2 = PhCH=CH
136: R1 = iBu, R2 = PhCH=CH
132: R1 = Et
133: R1 = iBu
O
R1
a
137: R1 = Et
138: R1 = iBu
 
 
Scheme 2.15. (a) TBSOTf, Et3N, Et2O; (b) R2CHO, BF3•Et2O, Et2O; (c) AcOH, TBAF, THF. 
 
Interestingly, reaction of diene 139 (derived from ketone 140), which has an aromatic ring 
conjugated to the diene system, with crotonaldehyde and cinnamaldehyde gave the classical 
Diels-Alder adducts 141 and 142 as the sole isolated products, rather than the expected 
HDA products (Scheme 2.16). 
 
OTBS
OMe
R
OTBS
O OMe
b
141: R = CH3
142: R = Ph
139
O
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a
140
 
Scheme 2.16. (a) TBSOTf, Et N, Et O; (b) RCH=CHCHO, BF •Et O, Et O, -30°C3 2 3 2 2 . 
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A possible rationalization for this observation is a decrease in the HOMO energy of the 
diene through conjugation to the aromatic ring. 
 
An expansion of the applicability of the current methodology would be the selective base-
catalyzed epimerization at C3. Especially in the case of a bulky substituent, the equatorial 
position should be favored over the axial. Indeed, when 131a was treated with base, it was 
slowly converted to 131d (Scheme 2.17). The product was shown to be different from 
131a, 131b and 131c by 1H and 13C NMR, showing coupling constants typical for a trans-
relationship of the C2 and C3 substituents. 
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O
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Scheme 2.17. (a) KOtBu, MeOH, 2 d (53%). 
 
Even though the recovery rate needs to be improved, the isomerization provides easy access 
to related tetrahydropyran-4-ones with different relative configuration.  
Another method to increase diversity within this strategy is nucleophilic addition to the 
ketone function. As an example, 128a was reacted with MeMgBr to afford a single 
diastereomer of tertiary alcohol 143 (Scheme 2.18). The excellent stereoselectivity is 
presumably caused by the adjacent axial methyl group, which makes equatorial attack 
unfavorable. 
O
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Scheme 2.18. (a) MeMgBr, THF (52%). 
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Also in this case, the yield needs to be optimized. However, this reaction demonstrates that 
the described tetrahydro-γ-pyrones can be easily and selectively modified by nucleophilic 
addition. 
 
Despite the fact that the described HDA reactions display a stereoselectivity preference 
opposite to the one desired for the ratjadone THP segment, its efficiency combined with the 
typically good stereocontrol spurred us to apply this methodology to a system in which it 
would lead to the desired absolute stereochemistry in the THP ring. Such a system was 
recognized in the phorboxazoles. 
 
2.3 Synthesis of the phorboxazole C22-C26 THP ring 
 
Phorboxazoles A (3a) and B (3b, see Fig. 2.7) are macrocyclic marine natural products 
isolated by Searle and Solinski45 from the sponge Phorbas sp.. They show remarkable 
cytotoxicity (mean GI50 <0.79 nM) against the full US NCI panel of 60 human cancer cell 
lines. The phorboxazoles cause cell cycle arrest in the S phase by a thus far unknown 
mechanism. Such a mode of action would be complementary in cancer therapy to e.g. 
microtubule-stabilizing agents such as paclitaxel or the epothilones.46,47 This extraordinary 
biological activity, combined with the challenging structure and restricted access to natural 
material have attracted great interest in the synthetic community, culminating in total 
syntheses by the groups of Forsyth,48 Evans,49-51 and Smith,52 and several other groups 
reported partial syntheses.13,53-58 Several approaches made use of asymmetric HDA 
methodology, including aldehyde-31 and catalyst-controlled30 variants. 
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O
O
N
O
O
O
O
R2
R1
O
Br
OMe
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H OH
OMe
Phorboxazole A (3a): R1= OH, R2= H
Phorboxazole B (3b): R1= H, R2= OH
1
3
11
15
22
2632
Figure 2.7. Structures of phorboxazoles A and B.
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Both phorboxazole A and B feature a 25-membered macrocycle and a linear side chain. 
They contain two oxazole rings and no less than four tetrahydropyran rings, three of which 
are embedded in the macrocycle. Most probably, these substituted THP rings play a 
prominent role in the overall conformation of the macrocycle. Synthetically, they constitute 
the major challenge in these molecules. Recently, Paterson and Lockhurst elegantly showed 
that Jacobsen´s catalytic asymmetric hetero Diels-Alder (HDA) methodology24 may be 
employed to combine two advanced intermediates (forming the C11-C15 THP ring), 
leading to formation of the major part of the macrocylic skeleton.30 Indeed, the HDA 
reaction may be the most efficient method for the stereocontrolled construction of THP 
rings. However, no examples of catalytic asymmetric HDA reaction in the synthesis of 
sterically demanding systems such as the phorboxazole C22-C26 THP ring have been 
described to date. Therefore, we decided to employ our diene-controlled asymmetric HDA 
methodology for the fast and efficient synthesis of phorboxazole C20-C32 fragment 144, 
previously reported by Paterson and Luckhurst in their synthesis of an advanced C4-C32 
fragment.30 Our retrosynthetic analysis of 144 is shown in Fig. 2.8. 
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Figure 2.8. Retrosynthetic analysis C20-C32 segment of phorboxazoles. 
 
The key step is the diene-controlled HDA reaction between diene 146 and 
3-benzyloxypropionaldehyde, leading to the all-cis HDA product. Absolute stereochemistry 
is induced by the C27 stereocenter (derived from D-lactate), which disappears in a later 
step. Thus, absolute stereochemistry can be switched simply by starting with the other 
lactate enantiomer (traceless induction). The C24 and C25 stereocenters are to be set by 
hydrolysis of the intermediate TBS enol ether and subsequent borohydride reduction, 
respectively, placing both substituents in the thermodynamically favored equatorial 
position. 
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The synthesis commenced with a Wittig reaction between known ylide 14759,60 and D-
lactate-derived aldehyde 148. The latter was synthesized from commercially available 
isobutyl D-lactate (149) in three straightforward steps (Scheme 2.19). 
 
O
OH
149
HO
OBn
151
O
OBn
148
O
O
OBn
150
O
a b c
 
 
Scheme 2.19. (a) NaH, BnBr, DMF, 99%; (b) LiAlH4, THF, 100%; (c) (COCl)2, DMSO, Et3N, CH2Cl2, 
74%. 
 
Aldehyde 148 was then used in a Wittig reaction with ylide 147.60 The resulting enone 152 
(not shown) was not converted to the corresponding TBS enol ether under standard 
conditions (TBSOTf, Et3N, 0°C), probably due to the presence of an additional methyl 
group at the ketone α-position. However, subsequent addition of one equivalent of 
NaHMDS to the reaction mixture at low temperature afforded the desired diene 146 in 
quantitative yield (2E/2Z = 9:1). The key BF3•Et2O-mediated HDA reaction between diene 
146 and 3-benzyloxypropionaldehyde (153, obtained by Swern oxidation61 of commercially 
available 3-benzyloxypropanol) led to a mixture of diastereomeric products in reasonable 
yield.  
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Scheme 2.20. (a) CH3CN, r.t., 14 h, 75%; (b) TBSOTf, Et3N, Et2O, then NaHMDS, -78→0°C, 100%, 
2E/2Z = 9:1; (c) 1.5 eq. 3-benzyloxypropionaldehyde, 1.5 eq. BF3•Et2O, Et2O, -40°C, 2 h, 63%; (d) 2.5 eq. 
AcOH, 1.5 eq. TBAF, THF, r.t., 1 h, 65%. 
 
The crude mixture of HDA products 154 (not shown) was desilylated (AcOH, TBAF) to 
give ketones 155 in 14:66:8:12 mixture of diastereomers (155a-d), of which the latter two 
were not separated. The two additional isomers (with respect to the HDA reactions 
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described earlier in this chapter) may be derived from the ~10% of 5Z-diene in 146. Isomer 
155a was assigned the (3R,5R) configuration as shown in Scheme 2.20 by NOE 
spectroscopy. Unfortunately, the configuration of the other diastereomers could not be 
determined unequivocally.  
Borohydride reduction of 155b led to the exclusive formation of a single diastereomer, 
presumably the equatorial alcohol 156.  
 
OH
OBn
BnO O
O
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BnO O
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a
156  
Scheme 2.21. (a) NaBH4, MeOH, 0°C, 1 h, 72%. 
 
2.4 Conclusion 
 
In conclusion, a versatile, unprecedented diene-controlled asymmetric HDA between α,β-
unsaturated aldehydes and monoactivated chiral dienes was developed, affording 
compounds that can be easily converted to highly substituted stereodefined THP building 
blocks for the construction of analogues of ratjadone and other natural products. 
 
2.5 Experimental section 
 
General. All commercial reagents were purchased from Fluka, Merck or Aldrich and used without further 
purification, unless otherwise stated. All oxygen- and water-sensitive reactions were carried out in oven-
dried glassware under argon. THF was distilled from potassium/benzophenone ketyl, Et2O was distilled 
from sodium/potassium/benzophenone ketyl, and CH2Cl2 was distilled from calcium hydride. Other dry 
solvents were purchased from Fluka. Flash chromatography was performed using silica gel 60 (230-400 
mesh, Merck). Thin-layer chromatography (TLC) was performed using silica plates (Merck, silica gel 60 
F254) and developed using Cer-MOP reagent [molybdatophosphoric acid (5.0 g), cerium (IV) sulfate (2.0 g), 
and concentrated H2SO4 (16 ml) in water (200 ml)]. Optical rotations were measured using a 1 ml cell with 
1 dm path length on a Jasco DIP-1000 digital polarimeter. IR spectra were recorded as CHCl3 solutions or 
as thin films between NaCl plates on a Bruker IFS 28. 1H and 13C NMR spectra were recorded in CDCl3 on 
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Varian Mercury VX 300 and VX 400 spectrometers using TMS as internal standard. Chemical shifts δ are 
reported in parts per million (ppm), coupling constants J are given in Hertz (Hz). High resolution ESI mass 
spectra were obtained from a Bruker Apex 70e Fourier transform ion cyclotron resonance mass 
spectrometer equipped with a 7.0 Tesla superconducting magnet and an external electrospray ion source 
(Agilent, off axis spray).  
 
 
General procedure for α´-alkylation of 1-triphenylphosphoranylidenepropan-2-one (98): To a solution 
of 98 (1.0 eq.) in THF (0.125 M) was added at -78°C n-BuLi (1.6 M in hexane, 1.4 eq.). The mixture was 
stirred at -78°C for 1 h, then the appropriate alkyl iodide (1.4 eq.) was added and the mixture was allowed 
to warm to room temperature over night. The solvent was removed in vacuo, the residue was taken up in 
CH2Cl2 and the mixture was washed three times with H2O, dried (Na2SO4), filtered and concentrated in 
vacuo. The off-white solid residue was washed with three portions of ice-cold ether and dried in vacuo to 
give the alkylated ylides as colorless or slightly brown solids, which were used immediately in the next 
reaction without further purification. 
 
General procedure for Wittig reactions: To a solution of an ylide in CH2Cl2 was added an aldehyde and 
the mixture was stirred 24-48 h at room temperature. The solvent was removed in vacuo and the residue 
was extracted several times with EtOAc/hexane 1:4. The combined extracts were concentrated in vacuo and 
purified by flash chromatography. 
 
 
General procedure for the synthesis of TBS enol ethers: To a solution of a ketone (1.0 eq.) in Et2O was 
added at 0°C Et3N (1.2 eq.) and then TBSOTf (1.1 eq.). The mixture was stirred for 1 h at 0°C, then 
quenched by addition of sat. aq. NaHCO3 and extracted three times with tBuOMe. The combined organic 
fractions were washed with brine, dried (Na2SO4), filtered and concentrated in vacuo to give a slightly 
yellow oil. The crude product was purified by flash chromatography on a small, Et3N-neutralized column to 
give the TBS enol ethers. 
 
 
General procedure for hetero Diels-Alder (HDA) reactions: To a solution of a diene in Et2O was added 
at -30°C crotonaldehyde or cinnamaldehyde (1.5 eq.) and then BF3•Et2O (1.5 eq.). The mixture was stirred 
at -20°C to -30°C for 1.5-4 h and then quenched by addition of Et3N (3 eq.). The mixture was diluted with 
H2O (50 ml) and extracted with tBuOMe (3 x 35 ml). The combined organic fractions were washed with 
brine (50 ml), dried (Na2SO4), filtered and concentrated in vacuo to give the crude HDA products, which 
were analyzed by 1H NMR for identity and diastereomeric ratio of the products and used in the next step 
without further purification. 
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General procedure for desilylation of TBS enol ethers: To a solution of a TBS enol ether in THF were 
added at 0°C acetic acid (2.5 eq.) and TBAF•3H2O (1.5 eq.). The mixture was stirred at room temperature 
until the starting material had been fully consumed (TLC). The mixture was diluted with sat. aq. NaHCO3 
(50 ml) and extracted with tBuOMe (3 x 35 ml). The combined organic fractions were dried (Na2SO4), 
filtered, concentrated in vacuo and purified by flash chromatography. 
 
 
E-(2S)-1,2-isopropylidenedioxy-3-hexen-5-one 114: 1-Triphenylphosphoranylidenepropan-2-one (98, 
6.37 g, 20.0 mmol) and (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxaldehyde (3.00 g, 23.0 mmol) were 
reacted over 48 h according to the general procedure for Wittig reactions. The residue was purified by flash 
chromatography (column dimensions: 25 x 3 cm, EtOAc/PE = 1:4) to give 114 (2.725 g, 16.0 mmol, 80%) 
as a colorless oil. [α]26D = +41.6 (c = 1.02, CHCl3). IR (film): 3423 (broad), 2989, 2938, 2882, 1682, 1641, 
1424, 1374, 1363, 1259, 1217, 1064, 979, 832 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 1.42 (s, 3H), 1.47 (s, 
3H), 2.29 (s, 3H), 3.69 (dd, J = 8.20, 7.33 Hz, 1H), 4.21 (dd, J = 8.20, 6.45 Hz, 1H), 4.68 (dddd, J = 7.33, 
6.45, 5.86, 1.18 Hz, 1H), 6.32 (dd, J = 15.83, 1.18 Hz, 1H), 6.70 (dd, J = 15.83, 5.86 Hz, 1H). 13C NMR 
(CDCl3, 50.3 MHz): δ = 25.3, 26.1, 27.0, 68.5, 74.7, 109.8, 130.7, 143.1, 197.5. Rf =0.24 (EtOAc/n-hexane 
= 1:6) 
 
 
E-(2S)-1,2-isopropylidenedioxy-3-hepten-5-one 99: Ylide 98 (7.96 g, 25.0 mmol), n-BuLi (1.6M in 
hexane, 21.88 ml, 35.0 mmol) and methyl iodide (2.16 ml, 4.91 g, 35.0 mmol) were reacted according to the 
general procedure for alkylation of ylide 98 to give 97 (6.44 g, 29.4 mmol, 78%) as a colorless solid. 1H 
NMR (CDCl3, 300 MHz): δ = 1.18 (t, J = 7.6 Hz, 3H), 2.33 (dq, J = 1.2, 7.6 Hz, 2H), 7.40-7.80 (m, 16H). 
Ylide 97 (6.44 g, 29.4 mmol) and (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxaldehyde (3.00 g, 
23.0 mmol) were reacted over 48 h according to the general procedure for Wittig reactions. The residue was 
purified by flash chromatography (column dimensions: 25 x 3 cm, EtOAc/PE = 1:5) to give 99 (1.521 g, 
8.16 mmol, 42%) as a colorless oil. [α]25D = +47.8 (c = 1.68, CHCl3). IR (CHCl3): 3674, 3027, 3013, 2982, 
2941, 2903, 2883, 1714, 1459, 1409, 1380, 1354, 1275, 1231, 1179, 1116, 1086, 1041, 981 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ = 1.11 (t, J = 7.33 Hz, 3H), 1.42 (s, 3H), 1.46 (s, 3H), 2.60 (q, J = 7.33 Hz, 2H), 3.68 
(dd, J = 8.21, 7.33 Hz, 1H), 4.19 (dd, J = 8.21, 6.43 Hz, 1H), 4.67 (dddd, J = 7.33, 6.43, 5.86, 1.56 Hz, 1H), 
6.35 (dd, J = 15.83, 1.56 Hz, 1H), 6.73 (dd, J = 15.83, 5.86 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ = 7.8, 
25.7, 26.4, 33.9, 68.8, 75.1, 110.1, 130.0, 141.9, 200.5. Rf = 0.51 (EtOAc/n-hexane = 1:4) 
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E-(2S)-1,2-isopropylidenedioxy-3-octen-5-one 115: Ylide 98 (15.92 g, 50.0 mmol), n-BuLi (1.6M in 
hexane, 43.8 ml, 70.0 mmol) and ethyl iodide (5.60 ml, 70.0 mmol) were reacted according to the general 
procedure for alkylation of ylide 98 to give 111 (15.27 g, 44.1 mmol, 88%) as a slightly brown solid. 1H 
NMR (CDCl3, 300 MHz): δ = 0.97 (dt, J = 0.3, 7.3 Hz, 3H), 1.69 (dq, J = 0.3, 7.3 Hz, 2H), 2.30 (ddt, J = 
0.3, 1.2, 7.3 Hz, 2H), 7.40-7.78 (m, 16H). Ylide 111 (3.46 g, 10.0 mmol) and (R)-(+)-2,2-dimethyl-1,3-
dioxolane-4-carboxaldehyde (1.95 g, 15.0 mmol) were reacted over 48 h according to the general procedure 
for Wittig reactions. The residue was purified by flash chromatography (column dimensions: 15 x 4 cm, 
EtOAc/PE = 1:6) to give 115 (845 mg, 4.26 mmol, 43%) as a slightly yellow oil. [α]25D = +40.0 (c = 2.26, 
CHCl3). IR (CHCl3): 3675, 3511, 3329 (broad), 3027, 3012, 2990, 2967, 2936, 2876, 1698, 1681, 1639, 
1457, 1384, 1375, 1256, 1230, 1185, 1063, 978, 862 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 0.94 (t, J = 
7.33 Hz, 3H), 1.42 (s, 3H), 1.46 (s, 3H), 1.65 (m, J = 7.33 Hz, 2H), 2.55 (t, J = 7.33 Hz, 2H), 3.68 (dd, J = 
8.21, 7.33 Hz, 1H), 4.19 (dd, J = 8.21, 6.74 Hz, 1H), 4.67 (dddd, J = 7.33, 6.74, 5.86, 1.56 Hz, 1H), 6.35 
(dd, J = 15.83, 1.56 Hz, 1H), 6.72 (dd, J = 15.83, 5.86 Hz, 1H). 13C NMR (CDCl3, 75.5 MHz): δ = 13.7, 
17.3, 25.6, 26.4, 42.5, 68.7, 75.0, 109.9, 129.9, 141.8, 199.6. Rf = 0.34 (EtOAc/ PE = 1:6). 
 
 
E-(2S)-1,2-isopropylidenedioxy-7-methyl-3-octen-5-one 116: Ylide 98 (19.10 g, 60.0 mmol), n-BuLi 
(1.6M in hexane, 52.5 ml, 84.0 mmol) and isopropyl iodide (8.40 ml, 84.0 mmol) were reacted according to 
the general procedure for alkylation of ylide 98 to give 112 (21.59 g, 59.9 mmol, 100%) as a slightly brown 
solid. 1H NMR (CDCl3, 300 MHz): δ = 0.90 (m, 1H), 0.96 (d, J = 6.5 Hz, 6H), 2.19 (m, 2H), 7.42-7.70 (m, 
16H). Ylide 112 (7.21 g, 20.0 mmol) and (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxaldehyde (3.90 g, 
30.0 mmol) were reacted over 48 h according to the general procedure for Wittig reactions. The residue was 
purified by flash chromatography (column dimensions: 16 x 4 cm, EtOAc/PE = 1:6) to give 116 (2.28 g, 
10.7 mmol, 54%) as a slightly yellow oil. [α]25D = +40.3 (c = 1.59, CHCl3). IR (CHCl3): 3675, 3514, 3026, 
2989, 2960, 2935, 2872, 1692, 1636, 1466, 1455, 1383, 1374, 1339, 1304, 1229, 1195, 1171, 1154, 1062, 
978, 859 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 0.94 (d, J = 7.45 Hz, 6H), 1.42 (s, 3H), 1.46 (s, 3H), 2.12 
(m, 1H), 2.44 (d, J = 6.75 Hz, 2H), 3.68 (dd, J = 8.21, 7.33 Hz, 1H), 4.19 (dd, J = 8.21, 6.45 Hz, 1H), 4.67 
(ddd, J = 7.33, 6.45, 5.86, 1.17 Hz, 1H), 6.34 (dd, J = 15.83, 1.17 Hz, 1H), 6.71 (dd, J = 15.83, 5.86 Hz, 
1H). 13C NMR (CDCl3, 75 MHz): δ = 22.5, 24.8, 25.6, 26.4, 49.6, 68.7, 75.0, 109.9, 130.2, 141.8, 199.3. Rf 
= 0.49 (EtOAc/n-hexane = 1:6). 
 
 
E-(2S)-5-tert-Butyldimethylsilyloxy-1,2-isopropylidenedioxy-3,5-hexadiene 117: Ketone 114 (2.04 g, 
12.0 mmol) Et3N (2.99 ml, 2.19 g, 21.6 mmol) and TBSOTf (3.31 ml, 3.81 g, 14.4 mmol) were reacted 
according to the general procedure for the synthesis of TBS enol ethers. The crude product was purified by 
flash chromatography on a small, Et3N-neutralized column (column dimensions 20 x 1.5 cm, EtOAc/PE = 
1:20) to give 117 (3.25 g, 11.4 mmol, 95%) as a colourless oil. [α]25D = +17.1 (c = 2.25, CHCl3). IR 
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(CHCl3): 3689, 3024, 3015, 2929, 2857, 1725, 1601, 1226, 1204, 839 cm-1. 1H NMR (CDCl3, 300 MHz): δ 
= 0.18 (s, 6H), 0.97 (s, 9H), 1.40 (s, 3H), 1.44 (s, 3H), 3.50 (dd, J = 8.19, 7.51 Hz, 1H), 4.01 (dd, J = 8.19, 
6.25 Hz, 1H), 4.23 (s, 1H), 4.24 (s, 1H), 4.49 (dddd, J = 7.51, 7.03, 6.25, 1.56 Hz, 1H), 5.84 (dd, J = 15.22, 
7.03 Hz, 1H), 6.05 (dd, J = 15.22, 1.56 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ = -4.8, -4.7, 18.2, 25.7, 
25.8, 26.5, 69.5, 76.2, 96.5, 109.2, 127.5, 130.7, 154.1. Rf = 0.91 (EtOAc/n-hexane = 1:6). HRMS: calcd. 
for C15H28O4Si (M+Na+O§)+ 323.1649 found 323.1648. 
 
 
3E,5Z-(2S)-5-tert-Butyldimethylsilyloxy-1,2-isopropylidenedioxy-3,5-heptadiene 95: Ketone 99 (720 
mg, 3.91 mmol), Et3N (1.00 ml, 729 mg, 7.20 mmol) and TBSOTf (1.10 ml, 1.27 g, 4.8 mmol) were reacted 
according to the general procedure for the synthesis of TBS enol ethers.  The crude product was purified by 
flash chromatography on a small, Et3N-neutralized column (column dimensions 20 x 1.5 cm, EtOAc/PE = 
1:20) to give 95 (1.08 g, 3.62 mmol, 92%) as a colourless oil. [α]25D =+10.4 (c = 1.15, CHCl3). 1H NMR 
(CDCl3, 300 MHz): δ = 0.11 (s, 3H), 0.12 (s, 3H), 1.01 (s, 9H), 1.40 (s, 3H), 1.42 (s, 3H), 1.64 (d, J = 7.03 
Hz, 3H), 3.58 (dd, J = 8.19, 7.51 Hz, 1H), 4.09 (dd, J = 8.21, 6.15 Hz, 1H), 4.54 (m, 1H), 4.89 (d, J = 7.03 
Hz), 5.72 (dd, J = 15.24, 7.63 Hz, 1H), 6.10 (d, J = 15.24 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ = -3.7, 
−3.6, 11.8, 18.4, 25.8, 25.9, 26.6, 69.5, 76.7, 109.2, 110.9, 124.8, 131.7, 148.3. Rf = 0.60 (EtOAc/n-hexane 
= 1:8). 
 
 
3E,5Z-(2S)-5-tert-Butyldimethylsilyloxy-1,2-isopropylidenedioxy-3,5-octadiene 118: Ketone 115 (1.29 
g, 6.50 mmol), Et3N (1.62 ml, 1.18 g, 11.7 mmol) and TBSOTf (1.79 ml, 2.06 g, 7.80 mmol) were reacted 
according to the general procedure for the synthesis of TBS enol ethers. The crude product was purified by 
flash chromatography on a small, Et3N-neutralized column (column dimensions 20 x 1.5 cm, EtOAc/PE = 
1:20) to give 118 (1.89 g, 6.04 mmol, 93%) as a colourless oil. [α]25D = +11.4 (c = 1.74, CHCl3). IR 
(CHCl3): 3688, 3025, 3014, 2933, 1723, 1253, 1226, 1205, 1069, 838 cm-1. 1H NMR (CDCl3, 300 MHz): δ 
= 0.10 (s, 3H), 0.12 (s, 3H), 0.95 (t, J = 7.33 Hz, 3H) 1.00 (s, 9H), 1.40 (s, 3H), 1.43 (s, 3H), 2.11 (m, 2H), 
3.59 (dd, J = 8.21, 7.63 Hz, 1H), 4.09 (dd, J = 8.21, 6.15 Hz, 1H), 4.54 (m, 1H), 4.89 (t, J = 7.04 Hz), 5.72 
(dd, J = 15.24, 7.62 Hz, 1H), 6.10 (d, J = 15.24 Hz, 1H). 13C NMR (CDCl3, 75 MHz): δ = -3.64, -3.58, 14.0, 
18.5, 19.5, 26.00 (3C), 26.7, 69.5, 76.6, 109.1, 118.6, 125.0, 131.7, 146.5. Rf = 0.21 (EtOAc/n-hexane = 
1:40). HRMS: calcd. for C17H32O3Si (M + Na + O)+ 351.1962 found 351.1972. 
 
 
 
§ All silyl enol ethers described here show the M+Na+O peak in exact mass measurements; this peak is 
probably caused by formation of an oxidation side product, which also seems to be the main decomposition 
product of these compounds. 
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3E,5Z-(2S)-5-tert-Butyldimethylsilyloxy-1,2-isopropylidenedioxy-7-methyl-3,5-octadiene 119: Ketone 
116 (1.061 g, 5.00 mmol), Et3N (1.248 ml, 911 mg, 9.00 mmol) and TBSOTf (1.378 ml, 1.586 g, 6.00 
mmol) were reacted according to the general procedure for the synthesis of TBS enol ethers. The crude 
product was purified by flash chromatography on a small, Et3N-neutralized column (column dimensions 20 
x 1.5 cm, EtOAc/PE = 1:20) to give 119 (1.517 g, 4.65 mmol, 93%) as a colourless oil. [α]25D = +13.8 (c = 
1.61, CHCl3). IR (CHCl3): 1718 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 0.11 (s, 3H), 0.13 (s, 3H), 0.95 (d, J 
= 6.74 Hz, 6H) 1.00 (s, 9H), 1.39 (s, 3H), 1.42 (s, 3H), 2.69 (m, 1H), 3.59 (dd, J = 8.21, 7.63 Hz, 1H), 4.08 
(dd, J = 8.21, 6.15 Hz, 1H), 4.52 (m, 1H), 4.64 (d, J = 9.68 Hz), 5.70 (dd, J = 15.25, 7.63 Hz, 1H), 6.07 (d, J 
= 15.25 Hz, 1H). 13C NMR (CDCl3, 75 MHz): δ = -3.8, -3.7, 18.4, 22.8, 22.8, 25.0, 25.87, 25.94, 26.6, 69.5, 
76.7, 109.2, 124.2, 125.2, 132.2, 145.3. Rf = 0.62 (EtOAc/n-hexane = 1:10). HRMS: calcd. for C18H34O3Si 
(M+Na+O)+ 365.2119 found 365.2122. 
 
 
 (2R,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2-E-propenyl-tetrahydropyran-4-one 103: Diene 117 
(1.42 g. 5.00 mmol), crotonaldehyde (618 μl, 523 mg, 7.50 mmol) and BF3•Et2O (950 μl, 1.06 g, 7.50 
mmol) were reacted at -30°C for 1.5 h according to the general procedure for HDA reactions to give crude 
120 (1.69 g, 4.76 mmol, 95%) as a slightly yellow oil. TBS enol ether 120 (1,69 g, 4.76 mmol), acetic acid 
(680 μl, 715 mg, 11.9 mmol) and TBAF•3H2O (2.25 g, 7.14 mmol) were reacted according to the general 
procedure for desilylation of TBS enol ethers to give a slightly yellow oil, which was purified by flash 
chromatography (column dimensions 30 x 2.5 cm, EtOAc/PE = 1:6) to give a total of 943 mg (3.92 mmol, 
78% over two steps) of three diastereomers of 103 in a 6.1:3.1:1.0 ratio, the two major components being 
the two all-cis isomers. The major isomer was isolated in pure form, but the two minor components were 
inseparable. Characterization data below are for the major product. Major product 103a: [α]24D = +24.8 (c 
= 1.50, CHCl3). 1H NMR (CDCl3, 300 MHz): δ = 1.35 (s, 3H), 1.41 (s, 3H), 1.72 (dd, J = 6.64, 0.78 Hz, 
3H), 2.39 (dd, J = 14.44, 11.71 Hz, 1H), 2.40 (d, J = 7.81 Hz, 2H), 2.58 (m, 1H), 3.58 (ddd, J = 11.71, 6.25, 
2.73 Hz, 1H), 3.93 (dd, J = 8.20, 4.29 Hz, 1H), 4.05-4.17 (m, 3H), 5.54 (ddq, J = 15.22, 6.25, 1.56 Hz, 1H), 
5.74 (dqd, J = 15.22, 6.64, 0.78 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ = 17.6, 24.9, 26.5, 43.6, 47.6, 
66.7, 77.4, 77.45, 77.53, 109.6, 128.5, 129.8, 206.2. Rf = 0.42 (EtOAc/n-hexane = 1:4). HRMS: calcd. for 
C13H20O4 (M+Na)+ 263.1254 found 263.1254. Minor isomer 26b: Rf = 0.31 (EtOAc/n-hexane = 1:4). 
HRMS: calcd. for C13H20O4 (M+Na)+ 263.1254 found 263.1255. 
 
 
(2R,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2-(E-2-phenylethenyl)tetrahydro-pyran-4-one 127: 
Diene 117 (1.42 g. 5.00 mmol), cinnamaldehyde (944 μl, 991 mg, 7.50 mmol) and BF3•Et2O (950 μl, 1.06 
g, 7.50 mmol) were reacted at -30°C for 1.5 h according to the general procedure for HDA reactions to give 
crude 121 (2.34 g, containing excess cinnamaldehyde) as a slightly yellow oil. 1H NMR (CDCl3, 300 MHz): 
δ = 0.17 (s, 3H), 0.18 (s, 3H), 0.93 (s, 9H), 1.37 (s, 3H), 1.45 (s, 3H), 2.08 (ddd, J = 16.78, 5.86, 3.12 Hz, 
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1H), 2.24 (m, 1H), 3.95-4.09 (m, 2H), 4.21-4.31 (m, 2H), 5.00 (t, J = 1.56 Hz, 1H), 6.25 (dd, J = 16.00, 
5.86 Hz, 1H), 6.61 (d, J = 16.00 Hz, 1H), 7.22-7.59 (m, 5H). TBS enol ether 121 (2.34 g, max. 5 mmol), 
acetic acid (715 μl, 751 mg, 12.5 mmol) and TBAF•3H2O (2.37 g, 7.50 mmol) were reacted according to 
the general procedure for desilylation of TBS enol ethers to give a slightly yellow oil, which was purified 
by flash chromatography (column dimensions 30 x 2.5 cm, EtOAc/PE = 1:5) to give a total of 1289 mg 
(4.26 mmol, 85% over two steps) of three diastereomers of 127 in a 1.6:1.0:0.29 ratio, the two major 
components being the two all-cis isomers. The major isomer was isolated in pure form, but the two minor 
components were inseparable. Characterization data below are for the major product. Major product 127a: 
[α]25D = +41.9 (c = 1.45, CHCl3). IR (CHCl3): 3675, 3502, 3026, 3012, 2990, 2934, 2891, 1719, 1626, 
1496, 1454, 1383, 1373, 1228, 1203, 1156, 1069, 967, 845 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 1.357(s, 
3H), 1.43 (s, 3H), 2.45 (dd, J = 14.44, 11.71 Hz, 1H), 2.51 (m, 2H), 2.62 (dd, J = 14.44, 1.17 Hz, 1H), 3.66 
(ddd, J = 8.98, 6.24, 2.74 Hz, 1H), 3.96 (dd, J = 8.59, 4.68 Hz, 1H), 4.13 (dd J = 8.59, 6.64 Hz , 1H), 4.20 
(dt, J = 6.25, 5.07 Hz, 1H), 4.31 (m, 1H), 6.22 (dd, J = 16.00, 6.25 Hz, 1H), 6.60 (d, J = 16.00 Hz, 1H), 
7.23-7.39 (m, 5H). 13C NMR (CDCl3, 100 MHz): δ = 25.2, 26.7, 43.8, 47.8, 66.8, 77.57, 77.65, 77.68, 
109.8, 126.4, 127.5, 128.0, 128.5, 131.4, 135.8, 205.6. Rf = 0.33 (EtOAc/n-hexane = 1:4). HRMS: calcd. for 
C18H22O4 (M+Na)+ 325.1410 found 325.1408. Minor isomer 127b: Rf = 0.24 (EtOAc/n-hexane = 1:4). 
HRMS: calcd. for C18H22O4 (M+Na)+ 325.1410 found 325.1410. 
 
 
(2R,3S,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-methyl-2-E-propenyltetrahydro-pyran-4-one 
94: Diene 95(1.64 g. 5.50 mmol), crotonaldehyde (680 μl, 578 mg, 8.25 mmol) and BF3•Et2O (1045 μl, 
1.17 g, 8.25 mmol) were reacted at -30°C for 1.5 h according to the general procedure for HDA reactions to 
give crude 100 (1.97 g, 5.34 mmol, 97%) as a slightly yellow oil. 1H NMR (CDCl3, 300 MHz): δ = 0.16 (s, 
3H), 0.18 (s, 3H), 0.93 (s, 9H), 0.99 (d, J = 6.74 Hz, 3H), 1.35 (s, 3H), 1.42 (s, 3H), 1.71 (d, J = 6.45 Hz, 
3H), 1.93 (m, 1H), 3.89 (dd, J = 6.45, 5.86 Hz, 1H), 3.97-4.03 (m, 2H), 4.10 (dt, J = 4.10, 1.76 Hz, 1H), 
4.15 (dt, J = 6.74, 1.76 Hz, 1H), 4.80 (d, J = 1.76 Hz, 1H), 5.47 (ddd, J = 15.54, 5.86, 1.76 Hz, 1H), 5.66 
(ddq, J = 15.54, 6.45, 1.17 Hz). TBS enol ether 100 (1.92 g, 5.21 mmol), acetic acid (745 μl, 782 mg, 13.0 
mmol) and TBAF•3H2O (2.47 g, 7.82 mmol) were reacted according to the general procedure for 
desilylation of TBS enol ethers to give a slightly yellow oil, which was purified by flash chromatography 
(column dimensions 30 x 2.5 cm, EtOAc/PE = 1:4) to give a total of 1150 mg (4.52 mmol, 84% over two 
steps) of the two all-cis diastereomers of 94 in a 4:1 ratio. Major isomer 94a: [α]25D = +37.0 (c = 1.02, 
CHCl3). IR (CHCl3): 3026, 3011, 2988, 2936, 2883, 2455, 1712, 1455, 1382, 1373, 1230, 1202, 1151, 1069, 
968, 929, 844 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 1.13 (d, J = 7.04 Hz, 3H), 1.36 (s, 3H), 1.41 (s, 3H), 
1.73 (d, J = 6.45 Hz, 3H), 2.36-2.46 (m, 2H), 2.55 (dd, J = 14.66, 11.14 Hz, 1H), 3.57 (ddd, J = 11.14, 6.25, 
3.23 Hz, 1H), 3.95 (m, 1H), 4.09-4.17 (m, 3H), 5.54 (ddq, J = 15.24, 5.86, 1.47 Hz, 1H), 5.74 (dqd, J = 
15.24, 6.45, 1.17 Hz, 1H). 13C NMR (CDCl3, 75 MHz): δ = 11.1, 17.8, 25.0, 26.6, 40.2, 50.0, 66.7, 77.5, 
77.6, 79.4, 109.5, 127.1, 128.2, 210.2. HRMS: calcd. for C14H22O4 (M+Na)+ 277.1410 found 277.1411. 
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Minor isomer 94b: [α]25D = +24.1 (c = 1.07, CHCl3). IR (CHCl3): 3026, 3012, 2988, 2936, 2883, 1712, 
1675, 1455, 1382, 1373, 1228, 1203, 1155, 1069, 969, 847 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 1.13 (d, J 
= 7.03 Hz, 3H), 1.38 (s, 3H), 1.45 (s, 3H), 1.73 (d, J = 6.64 Hz, 3H), 2.17 (dd, J = 14.83, 3.12, 1.17 Hz, 
1H), 2.40 (qdd, J = 7.03, 3.12, 1.17 Hz, 1H), 2.63 (dd, J = 14.83, 11.71 Hz, 1H), 3.75 (ddd, J = 11.71, 4.68, 
3.12 Hz, 1H), 3.96 (dd, J = 8.58, 6.25 Hz, 1H), 4.05 (dd, J = 8.58, 6.64 Hz, 1H), 4.15 (m, 1H), 4.23 (m, 
1H), 5.45 (ddq, J = 15.54, 5.86, 1.76 Hz, 1H), 5.75 (dqd, J = 15.54, 6.45, 1.18 Hz, 1H). 13C NMR (CDCl3, 
100 MHz): δ = 11.2, 18.0, 25.3, 26.1, 39.0, 50.2, 65.0, 76.5, 76.7, 79.5, 109.6, 127.1, 128.3, 210.4. HRMS: 
calcd. for C14H22O4 (M+Na)+ 277.1410 found 277.1411. 
 
 
(2R,3S,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-methyl-2-(E-2-phenylethenyl)-tetrahydropyran-
4-one 128: Diene 95 (597 mg. 2.00 mmol), cinnamaldehyde (378 μl, 396 mg, 3.00 mmol) and BF3•Et2O 
(380 μl, 426 mg, 3.00 mmol) were reacted at -20°C for 4 h according to the general procedure for HDA 
reactions to give crude 122 (944 mg, containing excess cinnamaldehyde) as a slightly yellow oil. 1H NMR 
(CDCl3, 300 MHz): δ = 0.18 (s, 3H), 0.20 (s, 3H), 0.94 (s, 9H), 1.04 (d, J = 6.95 Hz, 1H), 1.38 (s, 3H), 1.43 
(s, 3H), 2.07 (m, 1H), 3.95 (dd, J = 6.40, 5.68 Hz, 1H), 4.05 (s, 1H), 4.07 (d, J = 1.46 Hz, 1H), 4.23 (dt, J = 
7.59, 1.65 Hz, 1H), 4.36 (m, 1H), 4.84 (d, J = 1.46 Hz, 1H), 6.16 (dd, J = 16.10, 5.31 Hz, 1H), 6.61 (d, J = 
16.10 Hz, 1H), 7.20-7.59 (m, 5H). TBS enol ether 122 (944 mg, max. 2.00 mmol), acetic acid (286 μl, 300 
mg, 5.00 mmol) and TBAF•3H2O (947 mg, 3.00 mmol) were reacted according to the general procedure for 
desilylation of TBS enol ethers to give a slightly yellow oil, which was purified by flash chromatography 
(column dimensions 30 x 2.5 cm, EtOAc/PE = 1:5) to give a total of 540 mg (1.71 mmol, 85% over two 
steps) of the two all-cis diastereomers of 128 in a 10:1 ratio. Major isomer 128a: [α]26D = +20.2 (c = 1.28, 
CHCl3). IR (CHCl3): 3674, 3028, 3011, 2989, 2937, 2887, 1714, 1636, 1578, 1496, 1383, 1373, 1231, 1069, 
968, 844 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 1.40 (d, J = 7.42 Hz), 1.36 (s, 3H), 1.43 (s, 3H), 2.49 (ddd, 
J = 14.83, 3.12, 1.18 Hz, 1H), 2.53 (m, 1H), 2.61 (dd, J = 14.83, 11.32 Hz, 1H), 3.66 (ddd, J = 11.32, 3.12, 
2.73 Hz, 1H), 4.00 (dd, J = 8.59, 5.68 Hz, 1H), 4.14-4.23 (m, 2H), 4.40 (ddd, J = 4.68, 2.73, 1.56 Hz, 1H), 
6.12 (dd, J = 16.00, 5.46 Hz, 1H), 6.64 (dd, J = 16.00, 1.17 Hz, 1H), 7.24-7.59 (m, 5H). 13C NMR (CDCl3, 
100 MHz): δ = 11.3, 25.0, 26.6, 40.1, 50.0, 66.7, 77.6, 77.7, 79.4, 109.8, 125.6, 126.4, 127.8, 128.5, 131.4, 
136.2, 210.2. Rf = 0.19 (EtOAc/n-hexane = 1:6). HRMS: calcd. for C19H24O4 (M+Na)+ 339.1567 found 
339.1563. Minor isomer 128b: IR (CHCl3): 3674, 3028, 3012, 2990, 2937, 1711, 1495, 1454, 1415, 1383, 
1373, 1230, 1174, 1070, 846 cm-1. TLC: Rf = 0.12 (EtOAc/n-hexane = 1:6). HRMS: calcd. for C19H24O4 
(M+Na)+ 339.1567 found 339.1563. 
 
 
(2R,3S,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-ethyl-2-E-propenyl-tetrahydropyran-4-one 104: 
Diene 118 (1.72 g. 5.50 mmol), crotonaldehyde (680 μl, 578 mg, 8.25 mmol) and BF3•Et2O (1045 μl, 1.17 
g, 8.25 mmol) were reacted at -30°C for 1.5 h according to the general procedure for HDA reactions to give 
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crude 123 (2.01 g, 5.27 mmol, 96%) as a slightly yellow oil. 1H NMR (CDCl3, 300 MHz): δ = 0.18 (s, 6H), 
0.92 (s, 9H), 0.91-0.96 (m, 3H), 1.35 (s, 3H), 1.42 (s, 3H), 1.40-1.46 (m, 1H), 1.58-1.65 (m, 1H), 1.72 (dt, J 
= 6.45, 1.17 Hz, 3H), 1.84 (m, 1H), 3.86 (dd, J = 6.75, 5.86 Hz, 1H), 3.96-4.05 (m, 2H), 4.09-4.13 (m, 2H), 
4.88 (d, J = 1.47 Hz, 1H), 5.49 (ddq, J = 15.24, 5.86, 1.46 Hz, 1H), 5.68 (dqd, J = 15.24, 6.45, 1.17 Hz). 
TBS enol ether 123 (1.93 g, 5.05 mmol), acetic acid (723 μl, 759 mg, 12.6 mmol) and TBAF•3H2O (2.39 g, 
7.58 mmol) were reacted according to the general procedure for desilylation of TBS enol ethers to give a 
slightly yellow oil, which was purified by flash chromatography (column dimensions 30 x 2.5 cm, 
EtOAc/PE = 1:5) to give a total of 1184 mg (4.41 mmol, 84% over two steps) of the two all-cis 
diastereomers of 104 in a 7:1 ratio. Major isomer 104a: [α]24D = -54.0 (c = 1.13, CHCl3). IR (CHCl3): 3466 
(broad), 3026, 3012, 2970, 2937, 2878, 1712, 1604, 1457, 1373, 1229, 1069, 967, 845 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ = 0.83 (t, J = 7.04 Hz, 3H), 1.35 (s, 3H), 1.40 (s, 3H),1.61-1.77 (m, 2H), 1.73 (d, J = 
6.64 Hz, 3H), 2.22 (ddd, J = 10.93, 4.68, 3.12 Hz, 1H), 2.42-2.48 (m, 2H), 3.56 (m, 1H), 3.94 (m, 1H), 
4.09-4.15 (m, 3H), 5.46 (ddq, J = 15.61, 5.85, 1.56 Hz, 1H), 5.72 (dqd, J = 15.61, 6.64, 1.18 Hz, 1H). 13C 
NMR (CDCl3, 100 MHz): δ = 11.6, 18.0, 18.9, 25.2, 26.7, 41.1, 58.0, 66.9, 77.7, 77.9, 80.0, 109.6, 127.3, 
128.0, 209.8. Rf = 0.47 (EtOAc/n-hexane = 1:6). Minor isomer 104b: [α]24D = +45.1 (c = 1.09, CHCl3). IR 
(CHCl3): 3446 (broad), 3025, 2969, 2936, 2878, 1718, 1610, 1457, 1383, 1229, 1069, 968, 855 cm-1. 1H 
NMR (CDCl3, 400 MHz): δ = 0.83 (t, J = 7.40 Hz, 3H), 1.38 (s, 3H), 1.45 (s, 3H), 1.62-1.74 (m, 2H), 1.72 
(dt, J = 6.64, 1.17 Hz, 3H), 2.18 (ddd, J = 14.44, 3.12, 1.17 Hz, 1H), 2.22 (m 1H), 2.57 (dd, J = 14.05, 
11.71 Hz, 1H), 3.73 (ddd, J = 11.71, 4.68, 3.12 Hz, 1H), 3.96 (dd, J = 8.59, 6.24 Hz, 1H), 4.05 (dd, J = 
8.59, 6.64 Hz, 1H), 4.14 (dt, J = 4.68, 1.17 Hz, 1H), 4.23 (ddd, J = 6.64, 6.24, 4.68 Hz, 1H), 5.50 (ddq, J = 
15.22, 5.85, 1.56 Hz, 1H), 5.72 (dqd, J = 15.22, 6.63, 1.18 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ = 11.6, 
18.0, 18.8, 25.3, 26.2, 39.9, 58.1, 65.0, 76.7, 76.8, 78.0, 109.7, 127.4, 128.0, 209.9. Rf = 0.40 (EtOAc/n-
hexane = 1:6).  
 
 
(2R,3S,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-ethyl-2-(E-2-phenylethenyl)-tetrahydropyran-4-
one 129: Diene 118 (350 mg. 1.12 mmol), cinnamaldehyde (184 μl, 193 mg, 1.46 mmol) and BF3•Et2O 
(143 μl, 160 mg, 1.12 mmol) were reacted at -20°C for 2.5 h according to the general procedure for HDA 
reactions to give crude 124 (494 mg, 1.11 mmol, 99%) a slightly yellow oil. 1H NMR (CDCl3, 300 MHz): δ 
= 0.19 (s, 3H), 0.20 (s, 3H), 0.94 (s, 9H), 0.92-0.96 (m, 3H), 1.38 (s, 3H), 1.46 (s, 3H), 1.52-1.66 (m, 2H), 
1.99 (m, 1H), 3.93 (dd, J = 6.74, 5.57 Hz, 1H), 4.05 (d, J = 0.88 Hz, 1H), 4.07 (d, J = 2.05 Hz, 1H), 4.19 
(ddd, J = 7.03, 2.05, 1.76 Hz, 1H), 4.36 (m, 1H), 4.91 (d, J = 1.76 Hz, 1H), 6.21 (dd, J = 16.13, 5.28 Hz, 
1H), 6.61 (dd, J = 16.13, 1.47 Hz), 7.28-7.46 (m, 5H). TBS enol ether 124 (489 mg, 1.10 mmol), acetic acid 
(314 μl, 5.50 mmol) and TBAF•3H2O (431 mg, 1.65 mmol) were reacted according to the general 
procedure for the desilylation of a TBS enol ether. The product was purified by flash chromatography 
(column dimensions: 32 x 3 cm, EtOAc/PE = 1:5) to give a total of 270 mg (0.82 mmol, 74% over two 
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steps) of the two all-cis diastereomers of 129 in a 8:1 ratio. Major isomer 129a: [α]24D = -8.4 (c = 1.34, 
CHCl3). IR (CHCl3): 3026, 2988, 2966, 2936, 2878, 1714, 1496, 1456, 1382, 1373, 1260, 1229, 1175, 1069, 
844 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 0.84 (t, J = 7.42 Hz, 3H), 1.38 (s, 3H), 1.43 (s, 3H), 1.66-1.79 
(m, 2H), 2.34 (m, 1H), 2.48-2.57 (m, 2H), 3.64 (m, 3H), 3.99 (dd, J = 8.20, 4.69 Hz, 1H), 4.15 (dd, J = 
8.20, 6.24 Hz, 1H), 4.20 (dt, 6.25, 4.69 Hz, 1H), 4.38 (m, 3H), 6.13 (dd, J = 16.00, 5.47 Hz, 1H), 6.63 (dd, 
J = 16.00, 1.17 Hz, 1H), 7.23-7.39 (m, 5H). 13C NMR (CDCl3, 75 MHz): δ = 11.6, 19.1, 25.1, 26.7, 41.0, 
57.9, 66.8, 77.7, 78.0, 79.8, 109.7, 125.8, 126.3, 127.7, 128.4, 130.9, 136.1, 209.4. Rf = 0.36 (EtOAc/n-
hexane = 1:6). HRMS: calcd. for C20H26O4 (M+Na)+ 353.1723 found 353.1717. Minor isomer 129b: [α]24D 
= +24.9 (c = 1.45, CHCl3). IR (CHCl3): 3674, 3419 (broad), 3026, 3012, 2975, 2933, 2877, 1715, 1495, 
1450, 1382, 1228, 1109, 967, 843 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 0.84 (t, J = 7.41 Hz, 3H), 1.40 (s, 
3H), 1.48 (s, 3H), 1.70-1.78 (m, 2H), 2.23 (ddd, J = 14.44, 2.74, 1.18 Hz, 1H), 2.35 (m, 1H), 2.65 (dd, J = 
14.44, 11.71 Hz, 1H), 3.80 (dddd, J = 11.71, 5.86, 4.30, 2.74 Hz, 1H), 4.03 (dd, J = 8.58, 6.25 Hz, 1H), 4.09 
(dd, J = 8.58, 6.64 Hz, 1H), 4.28 (dt, 6.24, 4.68 Hz, 1H), 4.38 (m, 1H), 6.15 (dd, J = 16.00, 5.47 Hz, 1H), 
6.65 (dd, J = 16.00, 1.17 Hz, 1H), 7.23-7.39 (m, 5H). Rf  = 0.24 (EtOAc/n-hexane = 1:6).  
 
 
(2R,3S,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-isopropyl-2-E-propenyl-tetrahydropyran-4-one 
130: Diene 119 (725 mg. 2.00 mmol), crotonaldehyde (247 μl, 210 mg, 3.00 mmol) and BF3•Et2O (380 μl, 
426 mg, 3.00 mmol) were reacted at -20°C for 2.5 h according to the general procedure for HDA reactions 
to give crude 125 a slightly yellow oil which was used immediately in the next step. 1H NMR (CDCl3, 300 
MHz): δ = 0.17 (s, 3H), 0.19 (s, 3H), 0.93 (s, 9H), 0.89-1.03 (m, 6H), 1.35 (s, 3H), 1.41 (s, 3H), 1.72 (dt, J 
= 6.16, 1.17 Hz, 3H), 1.84 (m, 1H), 2.01 (m, 1H), 3.85 (dd, J = 7.62, 5.86 Hz, 1H), 4.00-4.12 (m, 4H), 4.98 
(d, J = 1.76 Hz, 1H), 5.50 (ddq, J = 15.54, 5.28, 1.47 Hz, 1H), 5.66 (dqd, J = 15.54, 6.45, 0.88 Hz). TBS 
enol ether 125 (max. 865 mg, max. 2.00 mmol), acetic acid (286 μl, 300 mg, 5.00 mmol) and TBAF•3H2O 
(947 mg, 3.00 mmol) were reacted according to the general procedure for the desilylation of a TBS enol 
ether. The product was purified by flash chromatography (column dimensions: 25 x 2 cm, EtOAc/PE = 1:5) 
to give a total of 434 mg (1.54 mmol, 77% over two steps) of the two all-cis diastereomers of 130 in a 4:1 
ratio. Major isomer 130a: [α]25D = +41.9 (c = 0.87, CHCl3). IR (CHCl3): 3688, 3460 (broad), 3026, 3011, 
2964, 2934, 2875, 1717, 1601, 1457, 1383, 1374, 1231, 1069 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 0.94 
(d, J = 7.64 Hz, 6H), 1.35 (s, 3H), 1.40 (s, 3H), 1.73 (ddd, J = 6.45, 1.47, 1.17 Hz, 3H), 2.18 (m, 1H), 2.37 
(dd, J = 14.95, 11.14 Hz, 1H), 2.44 (d, J = 6.74 Hz, 1H), 2.57 (ddd, J = 14.95, 2.93, 0.88 Hz, 1H), 3.66 (m, 
1H), 3.96 (m, 1H), 4.11 (m, 2H), 4.18 (m, 1H), 5.53 (ddq, J = 15.22, 5.86, 1.76 Hz, 1H), 5.70 (dqd, 15.22, 
6.45, 1.47 Hz, 1H). 13C NMR (CDCl3, 75 MHz): δ = 17.9, 21.0, 23.2, 25.3, 25.7, 26.2, 42.8, 61.7, 65.0, 
76.2, 76.8, 80.2, 109.7, 127.1, 128.2, 209.1. Rf = 0.44 (EtOAc/n-hexane = 1:6). Minor isomer 130b: [α]26D 
= +46.8 (c = 1.78, CHCl3). IR (CHCl3): 3670, 3496 (broad), 3027, 2965, 2934, 2875, 1712, 1599, 1456, 
1418, 1382, 1373, 1231, 1155, 1070, 971, 849 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 0.94 (d, J = 6.64 Hz, 
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3H), 0.97 (d, J = 6.24 Hz, 3H), 1.38 (s, 3H), 1.44 (s, 3H), 1.73 (ddd, J = 6.64, 1.56, 1.17 Hz, 3H), 2.20 (m, 
1H), 2.31 (ddd, J = 14.83, 3.13, 1.17Hz, 1H), 2.47 (dd, J = 14.83, 11.71 Hz, 1H), 3.75 (ddd, J = 11.71, 4.69, 
3.12 Hz, 1H), 3.95 (dd, J = 8.19, 6.63 Hz, 1H), 4.05 (dd, J = 8.19, 6.63 Hz, 1H), 4.18-4.21 (m, 2H), 5.54 
(ddq, J = 15.22, 5.86, 1.56 Hz, 1H), 5.75 (dqd, J = 15.22, 6.64, 1.17 Hz, 1H). 13C NMR (CDCl3, 100 MHz): 
δ = 17.8, 20.9, 23.1, 25.2, 25.6, 26.1, 42.8, 61.6, 64.9, 76.2, 76.8, 80.2, 109.7, 127.2, 128.3, 209.4. Rf = 0.33 
(EtOAc/n-hexane = 1:6). 
 
 
(2R,3S,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-isopropyl-2-(E-2-phenylethenyl)tetrahydro-
pyran-4-one 131: Diene 119 (725 mg. 2.00 mmol), cinnamaldehyde (378 μl, 396 mg, 3.00 mmol) and 
BF3•Et2O (380 μl, 426 mg, 3.00 mmol) were reacted at -20°C for 4 h according to the general procedure for 
HDA reactions to give crude 126 as a slightly yellow oil. 1H NMR (CDCl3, 400 MHz): δ = 0.20 (s, 3H), 
0.21 (s, 3H), 0.94 (s, 9H), 0.96 (d, J = 7.02 Hz, 3H), 1.03 (d, J = 7.03 Hz, 3H), 1.37 (s, 3H), 1.44 (s, 3H), 
1.97-2.03 (m, 2H), 3.91 (dd, 7.41, 5.46 Hz, 1H), 4.06-4.13 (m, 3H), 4.36 (m, 1H), 5.02 (d, J = 1.95 Hz, 1H), 
6.22 (dd, J = 16.00, 1.56 Hz, 1H), 6.60 (dd, J = 16.00, 4.69 Hz, 1H), 7.22-7.58, (m, 5H). TBS enol ether 
126 (max. 2.00 mmol), acetic acid (286 μl, 300 mg, 5.00 mmol) and TBAF•3H2O (947 mg, 3.00 mmol) 
were reacted according to the general procedure for desilylation of TBS enol ethers to give a slightly yellow 
oil, which was purified by flash chromatography (column dimensions 30 x 2.5 cm, EtOAc/PE = 1:6) to give 
a total of 472 mg (1.37 mmol, 69% over two steps) of the two all-cis diastereomers of 131 in a 4:1 ratio, 
accompanied by a small amount of a third, unidentified diastereomer and some  desilylated diene, the latter 
two being inseparable. Major isomer 131a: [α]25D = +10.2 (c = 0.40, CHCl3). IR (CHCl3): 3687, 3499, 
3025, 3013, 2964, 2934, 2874, 1784, 1732, 1603, 1452, 1230, 1213, 1169, 1090 cm-1. 1H NMR (CDCl3, 400 
MHz): δ = 0.93 (d, J = 6.64 Hz, 3H), 0.99 (d, J = 6.44 Hz, 3H), 1.38 (s, 3H), 1.43 (s, 3H), 2.22 (m, 1H), 
2.27 (ddd, J = 7.03, 3.12, 1.17 Hz, 1H), 2.44 (dd, J = 14.83, 11.51 Hz, 1H), 2.61 (ddd, J = 14.83, 3.13, 1.17 
Hz, 1H), 3.66 (ddd, J = 11.51, 6.44, 3.12, Hz, 1H), 4.00 (m, 1H), 4.17 (m, 1H), 4.41 (ddd, J = 5.27, 3.12, 
1.76 Hz, 1H), 6.18 (dd, J = 16.00, 5.27 Hz, 1H), 6.64 (dd, J = 16.00, 1.56 Hz), 7.23-7.39 (m, 5H). 13C NMR 
(CDCl3, 75 MHz): δ = 21.0, 23.4, 25.1, 25.8, 26.7, 43.8, 62.0, 66.8, 77.5, 77.8, 80.0, 109.7, 126.2, 126.6, 
127.6, 128.5, 129.8, 136.3, 208.7. Rf = 0.34 (EtOAc/n-hexane =1:6). HRMS: calcd. for C21H28O4 (M+Na)+ 
367.1880 found 367.1874. Minor Isomer 131b: [α]25D = +16.7 (c = 1.165, CHCl3). IR (CHCl3): 3670, 3408 
(broad), 3027, 3011, 2964, 2934, 2874, 1711, 1603, 1495, 1455, 1366, 1229, 1072, 909, 848 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ = 0.96 (d, J = 7.02 Hz, 3H), 0.98 (d, J = 6.63 Hz, 3H), 1.40 (s, 3H), 1.48 (s, 3H), 2.23 
(m, 1H), 2.32 (ddd, J = 7.03, 3.12, 1.17 Hz, 1H), 2.35 (ddd, J = 14.83, 3.12, 1.17 Hz, 1H), 2.56 (dd, J = 
14.83, 11.71 Hz, 1H), 3.82 (ddd, J = 11.71, 4.29, 3.12 Hz, 1H), 4.03 (dd, J = 8.19, 6.64 Hz, 1H), 4.08-4.15 
(m, 2H), 4.27 (td, 6.64, 4.29 Hz, 1H), 4.43 (m, 1H), 6.21 (dd, J = 16.00, 5.47 Hz, 1H), 6.68 (dd, J = 16.00, 
1.56 Hz, 1H), 7.24-7.40 (m, 5H). 13C NMR (CDCl3, 100 MHz): δ = 21.0, 23.3, 25.3, 25.9, 26.1, 42.7, 62.0, 
65.0, 76.5, 76.8, 80.0, 109.9, 126.4, 126.8, 127.7, 128.6, 130.1, 136.5, 209.2. Rf = 0.22 (EtOAc/n-hexane 
=1:6).  
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(2R,3S,4R,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-methyl-2-E-propenyl-tetrahydropyran-4-ol 
102b: To a solution of 94a (53.6 mg, 0.211 mmol) in MeOH (5.0 ml) at 0°C was added NaBH4 (16 mg, 
0.422 mmol). The reaction was stirred overnight at room temperature, after which the reaction was 
complete as judged by TLC. The volume was reduced in vacuo and the mixture was diluted with sat. aq. 
NH4Cl (5 ml) and water (15 ml) and extracted with tBuOMe (3 x 25 ml). The combined organic fractions 
were dried (Na2SO4), filtered, concentrated in vacuo, and purified by flash chromatography (20 x 1.5 cm, 
EtOAc/PE = 1:3) to give 102b (54.2 mg, 0.211 mmol, 100%) as a colorless oil. [α]25D = -20.5 (c = 1.375, 
CHCl3). IR (CHCl3): 3609, 3207 (broad), 3025, 3012, 2987, 2933, 1455, 1382, 1372, 1228, 1205, 1149, 
1068, 1032, 969, 845 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 0.87 (d, J = 6.64 Hz, 3H), 1.35 (s, 3H), 1.41 
(s, 3H), 1.42 (m, 3H), 1.86-1.91 (m, 2H), 3.32 (ddd, J = 11.32, 7.03, 2.34 Hz, 1H), 3.86 (pseudo d, J = 5.46 
Hz, 1H), 3.91-3.98 (m, 2H), 4.00 (dt, J = 5.86, 5.07 Hz, 1H), 4.08 (m, 1H), 5.44 (ddq, J = 15.22, 5.46, 1.56 
Hz, 1H), 5.65 (dqd, J = 15.22, 6.64, 1.56 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ = 5.3, 18.0, 25.4, 26.8, 
31.5, 39.5, 67.1, 70.7, 76.8, 77.7, 79.3, 109.2, 126.6, 129.4. Rf = 0.30 (EtOAc/n-hexane = 1:2). HRMS: 
calcd. for C14H24O4 (M + Na)+ 279.1567 found 279.1564. 
 
 
(2R,3S,4S,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-methyl-2-E-propenyl-tetrahydropyran-4-ol 
102a: To a solution of ketone 94a (51.4 mg, 0.202 mmol) in THF (5 ml) was added at -78°C K-Selectride® 
(1M in THF, 303 μl, 0.303 mmol). The mixture was stirred at that temperature for 30 min, allowed to warm 
to -30°C over a period of 2.5 h and then quenched by addition of 0.2N aq. NaOH (3 ml) and 30% aq. H2O2 
(0.5 ml). The mixture was diluted with H2O and extracted with tBuOMe (3 x 20 ml). The combined organic 
fractions were dried (Na2SO4), filtered, concentrated in vacuo and purified by flash chromatography 
(column dimensions 25 x 1.5 cm, EtOAc/PE = 1:3) to give axial alcohol 102a (10.5 mg, 0.041 mmol, 20%) 
and equatorial alcohol 102b (41.5 mg, 0.162 mmol, 80%, characterization see above) as colourless oils. 1H 
NMR (CDCl3, 400 MHz): δ = 0.92 (d, J = 7.13 Hz, 3H), 1.35 (s, 3H), 1.41 (s, 3H), 1.50-1.68 (m, 3H), 1.70 
(ddd, J = 6.40, 1.46, 1.10 Hz, 3H), 3.74 (dd, J = 14.09, 6.95 Hz, 1H), 3.85-4.11 (m, 4H), 4.38 (m, 1H), 5.42 
(ddq, J = 15.37, 5.86, 1.46 Hz, 1H), 5.66 (dqd, J = 15.37, 6.40, 1.28 Hz, 1H). Rf = 0.38 (EtOAc/n-hexane = 
1:2). HRMS: calcd. for C14H24O4 (M + Na)+ 279.1567 found 279.1564. 
 
 
(2R,4S,6R)-2-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)-6-E-propenyltetrahydropyran-4-ol 105b: To a 
solution of ketone 103 (31.2 mg, 0.128 mmol) in MeOH (5 ml) was added NaBH4 (10 mg, 0.26 mmol) and 
the mixture was stirred for 1.5 h at rt. The volume was reduced to ±1 ml in vacuo and the residue was 
diluted with Et2O (75 ml), washed with sat. aq. NH4Cl (25 ml) and brine (25 ml), dried (Na2SO4), filtered, 
and concentrated in vacuo to give 105b (32 mg, 0.132 mmol, quant.; 4S:4R = 91:9) as a colorless oil. 1H 
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NMR (CDCl3, 200 MHz): δ = 1.35 (s, 3H), 1.41 (s, 3H), 1.71 (d, J = 6.4 Hz, 3H), 1.88 (m, 1H), 1.97 (m, 
1H), 2.17 (m, 1H), 3.30 (m, 1H), 3.75-3.90 (m, 2H), 3.95 (m, 1H), 4.01 (m, 1H), 4.08 (m, 1H), 5.50 (m, 
1H), 5.68 (m, 1H) ppm. 
 
 
(2R,4R,6R)-2-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)-6-E-propenyltetrahydropyran-4-ol 105a: To a 
solution of ketone 103 (112 mg, 0.466 mmol) in THF (10 ml) was added at -78°C K-Selectride® (1 M 
solution in THF, 699 μl, 0.699 mmol). The mixture was stirred for 2 h at −78°C. The reaction was 
quenched by addition of 30% aq. H2O2 (0.5 ml) and 1N NaOH (3 ml), and diluted with H2O (20). The 
mixture was extracted with tBuOMe (3 × 15 ml). The combined organic extracts were dried (Na2SO4), 
filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (column 
dimensions 25 × 2 cm, EtOAc/PE = 1:2) to give 105a (27 mg, 0.111 mmol, 24%; 4R:4S = 89:11) as a 
colorless oil. [α]27D = + 11.1 (c = 1.35, CHCl3). 1H NMR (CDCl3, 400 MHz): δ = 1.35 (s, 3H), 1.42 (s, 3H), 
1.53-1.66 (m, 2H), 1.69 (d, J = 7.03 Hz, 3H), 1.69-1.73 (m, 1H), 1.87 (dd, J = 14.05, 3.12 Hz, 1H), 3.78 
(ddd, J = 11.71, 7.02, 1.95 Hz, 1H), 3.91 (dd, J = 8.20, 5.47 Hz, 1H), 4.00 (td, J = 6.64, 5.47 Hz, 1H), 4.09 
(dd, J = 8.20, 6.25 Hz, 1H), 4.26 (m, 1H), 4.32 (m, 1H), 5.47 (ddq, J = 15.22, 6.25, 1.56 Hz, 1H), 5.69 (dqd, 
J = 15.22, 6.64, 1.18 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 17.8, 25.2, 26.6, 34.5, 38.4, 64.1, 
67.2, 72.3, 72.6, 78.0, 109.4, 127.3, 131.6 ppm. Rf = 0.40 (EtOAc/n/hexane = 1:2). 
 
 
(2R,3S,4S,6R)-6-((1R)-1,2-dihydroxyethyl)-3-methyl-2-E-propenyl-tetrahydropyran-4-ol 101b: To a 
solution of 102a (10.5 mg, 0.041 mmol) in acetone/water 1:1 (1.0 ml) was added PPTS (1.0 mg, 0.0041 
mmol). The mixture was stirred for 2 d at room temperature, then diluted with brine and extracted three 
times with tBuOMe. The combined organic fractions were dried (NaSO4), filtered, concentrated in vacuo, 
and purified by flash chromatography (20 x 1 cm, CH2Cl2/MeOH = 20:1) to give 101b (5.1 mg, 0.024 
mmol, 58%) as a colorless oil. IR (CHCl3): 3675, 3606, 3416 (broad), 3025, 3011, 2967, 2925, 2884, 1712, 
1673, 1601, 1450, 1436, 1379, 1230, 1203, 1076, 1050, 1006, 969, 933, 883 cm-1. 1H NMR (CDCl3, 400 
MHz): δ = 0.91 (d, J = 7.03 Hz, 3H), 1.65-1.78 (m, 3H), 1.71 (dd, J = 6.63, 1.17 Hz, 3H), 2.46 (bs, 1H), 
2.65 (bs, 1H), 3.67 (m, 3H), 3.94-4.03 (m, 2H), 4.41 (m, 1H), 5.41 (ddq, J = 15.22, 6.24, 1.56 Hz, 1H), 5.66 
(dqd, J = 15.22, 6.63, 1.17 Hz, 1H). HRMS: calcd. for C11H20O4 (M + Na)+ 239.1254 found 239.1251. 
 
 
(2R,3S,4R,6R)-6-((R)-1,2-Dihydroxyethyl)-3-methyl-2-E-propenyltetrahydropyran-4-ol 107b: To a 
solution of acetonide 102b (277 mg, 1.09 mmol) in MeOH (20 ml) was added PPTS•H2O (274 mg, 1.09 
mmol). The mixture was stirred for 3 d at rt. The mixture was diluted with brine (50 ml) and extracted with 
tBuOMe (3 × 50 ml). The combined organic extracts were dried (Na2SO4), filtered, and concentrated in 
vacuo. Purification by flash chromatography (column dimensions 25 × 2 cm, CH2Cl2/MeOH = 10.1) 
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afforded 107b (192 mg, 0.89 mmol, 82 %) as a viscous, turbid oil, accompanied by the starting material (43 
mg, 0.17 mmol, 16%). The yield based on recovered starting material is therefore 97%. [a]21D = −22.3 (c = 
1.14, CHCl3). 1H NMR (CDCl3, 400 MHz): δ = 0.88 (d, J = 7.03 Hz, 3H), 1.50-1.70 (m, 3H), 1.71 (d, J = 
6.24 Hz, 3H), 1.92 (t, J = 6.64 Hz, 1H, OH), 2.30, (bs, 1H, OH), 2.60 (bs, 1H, OH), 3.56 (ddd, J = 11.71, 
4.29, 2.73 Hz, 1H), 3.68-3.73 (m, 2H), 3.79 (dd, J = 11.31, 5.46 Hz, 1H), 3.87 (d, J = 5.07 Hz, 1H), 3.97 
(dt, J = 11.32, 4.68 Hz, 1H), 5.44 (ddq, J = 15.62, 5.47, 1.57 Hz, 1H), 5.65 (dqd, J = 15.61, 6.64, 1.17 Hz, 
1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 5.32, 17.98, 30.44, 39.47, 63.48, 70.58, 73.41, 77.50, 79.49, 
126.93, 129.25 ppm. Rf = 0.57 (CH2Cl2/MeOH = 9:1). 
 
 
(2R,3S,4R,6R)-4-tert-Butyldimethylsilyloxy-6-((R)-1,2-bis(tert-butyldimethylsilyloxy)-ethyl)-3-methyl-
2-E-propenyltetrahydropyran 107a: To a solution of triol 107b (131 mg, 0.606 mmol) and 2,6-lutidine 
(421 μl, 389 mg, 3.63 mmol) in CH2Cl2 (15 ml) was added at -78°C TBSOTf (626 μl, 721 mg, 2.73 mmol). 
The mixture was allowed to warm to rt and the reaction was quenched by addition of sat. aq. NaHCO3 (10 
ml).. The phases were separated and the aqueous phase was extracted with CH2Cl2 (2 × 15 ml). The 
combined organic extracts were washed with dilute aq. NH4Cl (20 ml) and brine (25 ml), dried (Na2SO4), 
filtered, and concentrated in vacuo. Purification by flash chromatography (column dimensions 25 × 2 cm, 
EtOAc/PE = 1:50) afforded 107a (334 mg, 0.597mmol, 99%) as a colorless oil. 1H NMR (CDCl3, 400 
MHz): δ = 0.02 (s, 3H), 0.03 (s, 3H), 0.04 (s, 3H), 0.05 (s, 3H), 0.07 (s, 3H), 0.09 (s, 3H), 0.84 (d, J = 7.03 
Hz, 3H), 0.88 (s, 9H), 0.89 (s, 18H), 1.51-1.61 (m, 2H), 1.70 (d, J = 6.64 Hz, 3H), 1.70-1.74 (m, 1H), 3.42 
(dt, J = 10.14, 4.30 Hz, 1H), 3.55 (d, J = 5.47 Hz, 2H), 3.77 (q, J = 5.07 Hz, 1H), 3.81-3.89 (m, 2H), 5.43 
(ddq, J = 15.61, 5.47, 1.17 Hz, 1H), 5.64 (dq, J = 15.61, 6.24 Hz, 1H) ppm. Rf = 0.76 (EtOAc/n-hexane = 
1:20). 
 
 
(2R,3S,4R,6R)-4-tert-Butyldimethylsilyloxy-6-((R)-1-(tert-butyldimethylsilyloxy)-2-(hydroxy)ethyl)-3-
methyl-2-E-propenyltetrahydropyran 107: Concentrated aq. HCl (10 ml) and CHCl3 (50 ml) were mixed 
in a separatory funnel and shaken exhaustively for 5 min. The organic phase (5 ml) was then poured on tris 
TBS ether 107a (368 mg, 0.658 mmol) and the mixture was stirred for 20 h at rt. The mixture was diluted 
with sat. aq. NaHCO3 (50 ml) and extracted with CHCl3 (3 × 25 ml). The combined organic extracts were 
dried (Na2SO4), filtered, and concentrated in vacuo. Purification by flash chromatography (column 
dimensions 30 × 3 cm, EtOAc/PE = 1:12) afforded 107 (267 mg, 0.600 mmol, 91%) as a colorless oil. 1H 
NMR (CDCl3, 400 MHz): δ = 0.05 (s, 3H), 0.10 (s, 3H), 0.10, (s, 6H), 0.85 (d, J = 7.02 Hz, 3H), 0.88 (s, 
9H), 0.89 (s, 9H), 1.40 (t, J = 6.25 Hz, 1H), 1.69 (d, J = 6.25 Hz, 3H), 1.73-1.78 (m, 2H), 2.47 (dd, J = 8.98, 
2.73 Hz, 1H, OH), 3.41 (ddd, J = 11.71, 6.63, 2.34 Hz, 1H), 3.62 (d, J = 6.25 Hz, 2H), 3.65-3.73 (m, 1H), 
3.85-3.89 (m, 2H), 5.43 (ddq, J = 15.61, 5.47, 1.56 Hz, 1H), 5.62 (dq, J = 15.61, 6.64 Hz, 1H) ppm. 13C 
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NMR (CDCl3, 100 MHz): δ = -4.8, -4.7, -4.4, -3.6, 5.5, 17.8, 18.0, 18.1, 25.6, 25.8, 32.5, 40.3, 65.3, 71.3, 
74.0, 78.1, 79.6, 126.5, 129.8 ppm. Rf = 0.38 (EtOAc/n-hexane = 1:10). 
 
 
(2R,3S,4R,6R)-4-tert-Butyldimethylsilyloxy-6-((S)-1-(tert-butyldimethylsilyloxy)-1-(formyl)methyl)-3-
methyl-2-E-propenyltetrahydropyran 108: To a solution of alcohol 107 (133 mg, 0.300 mmol) in CH2Cl2 
(5 ml) was added Dess-Martin periodinane (153 mg, 0.360 mmol) and the mixture was stirred for 2 h at rt. 
The mixture was diluted with sat. aq. NaHCO3 (50 ml) and extracted with tBuOMe (3 × 50 ml). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The residue was 
purified by flash chromatography (column dimensions: 25 × 2 cm, EtOAc/PE = 1:15) to give 108 (111 mg, 
0.250 mmol, 83%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.04 (s, 6H), 0.10 (s, 6H), 0.85 (d, 
J = 7.02 Hz, 3H), 0.88 (s, 9H), 0.93 (s, 9H), 1.45 (ddd, J = 12.49, 4.69, 2.34 Hz, 1H), 1.66 (dd, J = 12.49, 
11.71 Hz, 1H), 1.70 (d, J = 6.64 Hz, 3H), 1.75 (dd, J = 6.63, 6.24 Hz, 1H), 3.63 (ddd, J = 11.71, 5.07, 2.34 
Hz, 1H), 3.84-3.89 (m, 2H), 4.09 (d, J = 5.07 Hz, 1H), 5.42 (ddq, J = 15.61, 5.46, 1.56 Hz, 1H), 5.64 (dq, 
J = 15.61, 6.64 Hz, 1H) ppm. Rf = 0.58 (EtOAc/n-hexane = 1:10). HRMS calcd. for C23H46O4Si2 (M+Na)+ 
465.2827 found 465.2835. 
 
 
(2S,3R,4S,6S)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-methyl-2-E-propenyltetrahydropyran-4-ol 
109: To a solution of 94b (762 mg, 3.00 mmol) in MeOH (15 ml) at 0°C was added NaBH4 (113 mg, 3.00 
mmol). The reaction was stirred overnight at room temperature, after which the reaction was complete as 
judged by TLC. The volume was reduced in vacuo and the mixture was diluted with sat. aq. NH4Cl (50 ml) 
and brine (100 ml) and extracted with tBuOMe (3 × 100 ml). The combined organic fractions were dried 
(Na2SO4), filtered, concentrated in vacuo, and purified by flash chromatography (25 × 2.5 cm, EtOAc/PE = 
1:2) to give 109 (664 mg, 2.59 mmol, 86%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.88 (d, J = 
7.02 Hz, 3H), 1.36 (s, 3H), 1.43 (s, 3H), 1.49 (t, J = 11.71 Hz, 1H), 1.57 (ddd, J = 12.49, 4.30, 2.73 Hz, 
1H), 1.70 (dd, J = 6.25, 1.17 Hz, 3H), 1.91 (m, 1H), 3.51 (ddd, J = 11.71, 5.85, 2.73 Hz, 1H), 3.83 (d, J = 
8.20, 6.64 Hz, 1H), 3.86 (d, J = 6.24 Hz, 1H), 3.94 (ddd, J = 11.70, 5.07, 4.69 Hz, 1H), 4.01 (dd, J = 8.20, 
6.64 Hz, 1H), 4.19 (td, J = 6.64, 5.85 Hz, 1H), 5.48 (ddq, J = 15.22, 6.24, 1.56 Hz, 1H), 5.67 (dqd, J = 
15.22, 6.64, 1.17 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 5.3, 18.0, 25.4, 26.4, 29.5, 39.8, 65.3, 
70.7, 76.1, 77.1, 79.5, 109.4, 126.9, 129.5 ppm. Rf = 0.32 (EtOAc/n/hexane = 1:2). 
 
 
(2S,3R,4R,6S)-4-Acetoxy-6-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-methyl-2-E-
propenyltetrahydropyran 110: To a solution of alcohol 109 (128 mg, 0.50 mmol), Ph3P (197 mg, 0.75 
mmol, acetic acid (43 μl, 45 mg, 0.75 mmol) in THF (5 ml) was added DIAD (145 μl, 152 mg, 0.75 mmol). 
The mixture was stirred for 5 h and quenched by addition of sat. aq. NH4Cl. The mixture was extracted with 
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tBuOMe (3 × 25 ml) and the combined organic extracts were dried (Na2SO4), filtered, and concentrated in 
vacuo. The residue was purified by flash chromatography (column dimensions 30 × 2 cm, EtOAc/PE = 
1:10→1:4) to afford the desired acetate 110 (49 mg, 0.163 mmol, 33 %), accompanied by the elimination 
product (39 mg, 0.163 mmol, 33%) and a third, unidentified product (21 mg). Acetate 110: 1H NMR 
(CDCl3, 400 MHz): δ = 0.96 (d, J = 7.02 Hz, 3H), 1.36 (s, 3H), 1.43 (s, 3H), 1.70 (d, J = 6.25 Hz, 3H), 
1.71-1.81 (m, 2H), 3.82 (ddd, J = 12.49, 5.46, 2.73 Hz, 1H), 3.85 (dd, J = 8.58, 6.64 Hz, 1H), 3.99 (dd, J = 
8.58, 6.64 Hz, 1H), 4.16 (td, J = 6.64, 5.46 Hz, 1H), 4.27 (d, J = 5.85 Hz, 1H), 4.98 (m, 1H), 5.43 (ddq, J = 
15.22, 6.25, 1.56 Hz, 1H), 5.69 (dqd, J = 15.22, 6.64, 1.18 Hz, 1H) ppm. Rf = 0.49 (EtOAc/n/hexane = 1:4). 
Elimination product 110a: 1H NMR (CDCl3, 400 MHz): δ = 1.37 (s, 3H), 1.43 (s, 3H), 1.55 (s, 3H), 1.71 
(dd, J = 6.63, 1.17 Hz, 3H), 1.78 (m, 1H), 1.99-2.06 (m, 1H), 3.64 (ddd, J = 10.92, 6.64, 3.12 Hz, 1H), 3.73 
(dd, J = 8.19, 7.42 Hz, 1H), 4.00 (dd, J = 8.19, 6.64 Hz, 1H), 4.18 (dt, J = 7.02, 6.64 Hz, 1H), 4.45 (d, J = 
8.20 Hz, 1H), 5.34 (ddq, J = 15.22, 8.58, 1.56 Hz, 1H), 5.55 (dd, J = 6.24, 1.17 Hz, 1H), 5.77 (dq, J = 
15.22, 6.63 Hz, 1H) ppm. Rf = 0.66 (EtOAc/n/hexane = 1:4). 
 
 
2-Methyloct-3-en-5-one 137: Ylide 111 (3.46 g, 10.0 mmol, see synthesis of 115) was reacted with 
isobutyraldehyde (1.10 ml, 962 mg, 12.0 mmol) were reacted according to the general procedure for Wittig 
reactions. The residue was purified by flash chromatography (column dimensions 12 x 4 cm, EtOAc/PE = 
1:4) to give 137 (210 mg, 1.50 mmol, 15%) as a slightly yellow oil. IR (film): 2962, 2933, 2873, 1696, 
1675, 1628, 1465, 1457, 1363, 1303, 1271, 1196, 1131, 1058, 982, 776, 742 cm-1. 1H NMR (CDCl3, 400 
MHz): δ = 0.94 (t, J = 7.42 Hz, 3H), 1.07 (d, J = 7.02 Hz, 6H), 1.64 (m, 2H), 2.46 (m, 1H), 2.52 (t, J = 7.42 
Hz), 6.05 (dd, J = 16.00, 1.56 Hz, 1H), 6.79 (dd, J = 16.00, 6.63 Hz, 1H). 13C NMR (CDCl3, 75 MHz): δ = 
13.8, 17.7, 21.3, 31.0, 41.9, 127.3, 152.9, 200.7. Rf = 0.50 (EtOAc/n-hexane = 1:10). 
 
 
2,8-Dimethylnon-3-en-5-one 138: Ylide 98 (17.5 g, 55.0 mmol), n-BuLi (1.6M in hexane, 41.8 ml, 77.0 
mmol) and isobutyl iodide (8.90 ml, 14.2 g, 77.0 mmol) were reacted according to the general procedure for 
alkylation of ylide 98 to give 113 (19.5 g, 52.1 mmol, 95%) as a brown oil. 1H NMR (300 MHz, CDCl3): 
δ = 0.83-0.98 (m, 7H), 1.57 (m, 2H), 2.32 (t, J = 7.81 Hz, 2H), 7.42-7.72 (m, 16H). Ylide 113 (5.62 g, 15.0 
mmol) was reacted with isobutyraldehyde (20.5 ml, 1.62 g, 22.5 mmol) were reacted according to the 
general procedure for Wittig reactions. The residue was purified by flash chromatography (column 
dimensions 10 x 5.5 cm, EtOAc/PE = 1:20) to give 138 (915 mg, 5.44 mmol, 36%) as a slightly yellow oil. 
IR (CHCl3): 3026, 3011, 2961, 2931, 2871, 2455, 1688, 1661, 1624, 1467, 1409, 1386, 1367, 1339, 1295, 
1272, 1233, 1191, 1078, 982, 950 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 0.91 (d, J = 6.25 Hz, 6H), 1.08 (d, 
J = 7.02 Hz, 6H), 1.47-1.63 (m, 3H), 2.47 (m, 1H), 2.54 (t, J = 7.81 Hz, 2H), 6.04 (dd, J = 16.00, 1.56 Hz, 
1H), 6.79 (dd, J = 16.00, 6.63 Hz, 1H). 13C NMR (CDCl3, 75 MHz): δ = 21.3, 22.4, 27.8, 31.1, 33.1, 38.2, 
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127.2, 152.9, 201.0. Rf = 0.36 (EtOAc/n-hexane = 1:20). HRMS: calcd. for C11H20O (M + Na)+ 191.1406 
found 191.1404. 
 
 
4-(tert-Butyldimethylsilyloxy)-7-methyl-3Z,5E-octadiene 132: Ketone 137 (190 mg, 1.35 mmol), Et3N 
(220 μl, 164 mg, 1.62 mmol) and TBSOTf (340 μl, 394 mg, 1.49 mmol) were reacted according to the 
general procedure for the synthesis of TBS enol ethers. The crude product was purified by flash 
chromatography on a small, Et3N-neutralized column (column dimensions 20 x 3 cm, EtOAc/PE = 1:100) 
to give 132 (230 mg, 0.90 mmol, 67%) as a colourless oil. IR (CHCl3): 3670, 3413 (broad), 2957, 2930, 
2883, 2857, 1706, 1689, 1621, 1471, 1463, 1387, 1362, 1255, 1098, 1078, 1005, 985, 939, 839 cm-1. 1H 
NMR (CDCl3, 400 MHz): δ = 0.10 (s, 3H), 0.95 (t, J = 7.41 Hz, 3H), 1.00 (d, J = 6.63 Hz, 6H), 1.00 (s, 
9H), 2.10 (m, 2H), 2.32 (m, 1H), 4.65 (dd, J = 7.41, 7.03 Hz, 1H), 5.74-5.81 (m, 2H). 13C NMR (CDCl3, 75 
MHz): δ = -3.5, 14.3, 18.5, 19.4, 22.6, 26.1, 30.9, 115.3, 125.6, 136.0, 147.4. Rf = 0.62 (EtOAc/n-hexane = 
1:100). HRMS: calcd. for C15H30OSi (M+H)+ 255.2139 found 255.2138. 
 
 
5-(tert-Butyldimethylsilyloxy)-2,8-dimethyl-3E,5Z-nonadiene 133: Ketone 138 (910 mg, 5.41 mmol), 
Et3N (2.09 ml, 1.52 g, 6.49 mmol) and TBSOTf (1.37 ml, 1.57 g, 5.95 mmol) were reacted according to the 
general procdure for the synthesis of TBS enol ethers. The crude product was purified by flash 
chromatography on a small, Et3N-neutralized column (column dimensions 20 x 1.5 cm, EtOAc/PE = 1:20) 
to give 133 (1.47 g, 5.22 mmol, 96%) as a colourless oil. IR (CHCl3): 3669, 3027, 2958, 2930, 2857, 1714, 
1623, 1471, 1387, 1362, 1299, 1258, 1094, 1005, 986, 939, 839 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 0.10 
(s, 3H), 0.89 (t, J = 6.15 Hz, 3H), 0.99 (s, 9H), 1.00 (d, J = 6.63 Hz, 6H), 1.53-1.59 (m, 1H), 1.96 (m, 2H), 
2.32 (m, 1H), 4.70 (dd, J = 7.41, 7.03 Hz, 1H), 5.68-5.83 (m, 2H). 13C NMR (CDCl3, 75 MHz): δ = -3.4, 
18.6, 22.6, 22.6, 26.1, 28.9, 30.9, 35.2, 112.1, 125.7, 135.9, 145.4. Rf = 0.90 (EtOAc/n-hexane = 1:20). 
HRMS :calcd. for C17H34OSi (M+Na+O)+ 321.2220 found 321.2222. 
 
 
3-Ethyl-2-E-propenyl-6-isopropyltetrahydropyran-4-one 134: Diene 132 (62 mg, 0.24 mmol), 
crotonaldehyde (27 μl, 22 mg, 0.32 mmol) and BF3•Et2O (30 μl, 34 mg, 0.24 mmol) were reacted according 
to the general procedure for HDA reactions to give TBS enol ether 134a. 1H NMR (CDCl3, 300 MHz): δ = 
0.17 (s, 3H), 0.18 (s, 3H), 0.89 (d, J = 7.04 Hz, 3H), 0.90 (d, J = 7.04 Hz, 3H), 0.93 (s, 9H), 1.08 (dd, J = 
6.74, 2.05 Hz, 3H), 1.43-1.84 (m, 2H), 1.72 (dd, 6.45, 1.17 Hz, 3H), 2.47 (m, 1H), 3.98 (m, 1H), 4.08 (m, 
1H), 4.67 (d, J = 1.76 Hz, 1H), 5.55 (ddd, 15.24, 6.16, 1.47 Hz, 1H), 5.72 (dqd, 15.24, 6.16, 1.18 Hz, 1H). 
TBS enol ether 134a (60 mg, 0.18 mmol), TBAF (70 mg, 0.27 mmol), and AcOH (51 μl, 54 mg, 0.90 
mmol) were reacted according to the general procedure for the desilylation of TBS enol ethers to give 134 
(12 mg, 0.06 mmol, 23%) as a colorless oil. IR (CHCl3): 3025, 3014, 2965, 2933, 2876, 2855, 1698 cm-1. 
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1H NMR (CDCl3, 300 MHz): δ = 0.82 (dd, J = 7.62, 7.33 Hz, 3H), 0.94 (d, J = 6.75 Hz, 3H), 0.98 (d, J = 
6.75, 3H), 1.65 (m, 2H), 1.73 (ddd, J = 6.45, 1.47, 1.17  Hz, 3H), 1.86 (m, 1H), 2.19 (m, 1H), 2.22 (ddd, J = 
14.07, 1.46, 1.17 Hz, 1H), 2.39 (dd, J = 14.07, 11.44 Hz, 1H), 3.34 (ddd, J = 11.43, 5.86, 2.64 Hz, 1H), 4.07 
(m, 1H), 5.47 (ddq, J = 15.24, 5.57, 1.76 Hz, 1H), 5.76 (dqd, J = 15.24, 6.45, 1.47 Hz, 1H). 13C NMR 
(CDCl3, 75 MHz): δ = 11.7, 17.8, 18.0, 18.4, 18.9, 33.3, 41.5, 58.1, 79.6, 82.0, 127.4, 128.0, 211.6. Rf = 
0.25 (EtOAc/n-hexane = 1:20). HRMS: calcd. for C13H22O2 (M+Na)+ 233.1512 found 233.1510. 
 
 
3-Ethyl-2-(E-2-phenylethenyl)-6-isopropyltetrahydropyran-4-one 135: Diene 132 (102 mg, 0.40 mmol), 
cinnamaldehyde (65 μl, 69 mg, 0.52 mmol) and BF3•Et2O (51 μl, 57 mg, 0.40 mmol) were reacted 
according to the general procedure for HDA reactions to give TBS enol ether 135a. 1H NMR (CDCl3, 300 
MHz): δ = 0.19 (s, 3H), 0.20 (s, 3H), 0.91-0.97 (m, 9H), 0.94 (s, 9H), 1.53 (m, 1H), 1.65 (m, 1H), 1.81 (m, 
1H), 1.96 (m, 1H), 4.04 (m, 1H), 4.32 (m, 1H), 4.72, (d, J = 1.46 Hz, 1H), 6.26 (dd, J = 15.83, 5.28 Hz, 
1H), 6.64 (dd, J = 15.83, 1.46 Hz, 1H), 7.21-7.44 (m, 5H). TBS enol ether 135a (142 mg, 0.37 mmol), 
TBAF (145 mg, 0.56 mmol), and AcOH (106 μl, 111 mg, 1.85 mmol) were reacted according to the general 
procedure for the desilylation of TBS enol ethers to give 135 (70 mg, 0.26 mmol, 64%) as a colorless oil. IR 
(CHCl3): 3691, 3568, 3527, 3029, 2962, 2935, 2876, 1713, 1602, 1496, 1465, 1416, 1283, 1229, 1203, 
1178, 938, 828 cm-1. 1H NMR (CDCl3, 400 MHz): δ = 0.83 (t, J = 7.63 Hz, 1H), 0.98 (d, J = 6.74 Hz, 3H), 
1.04 (d, J = 6.74 Hz), 1.73 (m, 2H), 1.91 (m, 1H), 2.29 (ddd, J = 14.07, 2.93, 1.18 Hz, 1H), 2.32 (m, 1H), 
2.45 (dd, J = 14.07, 11.44 Hz, 1H), 3.41 (ddd, J = 11.44, 5.86, 2.93 Hz, 1H), 4.32 (ddd, J = 4.98, 2.64, 1.76 
Hz, 1H), 6.15 (dd, J = 16.12, 4.98 Hz, 1H), 6.68 (dd, J = 16.12, 1.76 Hz, 1H), 7.22-7.41 (m, 5H). 13C NMR 
(CDCl3, 75 MHz): δ = 11.7, 17.9, 18.4, 19.2, 33.3, 41.6, 57.9, 79.2, 82.0, 126.3, 126.5, 127.5, 128.4, 130.5, 
136.4, 211.0. Rf = 0.35 (EtOAc/n-hexane = 1:10). HRMS: calcd. for C18H24O2 (M + Na)+ 295.1669 found 
295.1666. 
 
 
3-Isobutyl-2-(E-2-phenylethenyl)-6-isopropyltetrahydropyran-4-one 136: Diene 133 (599 mg, 2.12 
mmol), cinnamaldehyde (321 μl, 337 mg, 2.55 mmol) and BF3•Et2O (269 μl, 301 mg, 2.12 mmol) were 
reacted according to the general procedure for HDA reactions to give TBS enol ether 136a. 1H NMR 
(CDCl3, 300 MHz): δ = 0.18 (s, 3H), 0.20 (s, 3H), 0.84 (d, J = 5.57 Hz, 3H), 0.86 (d, J = 5.57 Hz, 3H), 0.93 
(d, J ≈ 7 Hz, 3H), 0.94 (s, 9H), 0.95 (d, J ≈ 7 Hz), 1.24 (m, 1H), 1.52 (m, 1H), 1.70 (m, 1H), 1.80 (m, 1H), 
2.00 (m, 1H), 4.06 (m, 1H), 4.32 (ddd, J = 5.57, 2.64, 1.17 Hz, 1H), 4.61 (d, J = 1.76 Hz, 1H), 6.20 (dd, J = 
16.12, 5.57 Hz), 6.63 (dd, J = 16.12, 1.17 Hz); 13C NMR (CDCl3, 75 MHz): δ = -4.4, -4.0, 17.9, 23.2, 25.8, 
27.0, 33.2, 38.5, 42.5, 77.4, 78.8, 101.4, 126.2, 127.1, 128.3, 128.96, 129.03, 129.3, 137.1, 154.3. TBS enol 
ether 136a (850 mg, 2.05 mmol), TBAF (803 mg, 3.07 mmol), and AcOH (586 μl, 616 mg, 10.3 mmol) 
were reacted according to the general procedure for the desilylation of TBS enol ethers to give 136 (460 
mg, 1.53 mmol, 72%) as a colorless oil. IR (CHCl3): 3674, 3523 (broad), 3083, 3027, 3009, 2961, 2935, 
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2872, 1705, 1627, 1599, 1577, 1496, 1469, 1449, 1413, 1386, 1368, 1295, 1261, 1243, 1186, 1125, 1101, 
1059, 969, 908, 838 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 0.87 (d, J = 5.86 Hz, 1H), 0.88 (d, J = 6.16 Hz, 
1H), 0.98 (d, J = 6.75 Hz, 3H), 1.04 (d, J = 6.74 Hz), 1.41 (m, 2H), 1.68 (m, 1H), 1.91 (m, 1H), 2.28 (ddd, J 
= 13.78, 2.64, 1.17 Hz, 1H), 2.45 (dd, J = 13.78, 11.43 Hz, 1H), 2.51 (m, 1H), 3.39 (ddd, J = 11.43, 6.16, 
2.64 Hz, 1H), 4.31 (ddd, J = 4.98, 2.35, 1.76 Hz, 1H), 6.11 (dd, J = 16.12, 4.99 Hz, 1H), 6.68 (dd, J = 
16.12, 1.76 Hz, 1H), 7.22-7.42 (m, 5H). 13C NMR (CDCl3, 75 MHz): δ = 18.0, 18.5, 21.2, 23.78 26.0, 33.3, 
34.9, 41.8, 54.6, 79.5, 82.4, 126.3, 126.5, 127.5, 128.4, 130.5, 136.5, 211.0. Rf = 0.50 (EtOAc/n-hexane = 
1:10). HRMS: calcd. for C20H28O2 (M+Na)+ 323.1982 found 323.1981. 
 
 
1-(4-Methoxyphenyl)-6-methylhept-1-en-3-one 140: Ylide 113 (5.62 g, 15.0 mmol, see synthesis of 37) 
and 4-methoxybenzaldehyde (2.74 ml, 3.06 g, 22.5 mmol) were reacted according to the general procedure 
for Wittig reactions. The residue was purified by flash chromatography (column dimensions 10 x 5.5 cm, 
EtOAc/PE = 1:8) to give 140 (1.62 g, 6.99 mmol, 47%) as off-white crystals. IR (CHCl3): 3028, 3012, 
2959, 2935, 2870, 2840, 1680, 1648, 1600, 1573, 1511, 1465, 1422, 1368, 1331, 1307, 1285, 1253, 1173, 
1137, 1112, 1079, 1033, 976, 823 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 0.93 (d, J = 6.16 Hz, 6H), 1.53-
1.66 (m, 3H), 2.64 (m, 2H), 3.84 (s, 3H), 6.63 (dd, 16.12, 1.76 Hz, 1H), 6.91 (m, 2H), 7.49-7.54 (m, 4H). 
13C NMR (CDCl3, 75 MHz): δ = 22.5, 27.9, 33.4, 39.0, 55.4, 114.3, 123.9, 127.1, 129.1, 141.9, 161.3, 
200.6. Rf = 0.35 (EtOAc/n-hexane = 1:8). HRMS: calcd. for C15H20O2 (M + Na)+ 255.1356 found 255.1354. 
 
 
3-(tert-Butyldimethylsilyloxy)-1-(4-methoxyphenyl)-6-methyl-1E,3Z-heptadiene 139: Ketone 140 (1.60 
g, 6.88 mmol), Et3N (1.14 ml, 835 mg, 8.26 mmol) and TBSOTf (1.74 ml, 2.00 g, 7.57 mmol) were reacted 
according to the general method for the synthesis of TBS enol ethers to give 139 (2.35 g, 6.79 mmol, 99%) 
as a colorless solid. IR (CHCl3): 3021, 3009, 2956, 2930, 2857, 1717, 1683, 1597, 1573, 1512, 1464, 1422, 
1387, 1362, 1330, 1303, 1290, 1256, 1172, 1094, 1033, 1004, 987, 901, 837 cm-1. 1H NMR (CDCl3, 300 
MHz): δ = 0.15 (s, 6H), 0.92 (d, J = 6.75 Hz, 6H), 1.04 (s, 9H), 1.62 (m, 1H), 2.03 (dd, J = 7.33, 7.04 Hz, 
2H), 3.80 (s, 3H), 4.91 (dd, J = 7.32, 6.63 Hz, 1H), 6.44 (d, J = 15.83 Hz, 1H), 6.59 (d, J = 15.83 Hz, 1H), 
6.84 (d, J = 8.79 Hz, 2H), 7.30 (d, J = 8.79 Hz, 2H). 13C NMR (CDCl3, 75 MHz): δ = -3.4, 18.6, 22.6, 26.2, 
28.9, 35.4, 55.2, 113.9, 114.6, 125.5, 126.2, 127.3, 129.9, 148.8, 158.8.  
 
 
4-(tert-Butyldimethylsilyloxy)-5-isobutyl-6-methyl-2-(4-methoxyphenyl)cyclohex-3-ene-1-
carboxaldehyde 141: Diene 139 (600 mg, 1.73 mmol), crotonaldehyde (160 μl, 190 mg, 2.25 mmol) and 
BF3•Et2O (220 μl, 240 mg, 1.73 mmol) were reacted at -30°C for 3 h according to the general procedure for 
HDA reactions and purified by flash chromatography (column dimensions: 25 x 3 cm, EtOAc/PE = 1:10)  
to give Diels-Alder product 141 (325 mg, 0.78 mmol, 45%) as a slightly yellow oil. IR (CHCl3): 3699, 
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3025, 3010, 2957, 2931, 2857, 1717, 1662, 1610, 1513, 1464, 1386, 1362, 1302, 1253, 1179, 1035, 908, 
836 cm-1. 1H NMR (CDCl3, 300 MHz): δ = 0.15 (s, 3H), 0.15 (s, 3H), 0.85-0.97 (m, 9H), 0.93 (s, 9H), 1.35 
(m, 2H), 1.87 (m, 1H), 2.06 (m, 1H), 2.33 (m, 2H), 3.75 (m, 1H), 3.77 (s, 3H), 4.65 (d, J = 2.93 Hz, 1H), 
6.80 (d, J = 8.79 Hz, 2H), 7.03 (d, J = 8.79 Hz, 2H), 9.62 (d, J = 4.10 Hz, 1H). Rf = 0.53 (EtOAc/n-hexane 
= 1:10). HRMS: calcd. for C25H40O3Si (M + Na)+ 439.2639 found 439.2639. 
 
 
4-(tert-Butyldimethylsilyloxy)-5-isobutyl-6-phenyl-2-(4-methoxyphenyl)cyclohex-3-ene-1-
carboxaldehyde 142: Diene 139 (600 mg, 1.73 mmol), cinnamaldehyde (260 μl, 270 mg, 2.08 mmol) and 
BF3•Et2O (220 μl, 240 mg, 1.73 mmol) were reacted at -30°C for 3 h according to the general procedure for 
HDA reactions and purified by flash chromatography (column dimensions: 30 x 3 cm, EtOAc/PE = 1:8) to 
give Diels-Alder product 142 (315 mg, 0.66 mmol, 38%) as a slightly yellow oil. IR (CHCl3): 3669, 3025, 
3012, 2957, 2930, 2857, 2359, 2341, 1710, 1601, 1513, 1463, 1362, 1304, 1253, 1204, 1179, 1035, 834 
cm−1. 1H NMR (CDCl3, 300 MHz): δ = 0.18 (s, 3H), 0.21 (s, 3H), 0.50 (d, J = 6.45 Hz, 3H), 0.73 (d, J = 
6.45 Hz), 0.84-0.97 (m, 3H), 0.94 (s, 9H), 1.35 (m, 2H), 1.32 (m, 1H), 2.28 (m, 1H), 3.05 (m, 1H), 3.56 (m, 
1H), 4.70-4.87 (m, 1H), 3.80 (s, 3H), 4.72 (d, J = 2.64 Hz, 1H), 6.85 (d, J = 8.80 Hz, 2H), 7.09 (d, J = 8.50 
Hz, 2H), 7.14-7.24 (m, 5H), 9.46 (d, J = 4.39 Hz, 1H). Rf = 0.47 (EtOAc/n-hexane = 1:8). HRMS: calcd. for 
C30H42O3Si (M + Na)+ 501.2795 found 501.2794. 
 
 
(2R,3R,6R)-6-((4R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-isopropyl-2-(E-2-phenylethenyl)-
tetrahydropyran-4-one (131d): To a solution of 131a (89.4 mg, 0.260 mmol) in MeOH (5.0 ml) was 
added KOtBu (1M in THF, 0.026 ml, 0.026 mmol) and the mixture was stirred for 2 days at room 
temperature. TLC analysis indicated that the starting material was fully converted. The mixture was diluted 
with sat. aq. NH4Cl (15 ml) and brine (15 ml) and extracted with tBuOMe (3 x 25 ml). The combined 
organic fractions were dried (Na2SO4), filtered, concentrated in vacuo, and purified by flash 
chromatography (20 x 1.5 cm, EtOAc/PE = 1:6) to give 131d (47.4 mg, 0.138 mmol, 53%) as a colorless 
oil. [α]24D = +12.4 (c = 2.06, CHCl3). IR (CHCl3): 3523 (broad), 3026, 3011, 2987, 2960, 2935, 2878, 1712, 
1496, 1449, 1383, 1373, 1311, 1258, 1228, 1204, 1155, 1071, 984, 967, 845 cm-1. 1H NMR (CDCl3, 400 
MHz): δ = 1.00 (d, J = 7.02 Hz, 3H), 1.07 (d, J = 7.02 Hz, 3H), 1.35 (s, 3H), 1.42 (s, 3H), 2.07 (m, 1H), 
2.39 (ddd, J = 10.14, 1.57, 0.78 Hz, 1H), 2.49 (ddd, J = 14.44, 11.32, 1.17 Hz, 1H), 2.59 (dd, J = 14.44, 
3.12 Hz, 1H), 3.67 (ddd, J = 11.32, 6.25, 3.12 Hz, 1H), 3.91 (dd, J = 8.20, 4.40 Hz, 1H), 4.11-4.22 (m, 3H), 
6.21 (dd, J = 16.00, 8.20 Hz, 1H), 6.64 (d, J = 16.00 Hz, 1H), 7.24-7.45 (m, 5H). 13C NMR (CDCl3, 100 
MHz): δ = 18.1, 20.4, 25.0, 25.7, 26.6, 44.8, 59.9, 66.7, 77.5, 77.6, 81.4, 109.8, 126.6, 127.7, 128.2, 128.6, 
133.6, 136.0, 206.8. Rf = 0.51 (EtOAc/n-hexane = 1:4). HRMS: calcd. for C21H28O4 (M+Na)+ 367.1880 
found 367.1877. 
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(2R,3S,4R,6R)-3,4-Dimethyl-6-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(E-2-phenylethe-nyl)-
tetrahydropyran-4-ol 143: To a solution of ketone 128a (158.2 mg, 0.50 mmol) in THF (10 ml) at -78°C 
was added MeMgBr (3 M solution in Et2O, 1.00 ml, 3.00 mmol). The mixture was stirred for 15 min. at 
−78°C, then warmed to room temperature and quenched by addition of sat. aq. NH4Cl (25 ml). The mixture 
was extracted with tBuOMe (3 x 25 ml) and the combined organic fractions were washed with brine (30 
ml), dried (Na2SO4), filtered, concentrated in vacuo and purified by flash chromatography (column 
dimensions 25 x 2 cm, EtOAc/PE = 1:3) to give 47 (82.3 mg, 0.248 mmol, 50%) as a colorless oil. [α]26D = 
+17.1 (c = 1.07, CHCl3). IR (CHCl3): 3670, 3599, 3458 (broad), 3027, 3010, 2987, 2935, 2885, 1713, 1636, 
1600, 1576, 1495, 1455, 1382, 1373, 1230, 1202, 1150, 1111, 1069, 947, 916, 886, 844 cm-1. 1H NMR 
(CDCl3, 400 MHz): δ = 0.98 (d, J = 7.03Hz, 3H), 1.37 (s, 3H), 1.44 (s, 3H), 1.47 (s, 3H), 1.57-1.72 (m, 3H), 
3.45 (ddd, J = 11.32, 6.63, 2.73 Hz, 1H), 4.00-4.06 (m, 2H), 4.12 (m, 1H), 4.27(m,1H), 6.12 (dd, J = 16.00, 
4.68 Hz, 1H), 6.56 (dd, J = 16.00, 1.56, 1H), 7.21-7.38 (m, 5H). 13C NMR (CDCl3, 100 MHz): δ = 7.8, 
25.3, 26.7, 27.1, 37.2, 44.7, 49.4, 66.9, 70.9, 76.0, 77.6, 78.0, 109.4, 126.3, 127.4, 128.5, 129.0, 129.7, 
136.9. Rf = 0.36 (EtOAc/n-hexane =1:2). HRMS: calcd. for C20H28O4 (M + Na)+ 355.1880 found 355.1881. 
 
 
2-Bromopentan-3-one 147a: Bromine (17.7 ml, 55.1 g, 345 mmol) was added to a solution of 3-pentanone 
(36.6 ml, 29.7 g, 345 mmol) in acetic acid (48 ml) and H2O (72 ml) and reacted according to reference59 to 
give 2-bromopentan-3-one (147a, 32.0 g, 194 mmol, 56%) after distillation. 1H NMR (400 MHz, CDCl3) 
δ = 1.12 (t, J = 7.42 Hz, 3H), 1.75 (d, J = 6.63 Hz, 3H), 2.61 (dq, J = 17.95, 7.42 Hz, 1H), 2.87 (dq, J = 
17.95, 7.42 Hz, 1H), 4.42 (q, J = 6.63 Hz, 1H) ppm. 
 
 
2-(Triphenylphosphoranylidene)pentan-3-one 147: 2-Bromopentan-3-one (147a, 32.0 g, 194 mmol) was 
added to a solution of PPh3 (48.5 g, 185 mmol) in benzene and the mixture was reacted according to 
reference59 to give crude 147 as a slightly brown solid that was used in the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ = 1.15 (t, J = 7.41 Hz, 3H), 1.65 (d, J = 16.00 Hz, 3H), 2.42 (q, 
J = 7.41 Hz, 2H), 7.40-7.70 (m, 15H) ppm. 
 
 
Isobutyl (R)-2-benzyloxypropanoate 150: Commercially available isobutyl D-lactate (149, 7.51 ml, 7.31 
g, 50.0 mmol) was added at 0°C to a suspension of NaH (60% dispension in mineral oil, 2.00 g, 50.0 mmol) 
in DMF (100 ml). The mixture was stirred for 5 min. at 0°C and benzyl bromide (5.92 ml, 8.55 g, 50.0 
mmol) was added. The mixture was stirred for 1.5 h at rt, quenched by addition of H2O (50 ml) and 
extracted with PE (5 × 75 ml). The combined organic fractions were washed with H2O (100 ml) and sat. aq. 
NH4Cl (100 ml), dried (Na2SO4), filtered and concetrated in vacuo to give crude 150 (11.68 g, 49.4 mmol, 
Synthesis of the ratjadone analogue A fragment 
 
 77
99%) as a colorless oil that was used in the next step without further purification. 1H NMR (400 MHz, 
CDCl3) δ = 0.95 (d, J = 7.03 Hz, 6H), 1.45 (d, J = 7.02 Hz, 3H), 1.98 (m, 1H), 3.91-4.00 (m, 2H), 4.07 (q, 
J = 7.02 Hz, 1H), 4.45 (d, J = 11.71 Hz, 1H), 4.72 (d, J = 11.71 Hz, 1H), 7.28-7.39 (m, 5H) ppm. Rf = 0.71 
(EtOAc/n-hexane = 1:4). 
 
 
(R)-2-Benzyloxypropanol 151: Isobutyl (R)-2-benzyloxypropanoate (150, 11.68 g, 49.4 mmol) was added 
at 0°C to a suspension of LiAlH4 (1.88 g, 49.4 mmol) in THF (100 ml). The mixture was stirred for 5 min. 
at 0°C, quenched by addition of sat.aq. NH4Cl (300 ml), and extracted with tBuOMe (3 × 250 ml). The 
combined organic fractions were washed with brine (300 ml), dried (Na2SO4), filtered and concetrated in 
vacuo to give crude 151 (8.20 g, 49.3 mmol, 100%) as a colorless oil that was used in the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ = 1.19 (d, J = 6.24 Hz, 3H), 2.02 (dd, J = 8.20, 4.30 Hz, 
1H, OH), 3.48-3.54 (m, 1H), 3.60-3.65 (m, 1H), 3.66-3.73 (m, 1H), 4.49 (d, J = 11.32 Hz, 1H), 4.66 (d, J = 
11.32 Hz, 1H), 7.27-7.38 (m, 5H) ppm. Rf = 0.23 (EtOAc/n-hexane = 1:4). 
 
 
(R)-2-Benzyloxypropanal 148: DMSO (3.91 ml, 4.30 ml, 55.0 mmol) was added at -78°C to a solution of 
oxalyl chloride (2.40 ml, 3.49 g, 27.5 mmol) in CH2Cl2 (125 ml). The mixture was stirred for 10 min. at 
-78°C and (R)-2-benzyloxypropanol (151, 4.16 g, 25.0 mmol) was added dropwise. The mixture was stirred 
for an additional 20 min. at -78°C and Et3N (10.40 ml, 7.59 g, 75.0 mmol) was added. The mixture was 
allowed to warm to room temperature, quenched by addition of sat. aq. NH4Cl (200 ml) and extracted with 
CH2Cl2 (3 × 150 ml). The combined organic fractions were dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by flash chromatography (column dimensions 30 × 4 cm, EtOAc/PE = 1:4) afforded 148 
(3.02 g, 18.4 mmol, 74%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 1.34 (d, J = 7.02 Hz, 3H), 3.90 
(qd, J = 7.03, 1.56 Hz, 1H), 4.60 (d, J = 11.71 Hz, 1H), 4.66 (d, J = 11.71 Hz, 1H), 7.29-7.38 (m, 5H), 9.76 
(d, J = 1.56 Hz, 1H) ppm. Rf = 0.50 (EtOAc/n-hexane = 1:4). 
 
 
(R)-(4E)-6-(Benzyloxy)-4-methylhept-4-en-3-one 152: To a solution of 2-(triphenylphospho-
ranylidene)pentan-3-one (147, 10 g, 28 mmol) in acetonitrile (100 ml) was added (R)-2-benzyloxypropanal 
(148, 3.02 g, 18.38 mmol) and Et3N (1.70 ml, 1.24 g, 12.29 mmol). The mixture was stirred overnight at rt. 
The solvent was removed in vacuo and the residue was extracted with several portions of EtOAc/n-hexane 
1:4. The extracts were concentrated in vacuo and the residue was purified by flash chromatography (column 
dimensions: 30 × 3.5 cm, EtOAc/PE = 1:6) to give 152 (3.22 g, 13.87 mmol, 75%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ = 1.09 (t, J = 7.42 Hz, 3H), 1.31 (d, J = 6.64 Hz, 3H), 1.76 (d, J = 1.17 Hz, 3H), 
2.68 (q, J = 7.42 Hz, 2H), 4.40 (dq, J = 8.20, 6.64 Hz, 1H), 4.42 (d, J = 12.10 Hz, 1H), 4.52 (d, J = 11.71 
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Hz, 1H), 6.51 (dd, J = 8.19, 1.17 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ = 8.5, 11.5, 20.2, 30.3, 70.6, 
71.5, 127.5, 128.1, 128.3, 137.0, 138.1, 142.7, 202.2 ppm. Rf = 0.81 (EtOAc/n-hexane = 1:4). 
 
 
(R)-(2Z,4E)-6-Benzyloxy-3-(tert-butyldimethylsilyloxy)hepta-2,4-diene 146: To a solution of ketone 152 
(1.39 g, 6.00 mmol) and Et3N (1.25 ml, 911 mg, 9.00 mmol) in Et2O (30 ml) was added at 0°C TBSOTf 
(1.65 ml, 1.90 g, 7.20 mmol). The mixture was stirred for 2 h at 0°C, but TLC analysis indicated that no 
reaction had taken place. The mixture was cooled to -78°C and NaHMDS (1 M solution in THF, 6.00 ml, 
6.00 mmol) was added. The mixture was allowed to warm to rt, diluted with sat. aq. NH4Cl (100 ml), and 
extracted with tBuOMe (3 × 100 ml). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. The residue was purified by flash chromatography on a Et3N-neutralized column 
(column dimensions: 20 × 2 cm, EtOAc/PE = 1:50) to give 146 (2.09 g, 6.02 mmol, 100%) as a colorless oil 
(2Z:2E = 9:1). 1H NMR (400 MHz, CDCl3) δ = 0.11 (s, 3H), 0.12 (s, 3H), 1.01 (s, 9H), 1.27 (d, J = 6.24 Hz, 
3H, 1.66, J = 7.03 Hz, 3H), 1.74 (d, J = 0.78 Hz, 3H), 4.32 (dq, J = 8.98, 6.24 Hz, 1H), 4.32 (d, J = 11.71 
Hz, 1H), 4.55 (d, J = 11.71 Hz, 1H), 5.01 (q, J = 7.03 Hz, 1H), 5.73 (d, J = 8.97 Hz, 1H) ppm. 13C NMR 
(100 MHz, CDCl3) δ = -3.7, -3.6, 11.9, 13.9, 18.4, 21.6, 26.0, 69.9, 71.2, 105.4, 127.3, 127.6, 128.3, 128.5, 
134.3, 138.9, 151.1 ppm. Rf = 0.89 (EtOAc/n-hexane = 1:8). 
 
 
3-Benzyloxypropanal 153: DMSO (3.91 ml, 4.30 ml, 55.0 mmol) was added at -78°C to a solution of 
oxalyl chloride (2.40 ml, 3.49 g, 27.5 mmol) in CH2Cl2 (125 ml). The mixture was stirred for 10 min. at 
-78°C and commercially available 3-benzyloxypropanol (4.16 g, 25.0 mmol) was added dropwise. The 
mixture was stirred for an additional 20 min. at -78°C and Et3N (10.40 ml, 7.59 g, 75.0 mmol) was added. 
The mixture was allowed to warm to room temperature, quenched by addition of sat. aq. NH4Cl (200 ml) 
and extracted with CH2Cl2 (3 × 150 ml). The combined organic fractions were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash chromatography (column dimensions 30 × 4 cm, EtOAc/PE = 
1:4) afforded 153 (3.99 g, 24.3 mmol, 97%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 2.71 (td, J = 
6.25, 1.95 Hz, 2H), 3.82 (t, J = 6.25 Hz, 2H), 4.54 (s, 2H), 7.27-7.37 (m, 5H), 9.80 (t, J = 1.95 Hz, 1H) 
ppm. 13C NMR (100 MHz, CDCl3) δ = 43.8, 63.7, 73.1, 127.6, 127.7, 128.3, 137.8, 201.1 ppm. Rf = 0.49 
(EtOAc/n-hexane = 1:4). 
 
 
2-(1-Benzyloxyethyl)-6-(2-benzyloxyethyl)-3,5-dimethyltetrahydropyran-4-one 155: To a solution of 
diene 146 (693 mg, 2.00 mmol) and 3-benzyloxypropanal (153, 394 mg, 2.40 mmol) in Et2O (20 ml) was 
added at −30°C BF3•Et2O (304 μl, 341 mg, 2.40 mmol). The mixture was stirred for 5 h between -30°C and 
-15°C. Et3N (665 μl, 486 mg, 4.80 mmol) was added, the mixture was diluted with H2O (50 ml) and sat. aq. 
NH4Cl (100 ml), and extracted with tBuOMe (3 × 100 ml). The combined organic fractions were dried 
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(Na2SO4), filtered, and concentrated in vacuo to give the crude diastereomeric mixture of HDA product 154. 
To a solution of crude silyl enol ether 154 (max. 2.00 mmol) in THF (20 ml) was added acetic acid (286 μl, 
300 mg, 5.00 mmol) followed by TBAF•3H2O (947 mg, 3.00 mmol) and the mixture was stirred overnight 
at rt. The mixture was diluted with sat. aq. NH4Cl (100 ml) and extracted with tBuOMe (3 × 100 ml). The 
combined organic fractions were washed with sat. aq. NaHCO3 (100 ml) and brine (100 ml), dried 
(Na2SO4), filtered, and concentrated in vacuo. The residue was purified by flash chromatography (column 
dimensions: 35 × 2.5 cm, EtOAc/PE = 1:8) to give four diastereomeric products (155a-d) in a 14:66:8:12 
ratio (the latter two, 155c and 155d, being inseparable; their configurations could not be determined) in a 
total yield of 647 mg (1.63 mmol, 82% over two steps). The former isomer (155a) was determined to have 
the (3x,5x) configuration, and may be derived (at least partially) from the E-diene. The configuration of 
major product 155b could not be determined unequivocally. Isomer 155a: 1H NMR (CDCl3, 500 MHz): δ 
= 0.98 (d, J = 6.64 Hz, 3H), 1.05 (d, J = 7.02 Hz, 3H), 1.27 (d, J = 5.85 Hz, 3H), 1.79 (ddt, J = 14.44, 9.76, 
5.07 Hz, 1H), 2.08 (dtd, J = 14.44, 7.42, 2.34 Hz, 1H), 2.46 (dq, J = 10.54, 6.64 Hz, 1H), 2.83 (qd, J = 7.03, 
2.34 Hz, 1H), 3.37 (ddd, J = 10.54, 9.76, 2.34 Hz, 1H), 3.38 (dd, J = 8.59, 2.34 Hz, 1H), 3.59 (dq, J = 8.59, 
5.85 Hz, 1H), 3.67 (dd, J = 7.42, 5.07 Hz, 2H), 4.36 (d, J = 11.70 Hz, 1H), 4.49 (d, J = 12.10 Hz, 1H), 4.53 
(d, J = 11.71 Hz, 1H), 4.65 (d, J = 11.71 Hz, 1H), 7.27-7.36, (m, 10H) ppm. 13C NMR (CDCl3, 125 MHz): 
δ = 9.2, 11.4, 16.7, 34.5, 46.1, 46.3, 66.6, 70.4, 72.6, 73.2, 80.3, 82.0, 127.63, 127.64, 127.67, 128.39, 
128.40, 138.1, 138.3, 212.7 ppm. Rf = 0.67 (EtOAc/n-hexane = 1:4). Isomer 155b: 1H NMR (CDCl3, 400 
MHz): δ = 0.97 (J = 6.63 Hz, 3H), 1.13 (d, J = 7.03 Hz, 3H), 1.30 (d, J =6.63 Hz, 3H), 1.67-1.74 (m, 1H), 
1.94-2.01 (m, 1H), 2.43 (qd, J = 7.03, 2.34 Hz, 1H), 2.52 (dq, J = 10.54, 6.64 Hz, 1H), 3.42 (dd, J = 10.53, 
2.34 Hz, 1H), 3.57-3.70 (m, 3H), 3.81 (ddd, J = 8.58, 4.29, 2.34 Hz, 1H), 4.48 (s, 2H), 4.55 (d, J = 12.10 
Hz, 1H), 4.59 (d, J = 12.10 Hz, 1H), 7.28-7.35 (m, 10H) ppm. Rf = 0.57 (EtOAc/n-hexane = 1:4). 
 
 
2-(1-Benzyloxyethyl)-6-(2-benzyloxyethyl)-3,5-dimethyltetrahydropyran-4-ol 156: To a solution of 
ketone 155b (198 mg, 0.50 mmol) in MeOH (10 ml) was added at 0°C NaBH4 (37 mg, 1.00 mmol) and the 
mixture was stirred for 1 h at 0°C. The mixture was quenched by addition of sat. aq. NH4Cl (10 ml), diluted 
with brine (50 ml) and extracted with tBuOMe (3 × 30 ml). The combined organic fractions were dried 
(Na2SO4), filtered and concentrated in vacuo to give 156 (144 mg, 0.36 mmol, 72%) as a colorless oil. 1H 
NMR (CDCl3, 400 MHz): δ = 0.89 (d, J = 7.02 Hz, 3H), 0.91 (d, J = 7.03 Hz, 3H), 1.28 (d, J = 5.86 Hz, 
3H), 1.63-1.71 (m, 1H), 1.81-1.92 (m, 2H), 2.30 (m, 1H), 3.16 (dd, J = 9.37, 2.34 Hz, 1H), 3.44-3.64 (m, 
4H), 3.91 (td, J = 5.07, 4.69 Hz, 1H), 4.36 (d, J = 10.93 Hz, 1H), 4.48 (d, J = 11.71 Hz, 1H), 4.53 (d, J = 
12.10 Hz, 1H), 4.66 (d, J = 11.31 Hz, 1H), 7.28-7.37 (m, 10H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 8.3, 
8.4, 16.9, 32.9, 35.3, 38.6, 67.2, 70.6, 73.0, 73.2, 73.5, 76.7, 83.0, 127.6 (2C), 127.66 (2C), 127.67 (2C), 
128.31 (2C), 128.34 (2C), 138.29, 138.32 ppm. 
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3 Synthesis of the ratjadone analogue B fragment 
 
3.1 Retrosynthesis 
 
The substituted THP and dihydro-α-pyrone ring systems of ratjadone are connected by a 
linear tetraene chain with methyl substituents at various positions. Radioactive labeling 
studies showed that this chain (like the rest of the molecule) is derived from polyketide 
metabolism (acetate and propionate residues).1 However, we recognized that this segment 
of ratjadone also resembles linear terpenoids, such as geraniol 157, nerol 158, and farnesol 
159. These compounds are derived from isoprenoid metabolism and formed from head/tail 
coupling of the basic building blocks dimethylallyl pyrophosphate (DMAPP) 160 and 
isopentenyl pyrophosphate (IPP) 161, and are available from natural sources in large 
quantities.  
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Figure 3.1. DMAPP, IPP, and simple linear isoprenoids. 
 
The incorporation of e.g. geraniol into ratjadone analogues would contribute ten of the total 
number of twenty-eight carbon atoms of the ratjadone skeleton, and is therefore highly 
desirable from an atom economy point of view. 
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In order to construct a building block that can serve as a connection between the other two 
fragments, functionalization of e.g. a geraniol derivative at the terminal E-methyl group is 
required. Although many selective allylic oxidation methods are known, only the SeO2 
oxidation (and its catalytic variations) selectively functionalize terminal E-methyl groups, 
and only when the Z substituent is not larger than a methyl group. This chemo- and 
regioselectivity is inherent to the mechanism of the reaction (Fig. 3.2).2 
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Figure 3.2. Mechanism of the SeO2 oxidation. 
 
Since the stoichiometric version of the SeO2 oxidation suffers from complications such as 
the large amount of red selenium formed during the reaction and high toxicity of selenium 
compounds, it is often replaced (especially in large-scale procedures) by a catalytic version 
using a stoichiometric oxidant (typically tBuOOH), which was first described by Sharpless 
and co-workers.3 Several procedures have been described in literature, varying in 
stoichiometry, reaction temperature and time, and additives. An efficient procedure has 
been developed in our group.4 
A major drawback of this methodology is the fact that the reaction typically does not 
proceed to completion. Instead, there seems to be an optimum in the yield of the desired 
allylic alcohol. An increase in reaction time and/or temperature, or the amount of 
stoichiometric oxidant or SeO2 does not result in an increase of the yield of the desired 
alcohol, but rather in formation of the corresponding aldehyde, which is only a minor side 
product under optimal conditions. A typical optimal yield of the desired alcohol is 50%, the 
major part of the remainder being the starting material. Therefore, yields in literature 
reports are often based on recovered starting material. It should be mentioned that these 
problems have (at least partly) been overcome by using alternative selenium catalysts, 
which are, however, expensive and not yet commercially available. 
 
Synthesis of the ratjadone analogue B fragment 
3.2 Synthesis 
 
We performed the catalytic SeO2 oxidation using several protected geraniol and nerol 
derivatives 162-168. The yield is not only dependent on reaction conditions, but also on the 
nature of the protective group. The yield of the reaction seems to increase with the polarity 
of the protective group, ranging from 11% for geranyl TBS ether to 54% (42% alcohol + 
12% aldehyde) for geranyl acetate. The reason for this observation is unclear. The reaction 
also proceeds quite well with THP-protected geraniol or nerol, but later selective cleavage 
of the THP ether in the presence of other protective groups such as Ac or TBS proved 
troublesome.  
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Scheme 3.1. (a) Ac2O, py, 87% from 158, quant. from 157; (b) cat. SeO2, tBuOOH, CH2Cl2, 11-54% (see 
text and Experimental section); (c) DHP, cat. PPTS, CH2Cl2, quant. for 165, quant. for 166; (d) TBSCl, 
imidazole, CH2Cl2, 100% from 157, 99% from 164, 89% from 165; (e) TESCl, imidazole, CH2Cl2, quant.; 
(f) LiAlH4, THF, 0°C, 100%; (g) K2CO3, MeOH, 68% for 166, 94% for 168; (h) MgBr2•Et2O, Et2O, 37% 
(+ 14% starting material). 
 
For example, treatment of the ω-OTBS ether of 165 with various Lewis acids (LiBr, ZnBr2, 
SnCl2) in MeOH or Et2O or PPTS in MeOH led either to no reaction, simultaneous 
cleavage of both protective groups or decomposition. Only reaction with MgBr2•Et2O led to 
selective cleavage of the THP ether to give 165, albeit in poor yield (37%, along with 14% 
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starting material). Thus, a number of monoprotected ω-hydroxylated geraniol and nerol 
derivatives were synthesized using standard reaction conditions.  
 
Since the terpenoid building blocks were to be connected to the other fragments by Wittig 
reaction with the phosphonium salt functionality being part of the terpenoid building block, 
the free alcohol was required to be transformed into a leaving group. Literature often 
reports the use of Appel-type reactions5,6 or bromide displacement of mesylates7 to generate 
bromides in similar cases, we chose to employ the corresponding chlorides. Studies in our 
group have shown that such allylic chlorides are sufficiently electrophilic to be displaced by 
nucleophilic phosphines such as tri-n-butylphosphine. The advantage of such chlorides over 
the corresponding bromides lies mainly in their higher stability. They are stable under flash 
chromatography conditions and therefore can be obtained in pure form; this is not possible 
for the corresponding bromides, which are, in addition, often contaminated by significant 
amounts of chloride. For these reasons, the chlorides can be analyzed unambiguously. 
Finally, the chlorides remain stable upon storage at -20°C (decomposition takes place over 
weeks at room temperature), whereas the bromides are sometimes unstable. 
 
Corey-Kim reaction 
Product Yield (%) 
169 63 
170 63 
171 77 
172 37 
173 52 
174 54 
 
AcO
X X
RO
OR
X
163: X = OH, R = TBS
164: X = OH, R = Ac
165: X = OH, R = THP
170: X = Cl, R = TBS
171: X = Cl, R = Ac
172: X = Cl, R = THP
177: X = PBu3Cl, R = TBS
178: X = PBu3Cl, R = Ac
179: X = PBu3Cl, R = THP
166: X = OH, R = THP
167: X = OH, R = TES
168: X = OH, R = TBS
173: X = Cl, R = THP
174: X = Cl, R = TES
175: X = Cl, R = TBS
180: X = PBu3Cl, R = THP
181: X = PBu3Cl, R = TES
182: X = PBu3Cl, R = TBS
162: X = OH
169: X = Cl
176: X = PBu3Cl
a
ab
b
a
b
 
175 77 
 
Scheme 3.2. (a) NCS, Me2S, CH2Cl2, -78→-10°C, 37-77%; (b) PBu3, 70°C, 3h, no solvent, quant. 
 
The Corey-Kim reaction8 proved to be an efficient and reliable method to generate the 
allylic chlorides. The functionalized allylic alcohols were converted to the corresponding 
chlorides in reasonable to excellent yields using this procedure. The allylic chlorides were 
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transformed into the corresponding tributylphosphonium salts by treatment with 1.0 eq. of 
tri-n-butylphosphine at 70°C fo 3h (no solvent). 
 
3.3 Conclusion 
 
Despite its limitations, the catalytic selenium dioxide oxidation provides a unique 
possibility to rapidly generate α,ω-bifuctional terpenoids. The resulting alcohols are 
reliably transformed to the corresponding chlorides, which are stable, isolable compounds. 
Treatment with tributylphosphine affords the phosphonium salts required for connection to 
the other segments quantitatively. 
 
3.4 Experimental section 
 
General. All commercial reagents were purchased from Fluka, Merck or Aldrich and used without further 
purification, unless otherwise stated. All oxygen- and water-sensitive reactions were carried out in oven-
dried glassware under argon. THF was distilled from potassium/benzophenone ketyl, Et2O was distilled 
from sodium/potassium/benzophenone ketyl, and CH2Cl2 was distilled from calcium hydride. Other dry 
solvents were purchased from Fluka. Flash chromatography was performed using silica gel 60 (230-400 
mesh, Merck). Thin-layer chromatography (TLC) was performed using silica plates (Merck, silica gel 60 
F254) and developed using Cer-MOP reagent [molybdatophosphoric acid (5.0 g), cerium (IV) sulfate (2.0 g), 
and concentrated H2SO4 (16 ml) in water (200 ml)]. Optical rotations were measured using a 1 ml cell with 
1 dm path length on a Jasco DIP-1000 digital polarimeter. IR spectra were recorded as CHCl3 solutions or 
as thin films between NaCl plates on a Bruker IFS 28. 1H and 13C NMR spectra were recorded in CDCl3 on 
Varian Mercury VX 300 and VX 400 spectrometers using TMS as internal standard. Chemical shifts δ are 
reported in parts per million (ppm), coupling constants J are given in Hertz (Hz). High resolution ESI mass 
spectra were obtained from a Bruker Apex 70e Fourier transform ion cyclotron resonance mass 
spectrometer equipped with a 7.0 Tesla superconducting magnet and an external electrospray ion source 
(Agilent, off axis spray).  
 
 
10-Hydroxyneryl acetate 162: To a cooled (0°C) mixture of pyridine (16.1 ml, 15.8 g, 200 mmol) and 
acetic anhydride (16.1 ml, 17.5 g, 170 mmol) was added nerol (15.4 g, 100 mmol). The mixture was stirred 
for 2 h at 0°C, diluted with EtOAc (100 ml), and washed with 1N aq. HCl (2 × 50 ml), H2O (2 × 50 ml), and 
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brine (50 ml). The organic fraction was dried (Na2SO4), filtered, and concentrated in vacuo, giving 162a 
(17.0 g, 86.6 mmol, 87%) as a colorless oil that was used in the next step without further purification. 1H 
NMR (CDCl3, 300 MHz): δ = 1.60 (s, 3H), 1.68 (s, 3H), 1.77 (d, J = 1.18 Hz, 3H), 2.06-2.14 (m, 4H), 4.55 
(dd, J = 7.33, 0.59 Hz, 2H), 5.09 (tq, J = 5.57, 1.47 Hz, 1H), 5.36 (t, J = 7.33 Hz, 1H) ppm. A mixture of 
neryl acetate (162a, 17.0 g, 86.6 mmol), SeO2 (2.41 g, 21.8 mmol), 70% aq. tBuOOH (12.3 ml, 93.5 mmol) 
and CH2Cl2 (150 ml) was stirred for 2 h at 0°C. The solvent was removed in vacuo, and toluene (100 ml) 
was added and removed in vacuo. This process was repeated three times in order to remove excess 
tBuOOH. The residue was purified by flash chromatography (column dimensions: 30 × 4 cm, EtOAc/PE = 
1:4→1:2) to give 162 (4.14 g, 19.5 mmol, 23%) as a colorless oil, accompanied by the starting material 
(10.8 g, 55.1 mmol). The yield based on recovered starting material is therefore 65%. 1H NMR (CDCl3, 200 
MHz): δ = 1.65 (s, 3H), 1.75 (d, J = 1.01 Hz, 3H), 2.03 (s, 3H), 2.12-2.14 (m, 4H), 3.97 (s, 2H), 4.55 (d, J = 
7.18 Hz, 1H), 5.30-5.37 (m, 2H) ppm. 
 
 
tert-Butyldimethylsilyl 10-hydroxygeranyl ether 163: To a solution of imidazole (1.56 g, 23.3 mmol) and 
geraniol (3.27 g, 21.2 mmol) in CH2Cl2 (25 ml) was added at 0°C TBSCl (3.35 g, 22.2 mmol). The mixture 
was stirred 2 h at rt, diluted with sat aq. NH4Cl (50 ml), and extracted with CH2Cl2 (3 × 50 ml). The organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo, giving TBS geranyl ether (163a, 5.67 g, 
21.1 mmol, 100 %) as a colorless oil that was pure as judged by 1H NMR and used in the next step without 
further purification. 1H NMR (CDCl3, 400 MHz): δ = 0.07 (s, 6H), 0.91 (s, 9H), 1.60 (s, 3H), 1.62 (s, 3H), 
1.68 (d, J = 0.78 Hz, 3H), 2.00-2.02 (m, 2H), 2.08-2.10 (m, 2H), 4.19 (d, J = 5.86 Hz, 2H), 5.09 (tdd, J = 
7.03, 1.56, 1.17 Hz, 1H), 5.30 (tt, J = 6.64, 1.17 Hz, 1H) ppm. A mixture of SeO2 (117 mg, 1.05 mmol), 
70% aq. tBuOOH (7.79 ml, 59.2 mmol) and CH2Cl2 (50 ml) was stirred for 40 min at rt. Then, TBS geranyl 
ether (163a, 5.67 g, 21.1 mmol) was added and the mixture was stirred for 24 h at rt. The solvent was 
removed in vacuo, and toluene (25 ml) was added and removed in vacuo. This process was repeated three 
times in order to remove excess tBuOOH. The residue was purified by flash chromatography (column 
dimensions: 25 × 3.5 cm, EtOAc/PE = 1:10) to give 163 (659 mg, 2.32 mmol, 11%) as a colorless oil, as 
well as a significant amount of unreacted starting material. 1H NMR (CDCl3, 400 MHz): δ = 0.07 (s, 6H), 
0.91 (s, 9H), 1.63 (s, 3H), 1.67 (s, 3H), 2.03-2.06 (m, 2H), 2.13-2.19 (m, 2H), 3.99 (d, J = 4.68 Hz, 2H), 
4.19 (d, J = 6.25 Hz, 2H), 5.30 (td, J = 6.24, 1.17 Hz, 1H), 5.38 (td, J = 7.03, 1.17 Hz, 1H) ppm. 
 
 
10-Hydroxygeranyl acetate 164: To a cooled (0°C) mixture of pyridine (8.05 ml, 7.91 g, 100 mmol) and 
acetic anhydride (8.03 ml, 8.73 g, mmol) was added geraniol (8.77 ml, 7.71 g, 50 mmol). The mixture was 
stirred for 2 h at 0°C and poured into ice water (200 ml). The mixture was extracted with EtOAc (3 × 100 
ml). The combined organic fractions were washed with 1N aq. HCl (2 × 100 ml), H2O (2 × 100 ml), and 
brine (100 ml), dried (Na2SO4), filtered, and concentrated in vacuo, giving 164a (9.99 g, quant.) as a 
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colorless oil that was used in the next step without further purification. Rf = 0.80 (EtOAc/n/hexane = 1:4) A 
mixture of SeO2 (277 mg, 2.5 mmol), 70% aq. tBuOOH (18.5 ml, 140 mmol) and CH2Cl2 (75 ml) was 
stirred for 30 min at rt. Then, geranyl acetate (164a, max. 50 mmol) was added and the mixture was stirred 
for 24 h at rt. The solvent was removed in vacuo, and toluene (50 ml) was added and removed in vacuo. 
This process was repeated three times in order to remove excess tBuOOH. The residue was purified by 
flash chromatography (column dimensions: 28 × 4 cm, EtOAc/PE = 1:4→1:2) to give 164 (4.41 g, 20.8 
mmol, 42% over two steps) as a colorless oil, accompanied by the corresponding aldehyde (1.22 g, 5.81 
mmol, 12%). 1H NMR (CDCl3, 400 MHz): δ = 1.38 (bs, 1H, OH), 1.67 (s, 3H), 1.71 (s, 3H), 2.06 (s, 3H), 
2.10 (dd, J = 7.42, 7.03 Hz, 2H), 2.18 (dt, J = 7.42, 7.02 Hz, 2H), 4.00 (s, 2H), 4.59 (d, J = 7.03 Hz, 2H), 
5.34 (td, J = 7.03, 1.17 Hz, 1H), 5.37 (t, J = 7.03 Hz) ppm. Rf = 0.22 (EtOAc/n−hexane = 1:3). 
 
 
10-Hydroxygeranyl THP ether 165: To a mixture of geraniol (87 ml, 77.1 g, 500 mmol) and DHP (50 ml, 
46.3 g, 550 mmol) was added AlCl3•H2O (1.21 g, 5.00 mmol). The mixture was stirred 5 h at rt, eluted over 
a short silica column with EtOAc/PE = 1:10 and concentrated in vacuo, giving geranyl THP ether (165a) in 
quantitative yield, as a colorless oil that was pure as judged by 1H NMR and used in the next step without 
further purification. A mixture of SeO2 (1.55 g, 14.0 mmol), 70% aq. tBuOOH (79 ml, 600 mmol) and 
CH2Cl2 (500 ml) was stirred for 30 min at rt. Then, geranyl THP ether (165a, 47.7 g, 200 mmol) was added 
and the mixture was stirred for 24 h at rt. Toluene (120 ml) was added and the solvent was removed in 
vacuo. The residue was taken in Et2O (300 ml), washed with 0.2 N NaOH (3 × 100 ml), and brine (150 ml), 
dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by flash chromatography 
(column dimensions: 25 × 6 cm, EtOAc/PE = 1:10) to give 165 (13.3 g, 52.4 mmol, 26%) as a colorless oil. 
1H NMR (CDCl3, 400 MHz): δ = 1.48-1.85 (m, 6H), 1.67 (s, 3H), 1.68 (s, 3H), 2.05-2.10 (m, 2H), 2.15-
2.19 (m, 2H), 3.49-3.54 (m, 1H), 3.86-3.92 (m, 1H), 3.99 (s, 2H), 4.02 (dd, J = 11.71, 7.42 Hz, 1H), 4.24 
(dd, J = 11.71, 6.64 Hz, 1H), 5.35 (ddd, J = 7.41, 6.64, 1.17 Hz, 1H), 5.37 (td, J = 6.64, 1.17 Hz, 1H) ppm. 
13C NMR (CDCl3, 100 MHz): δ = 13.8, 16.4, 19.6, 25.5, 25.8, 30.7, 39.2, 62.2, 63.6, 68.8, 97.7, 120.8, 
125.3, 134.9, 139.5 ppm. 
 
 
10-(Tetrahydropyran-2-yl)oxygeraniol 166: To a solution of 10-hydroxygeranyl acetate (164, 5.80 g, 
27.3 mmol) and PPTS•H2O (690 mg, 2.7 mmol) in CH2Cl2 (135 ml) was added DHP (4.63 g, 55.0 
mmol).The mixture was stirred for 5 h at rt, diluted with Et2O (200 ml), washed with brine (125 ml), dried 
(MgSO4), filtered, and concentrated in vacuo to give crude 166a (8.25 g, 27.8 mmol, quant.) that was pure 
as judged by TLC and 1H NMR and used in the next step without further purification. K2CO3 (459 mg, 3.32 
mmol), was added at rt to a solution of 10-(tetrahydropyran-2-yl)oxygeranyl acetate (166a, 4.76 g, 16.6 
mmol) in MeOH (10 ml) and the mixture was stirred overnight at rt. The mixture was diluted with EtOAc 
(250 ml) and washed with 1N aq. NH4Cl (100 ml), H2O (100 ml), and brine (100 ml), dried (MgSO4), 
 91
Chapter 3 
 
 92
filtered and concentrated in vacuo. The residue was purified by flash chromatography (column dimensions 
25 × 4 cm, EtOAc/PE = 1:4) to give 166 (2.88 g, 11.32 mmol, 68%) as a colorless oil. 1H NMR (CDCl3, 
200 MHz): δ = 1.34-1.77 (m, 6H), 1.46 (s, 2 × 3H), 1.83-2.00 (m, 4H), 2.86 (bs, 1H, OH), 3.22-3.33 (m, 
1H), 3.61-3.72 (m, 2H), 3.86-3.93 (m, 3H), 5.12-5.20 (m, 2H) ppm. 13C NMR (CDCl3, 50 MHz): δ = 13.5, 
15.6, 18.9, 24.9, 25.4, 38.6, 58.4, 61.4, 72.3, 96.5, 123.9, 127.2, 131.5, 137.4 ppm. 
 
 
10-Triethylsilyloxygeraniol 167: Triethylsilyl chloride (9.23 ml, 8.29 g, 55.0 mmol) was added in at 0°C 
to a solution of 10-hydroxygeranyl acetate (164, 10.61 g, 50.0 mmol) and imidazole (4.43 g, 65.0 mmol) in 
CH2Cl2 (250 ml) and the mixture was stirred for 2 h at rt. After dilution with CH2Cl2 (250 ml), the mixture 
was washed with H2O (200 ml), sat. aq. NH4Cl (200 ml) and brine (250 ml). The organic fraction was dried 
(Na2SO4), filtered, and concentrated in vacuo, affording 167a (16.9 g, quant.) as a colorless oil that was 
used in the next step without further purification. 1H NMR (CDCl3, 400 MHz): δ = 0.61 (q, J = 8.00 Hz, 
6H), 0.96 (t, J= 8.00 Hz, 9H), 1.61 (s, 3H), 1.71 (s, 3H), 2.06 (s, 3H), 2.09 (m, 2H), 2.16 (m, 2H), 4.00 (s, 
2H), 4.59 (d, J = 7.03 Hz, 2H), 5.37 (m, 2H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 4.4, 6.7, 13.4, 16.4, 
21.0, 25.7, 39.1, 61.3, 68.2, 118.3, 123.8, 134.7, 142.0, 171.1 ppm. Rf = 0.80 (EtOAc/n/hexane = 1:4).To a 
solution of 167a (max. 50.0 mmol) in THF (250 ml) was added at 0°C LiAlH4 (1.88 g, 50.0 mmol) and the 
mixture was stirred for 10 min. at 0°C. The mixture was diluted with sat. aq. NH4Cl (500 ml) and extracted 
with with tBuOMe (3 × 300 ml). The combined organic fractions were dried (Na2SO4), filtered, and 
concentrated in vacuo to give crude 167 (14.28 g, 50.2 mmol, 100% over two steps) as a colorless oil that 
was pure as judged by TLC, 1H and 13C NMR. 1H NMR (CDCl3, 400 MHz): δ = 0.59 (q, J = 7.81 Hz, 6H), 
0.95 (t, J= 7.81 Hz, 9H), 1.60 (s, 3H), 1.66 (s, 3H), 1.93 (bs, 1H), 2.05 (m, 2H), 2.15 (m, 2H), 3.98 (s, 2H), 
4.11 (d, J = 7.02 Hz, 2H), 5.37 (m, 2H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 4.3, 6.7, 13.4, 16.1, 25.7, 
39.1, 59.1, 68.2, 123.6, 124.1, 134.5, 138.9 ppm. Rf = 0.40 (EtOAc/n/hexane = 1:4) 
 
 
10-tert-Butyldimethylsilyloxygeraniol 168: From 164: tert-Butyldimethylsilyl chloride (3.29 g, 21.8 
mmol) was added in one portion at 0°C to a solution of 10-hydroxygeranyl acetate (164, 4.41 g, 20.8 mmol) 
and imidazole (1.56 g, 22.8 mmol) in CH2Cl2 (50 ml) and the mixture was stirred for 15 min. at rt. After 
dilution with sat aq. NH4Cl (50 ml) the phases were separated and the aqueous phase was extracted one 
more time with CH2Cl2 (50 ml). The combined organic fractions were washed with brine (50 ml), dried 
(Na2SO4), filtered, and concentrated in vacuo, affording 168a (6.70 g, 20.5 mmol, 99%) as a colorless oil 
that was used in the next step without further purification. 1H NMR (CDCl3, 300 MHz): δ = 0.06 (s, 6H), 
0.91 (s, 9H), 1.59 (s, 3H), 1.71 (s, 3H), 2.06 (s, 3H), 2.09 (m, 2H), 2.15 (m, 2H), 4.00 (s, 2H), 4,58 (d, J = 
7.13 Hz, 2H), 5.35-5.36 (m, 2H) ppm. Rf = 0.77 (EtOAc/PE = 1:4). To a solution of 168a (6.69 g, 20.5 
mmol) in MeOH (150 ml) was added K2CO3 (567 mg, 4.10 mmol) and the mixture was stirred for 45 min. 
at rt. The volume was reduced in vacuo and the mixture was diluted with sat. aq. NH4Cl (100 ml) and brine 
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(200 ml) and extracted with with tBuOMe (3 × 150 ml). The combined organic fractions were dried 
(Na2SO4), filtered, and concentrated in vacuo to give 168 (5.51 g, 19.4 mmol, 94%) as a colorless oil that 
was used in the next step without further purification. 
From 165: tert-Butyldimethylsilyl chloride (791 mg, 5.25 mmol) was added in one portion at 0°C to a 
solution of 10-hydroxygeranyl THP ether (165, 1.27 g, 5.00 mmol) and imidazole (374 mg, 5.50 mmol) in 
CH2Cl2 (10 ml) and the mixture was stirred for 2 h at 0°C. After dilution with tBuOMe (50 ml), the mixture 
was washed with sat. aq. NH4Cl (25 ml), sat. aq. NaHCO3 (25 ml) and brine (25 ml). The organic fraction 
was dried (Na2SO4), filtered, and concentrated in vacuo, affording 168b (1.65 g, 4.47 mmol, 89%) as a 
colorless oil that was used in the next step without further purification. 1H NMR (MHz): δ = 0.06 (s, 6H), 
0.91 (s, 9H), 1.51-1.58 (m, 4H), 1.59 (s, 3H), 1.68 (s, 3H), 1.70-1.76 (m, 1H), 1.81-1.86 (m, 1H), 2.07 (m, 
2H), 2.16 (m, 2H), 3.49-3.53 (m, 1H), 3.86-3.92 (m, 1H), 4.00 (s, 2H), 4.02 (dd, J = 12.10, 7.42 Hz, 1H), 
4.24 (dd, J = 12.10, 6.64 Hz, 1H), 4.62 (m, 1H), 5.35-5.38 (m, 2H) ppm. To a solution of THP ether 168b 
(737 mg, 2.00 mmol) in Et2O (40 ml) was added MgBr2•Et2O (1.55 g, 6.00 mmol) and the mixture was 
stirred overnight at rt. The mixture was diluted with sat. aq. NaHCO3 (100 ml) and extracted with with 
tBuOMe (3 × 75 ml). The combined organic fractions were dried (Na2SO4), filtered, and concentrated in 
vacuo. The product was purified by flash chromatography (column dimensions: 25 × 2.5 cm, EtOAc/PE = 
1:4) to give 168 (211 mg, 0.741 mmol, 37%) as a colorless oil, accompanied by the starting material (107 
mg, 0.29 mmol, 14 %). 1H NMR (CDCl3, 300 MHz): δ = 0.06 (s, 6H), 0.91 (s, 9H), 1.59 (s, 3H), 1.68 (s, 
3H), 2.06 (m, 2H), 2.15 (m, 2H), 4.00 (s, 2H), 4.15 (d, J = 5.85 Hz, 2H), 5,36 (t, J = 5.85 Hz), 5.42 (t, J = 
7.03 Hz, 1H) ppm. 13C NMR (CDCl3, 75 MHz): δ = -5.1, 13.6, 16.3, 18.5, 25.8, 26.0, 39.2, 59.4, 68.5, 
123.4, 123.7, 134.5, 139.4 ppm. Rf = 0.37 (EtOAc/PE = 1:4). Rf = 0.16 (EtOAc/n-hexane = 1:6). 
 
 
10-Chloroneryl acetate 169: To a solution of NCS (421 mg, 3.15 mmol) in CH2Cl2 (15 ml) was added at 
−10°C Me2S (251 μl, 214 mg, 3.44 mmol). The mixture was stirred for 10 min. at -10°C, and the resulting 
white suspension was cooled to -78°C. 10-Hydroxygeranyl acetate (162, 608 mg, 2.87 mmol) was added 
and the mixture was stirred for 1 h at -10°C. After dilution with sat. aq. NH4Cl (100 ml), the mixture was 
extracted with CH2Cl2 (3 × 50 ml). The combined organic fractions were dried (Na2SO4), filtered, and 
concentrated in vacuo. The product was purified by flash chromatography (column dimensions: 25 × 2 cm, 
EtOAc/PE = 1:10) to give 169 (415 mg, 1.80 mmol, 63%) as a colorless oil. 1H NMR (CDCl3, 300 MHz): 
δ = 1.74 (d, J = 0.88 Hz, 3H), 1.77 (s, 3H), 2.05 (s, 3H), 2.15-2.16 (m, 4H), 4.01 (s, 2H), 4.55 (d, J = 7.04 
Hz, 2H), 5.39 (td, J = 7.03, 1.17 Hz, 1H), 5.50 (m, 1H) ppm. 
 
 
tert-Butyldimethylsilyl 10-chlorogeranyl ether 170: To a solution of NCS (588 mg, 4.40 mmol) in 
CH2Cl2 (25 ml) was added at -10°C Me2S (351 μl, 298 mg, 4.80 mmol). The mixture was stirred for 10 min. 
at -10°C, and the resulting white suspension was cooled to -78°C. tert-Butyldimethylsilyl 
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10−hydroxygeranyl ether (163, 1.14 g, 4.00 mmol) was added and the mixture was stirred for 1 h at -10°C. 
After dilution with sat. aq. NH4Cl (20 ml) and H2O (50 ml), the mixture was extracted with CH2Cl2 (1 × 75 
ml) and Et2O (2 × 75 ml). The combined organic fractions were dried (Na2SO4), filtered, and concentrated 
in vacuo. The product was purified by flash chromatography (column dimensions: 25 × 2 cm, EtOAc/PE = 
1:40) to give 170 (760 mg, 2.51 mmol, 63%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.08 (s, 
6H), 0.91 (s, 9H), 1.63 (s, 3H), 1.74 (d, J = 0.78 Hz, 3H), 2.03-2.07 (m, 2H), 2.14-2.19 (m, 2H), 4.00 (s, 
2H), 4.19 (d, J = 6.24 Hz, 2H), 5.30 (tt, J = 6.24, 1.17 Hz, 1H), 5.51 (t, J = 7.03 Hz, 1H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ = -4.9, 14.2, 16.4, 18.5, 26.1, 26.3, 38.7, 52.5, 60.3, 124.7, 130.2, 131.6, 135.9 ppm. 
Rf = 0.76 (EtOAc/PE = 1:20). 
 
 
10-Chlorogeranyl acetate 171: To a solution of NCS (586 mg, 4.40 mmol) in CH2Cl2 (25 ml) was added at 
−10°C Me2S (351 μl, 298 mg, 4.80 mmol). The mixture was stirred for 10 min. at -10°C, and the resulting 
white suspension was cooled to -78°C. 10-Hydroxygeranyl acetate (164, 849 mg, 4.00 mmol) was added 
and the mixture was stirred for 1 h at -10°C. After dilution with sat. aq. NH4Cl (150 ml), the mixture was 
extracted with CH2Cl2 (3 × 100 ml). The combined organic fractions were dried (Na2SO4), filtered, and 
concentrated in vacuo. The product was purified by flash chromatography (column dimensions: 25 × 2.5 
cm, EtOAc/PE = 1:15) to give 171 (714 mg, 3.09 mmol, 77%) as a colorless oil. 1H NMR (CDCl3, 400 
MHz): δ = 1.71 (s, 3H), 1.74 (s, 3H), 2.06 (s, 3H), 2.10 (m, 2H), 2.17 (m, 2H), 4.01 (s, 2H), 4.59 (d, J = 
7.14 Hz, 2H), 5.34 (m, 1H), 5.50 (m, 1H) ppm. Rf = 0.37 (EtOAc/n-hexane = 1:10). 
 
 
10-Chlorogeranyl tetrahydropyran-2-yl ether 172: To a solution of NCS (734 mg, 5.50 mmol) in CH2Cl2 
(25 ml) was added at -10°C Me2S (439 μl, 373 mg, 6.00 mmol). The mixture was stirred for 10 min. at 
−10°C, and the resulting white suspension was cooled to -78°C. 10-Hydroxygeranyl tetrahydropyran-2-yl 
ether (165, 1.27 g, 5.00 mmol) was added and the mixture was stirred for 1 h at -10°C. After dilution with 
sat. aq. NH4Cl (50 ml), the phases were separated and the aqueoues phase was extracted with Et2O (2 × 50 
ml). The combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product 
was purified by flash chromatography (column dimensions: 25 × 3 cm, EtOAc/PE = 1:20) to give 172 (510 
mg, 1.87 mmol, 37%) as a colorless oil. 1H NMR (CDCl3, 300 MHz): δ = 1.50-1.88 (m, 6H), 1.68 (s, 3H), 
1.73 (d, J = 0.73 Hz, 1H), 2.05-2.11 (m, 2H), 2.15-2.22 (m, 2H), 3.48 (m, 1H), 3.86 (m, 1H), 4.01 (s, 2H), 
4.02 (dd, J = 11.89, 7.50 Hz, 1H), 4.24 (dd, J = 11.89, 7.32 Hz, 1H), 4.62 (dd, J = 4.02, 2.93 Hz, 1H), 5,37 
(ddd, J = 7.32, 6.40, 1.10 Hz, 1H), 5.51 (t, J = 6.40 Hz, 1H) ppm. 
 
 
10-(Tetrahydropyran-2-yl)oxygeranyl chloride 173: To a solution of NCS (706 mg, 5.29 mmol) in 
CH2Cl2 (25 ml) was added at -10°C Me2S (422 μl, 359 mg, 5.77 mmol). The mixture was stirred for 10 min. 
Synthesis of the ratjadone analogue B fragment 
at -10°C, and the resulting white suspension was cooled to -78°C. 10-(Tetrahydropyran-2-yl)oxygeraniol 
(166, 1.22 g, 4.81 mmol) was added and the mixture was stirred for 1 h at -10°C. After dilution with sat. aq. 
NH4Cl (50 ml), the phases were separated and the aqueoues phase was extracted with Et2O (2 × 50 ml). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo to give crude 173 (1.24 
g, 4.54 mmol, 94%) as a yellow oil. The product was purified by flash chromatography (column 
dimensions: 25 × 3 cm, EtOAc/PE = 1:20) to give 173 (682 mg, 2.50 mmol, 52%) as a colorless oil. 1H 
NMR (CDCl3, 300 MHz): δ = 1.51-1.94 (m, 6H), 1.66 (s, 3H), 1.73 (d, J = 1.17 Hz, 3H), 2.07-2.21 (m, 4H), 
3.50 (m, 1H), 3.82-3.91 (m, 2H), 4.08-4.11 (m, 3H), 4.60 (dd, J = 3.82, 2.93 Hz, 1H), 5.40 (td, J = 7.04, 
1.17 Hz, 1H), 5.45 (td, J = 8.21, 1.17 Hz, 1H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 14.0, 16.0, 19.5, 25.4, 
30.6, 38.9, 40.9, 62.0, 72.6, 97.2, 120.3, 126.5, 132.2, 142.03 ppm. 
 
 
10-Triethylsilyloxygeranyl chloride 174:  To a solution of NCS (1.469 g, 11.0 mmol) in CH2Cl2 (100 ml) 
was added at -10°C Me2S (877 μl, 745 mg, 12.0 mmol). The mixture was stirred for 10 min. at -10°C, and 
the resulting white suspension was cooled to -78°C. 10-Triethylsilyloxygeraniol (167, 2.845 mg, 10.0 
mmol) was added and the mixture was stirred for 1 h at -10°C. After dilution with sat. aq. NH4Cl (300 ml), 
the mixture was extracted with CH2Cl2 (3 × 200 ml). The combined organic fractions were dried (Na2SO4), 
filtered, and concentrated in vacuo to give crude 174 (3.018 g, 9.96 mmol, 100%) as a colorless oil. The 
product, which was estimated ~90% pure by 1H NMR, was used in the next step without further 
purification, since flash chromatography under various conditions resulted in significant loss of material. 1H 
NMR (CDCl3, 400 MHz): δ = 0.61 (q, J = 7.81 Hz, 6H), 0.96 (t, J = 7.81 Hz, 9H), 1.61 (s, 3H), 1.73 (s, 
3H), 2.10 (m, 2H), 2.16 (m, 2H), 4.00 (s, 2H), 4.10 (d, J = 7.80 Hz, 2H), 5.37 (t, J = 6.25 Hz, 1H), 5.45 (t, 
J = 8.00 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 6.7, 13.4, 16.0, 25.5, 29.5, 38.9, 41.0, 68.6, 120.5, 
123.6, 134.7, 142.4 ppm. Rf = 0.72 (EtOAc/n-hexane = 1:6). 
 
 
10-tert-Butyldimethylsilyloxygeranyl chloride 175: To a solution of NCS (105 mg, 0.788 mmol) in 
CH2Cl2 (5 ml) was added at -10°C Me2S (63 μl, 53 mg, 0.859 mmol). The mixture was stirred for 10 min. at 
-10°C, and the resulting white suspension was cooled to -78°C. 10-tert-Butyldimethylsilyloxygeraniol (168, 
204 mg, 0.716 mmol) was added and the mixture was stirred for 1 h at -10°C. After dilution with sat. aq. 
NH4Cl (25 ml), the mixture was extracted with CH2Cl2 (3 × 25 ml). The combined organic fractions were 
dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash chromatography 
(column dimensions: 25 × 2 cm, EtOAc/PE = 1:40) to give 175 (168 mg, 0.555 mmol, 77%) as a colorless 
oil. 1H NMR (CDCl3, 300 MHz): δ = 0.06 (s, 6H), 0.91 (s, 9H), 1.59 (s, 3H), 1.73 (d, J = 1.28 Hz, 3H), 
2.09-2.17 (m, 4H), 4.00 (s, 2H), 4.10 (d, J = 8.05 Hz, 2H), 5.35 (m, 1H), 5.45 (td, J = 8.59, 1.28 Hz, 1H) 
ppm.  
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4 Synthesis of the ratjadone analogue C fragment 
 
4.1 Retrosynthesis 
 
A suitable building block representing the C1-C6 fragment of ratjadone should be aldehyde 
30, in which the sensitive lactone functionality is protected as an isopropyl acetal (Fig. 4.1). 
This is a known compound, employed in several total syntheses, including not only 
Kalesse´s total synthesis of ratjadone,1,2 but also syntheses of callystatin A3-6 and 
fostriecin7. 
 
O
O OiPr
30
O O
O
OH
OH
5: Ratjadone  
 
Figure 4.1. Ratjadone and its C ring building block 30. 
 
The strategies employed to obtain compound 30 (or derivatives) are diverse, and include 
methods involving catalytic asymmetric hetero Diels-Alder reactions4, Brown asymmetric 
allylation and subsequent acrylation of the resulting alcohol followed by RCM8, and vinyl 
Grignard addition to a glycidol derivative followed by transacetalization and RCM3. 
Jacobsen and co-workers demonstrated that their chiral HDA catalyst can also be used to 
construct a similar compound.9 We chose to employ an eclectic approach, combining 
efficient literature procedures to achieve an optimal process.  
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4.2 Synthesis 
 
Commercially available (tert-butyldimethylsilyloxy)acetaldehyde and 1-methoxy-1,3-
butadiene were subjected to a Jacobsen catalytic asymmetric HDA reaction,9 affording 183 
in very good yield with only 0.5 mol% of catalyst 83a, even in larger scale procedures. 
Subsequently, the equatorial methyl acetal was converted to the more stable axial isopropyl 
acetal.2 Interestingly, this axial isopropyl acetal is used as a protective group in nearly all 
syntheses of complex molecules carrying an α,β-unsaturated δ-lactone, even in cases where 
the lactone is formed.7 The reason for this is probably the sensitivity of this lactone moiety 
to both basic and acidic conditions, as well as its incompatibility with a variety of other 
reagents and conditions.  
 
O
O OiPr
30
RO
O OiPr
184: R = TBS
44:   R = H
TBSO
O OMe
183
TBSO
O OMe
a b d
c
 
 
Scheme 4.1. (a) 83a (0.5 mol%), crushed 4Å mol. sieves, 88%; (b) PPTS, iPrOH; (c) TBAF, THF, 61% 
over two steps; (d) DMP, CH2Cl2, 96%. 
 
The inversion of the acetal was accompanied on some occasions with partial desilylation. 
This is not a problem, since the next reaction is the cleavage of the TBS ether under 
standard conditions (TBAF, THF). Because of concerns about possible partial 
epimerization at C5, the basic conditions of the Swern oxidation10 were deemed 
inappropriate for conversion to aldehyde 30. Instead, Dess-Martin oxidation11 was 
employed to obtain the required aldehyde 30 in excellent yield. 
 
In preliminary studies, we attempted to use unprotected lactone 185. At this point in time, it 
was still unclear if this was a useful building block. Reports that avoid the use of the 
lactone and similar compounds as building blocks and use protected lactols instead are 
quite recent and were not available at the beginning of our study. 
 
Synthesis of the ratjadone analogue C fragment 
O
O O
185  
Figure 4.2. Unprotected C ring building block 185. 
 
Commercially available (S)-glycidol was protected as a TBS ether. TBS ether 186 was 
treated with lithiated methyl propiolate at -78°C in the presence of BF3•Et2O to facilitate 
epoxide opening. It should be noted that in our hands none of the desired product was 
obtained when the literature procedure12 was followed (alkyne, then n-BuLi, then 
BF3•Et2O, then epoxide), whereas when the order of addition was changed to a more logical 
sequence (alkyne, then n-BuLi, then epoxide, then BF3•Et2O), the desired product 187 was 
obtained in up to 88% yield (vs. 65% reported). Selective hydrogenation of the alkyne to 
the desired Z-alkene 188 was achieved with Lindlar catalyst in EtOAc. Ring closure to δ-
lactone 188 then proceeded smoothly by treatment with PPTS in refluxing benzene. 
Cleavage of the TBS ether was achieved by treatment with TBAF in the presence of AcOH.  
 
RO
O O
RO
b cO
TBSO
O
OMe
OH 187
TBSO
OH
188
O
OMe d
R = H
186: R = TBS
a 189: R = TBS
190: R = He
 
Scheme 4.2. (a) TBSCl, imidazole, CH2Cl2, 83%; (b) methyl propiolate, n-BuLi, THF, -78°C, then 186, 
then BF3•Et2O, 84%; (c) H2 (1 atm), Lindlar catalyst, EtOAc, 93%; (d) PPTS, benzene, Δ, 85%; (e) TBAF, 
AcOH, THF, 57%. 
 
Thus, we were able to obtain (R)-6-hydroxymethyl-5,6-dihydro-α-pyrone 190, but further 
conversion to aldehyde 185 was unsuccessful under various conditions (Swern, Dess-
Martin). The apparent instability of this aldehyde is the probable reason that this compound 
is not used in any synthesis of a complex natural product. The only report of the use of this 
compound for a total synthesis is that of (+)-goniothalamin and (−)-argentilactone by 
Tsubuki et al., who generated the aldehyde in situ by Swern oxidation and used it 
immediately in the subsequent Wittig reaction.13 Even in this case, the yield did not exceed 
37%. 
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Boger and co-workers also attempted to use fragment 185 in their total synthesis of 
fostriecin.7 They were, however, not successful, and protected the lactone as an axial 
isopropyl acetal for further conversions. These findings indeed suggest that protection of 
such lactones is necessary for multistep syntheses, since the presence of the unprotected 
lactone is incompatible with a wide variety of conditions commonly used in organic 
synthesis. The only reported example of a synthesis where such a lactone is present in its 
unprotected form over a longer sequence of reactions is the elegant total synthesis of 
fostriecin by Chavez and Jacobsen.14 In syntheses of compounds of the leptomycin family, 
the main problem seems to be the combination of the unsaturated lactone and the tetraene 
chain. 
 
4.3 Conclusion 
 
The synthesis of (R)-6-hydroxymethyl-5,6-dihydro-α-pyrone was achieved in four steps, 
including nucleophilic ring opening of a protected glycidol derivative, Lindlar 
hydrogenation, acid-catalyzed cyclization, and desilylation. Unfortunately, the 
corresponding aldehyde proved to be extremely unstable, rendering this route impractical if 
not useless for the synthesis of complex molecules. Various groups reported the use of 
isopropyl acetal 30 in the synthesis of 6-substituted 5,6-dihydro-α-pyrones.1-6 This 
compound was obtained via a new reaction sequence featuring a very efficient catalytic 
asymmetric HDA reaction using Jacobsen's HDA catalyst 83a.9 Subsequent 
transacetalization, desilylation, and Dess-Martin oxidation11 afforded the required building 
block 30. This four step sequence not only provides the desired fragment in good overall 
yield, but also does not require enantiomerically pure starting materials, and uses only a 
very small amount (0.5 mol%) of catalyst 83a. 
 
4.4 Experimental section 
 
General. All commercial reagents were purchased from Fluka, Merck or Aldrich and used without further 
purification, unless otherwise stated. All oxygen- and water-sensitive reactions were carried out in oven-
Synthesis of the ratjadone analogue C fragment 
dried glassware under argon. THF was distilled from potassium/benzophenone ketyl, Et2O was distilled 
from sodium/potassium/benzophenone ketyl, and CH2Cl2 was distilled from calcium hydride. Other dry 
solvents were purchased from Fluka. Flash chromatography was performed using silica gel 60 (230-400 
mesh, Merck). Thin-layer chromatography (TLC) was performed using silica plates (Merck, silica gel 60 
F254) and developed using Cer-MOP reagent [molybdatophosphoric acid (5.0 g), cerium (IV) sulfate (2.0 g), 
and concentrated H2SO4 (16 ml) in water (200 ml)]. Optical rotations were measured using a 1 ml cell with 
1 dm path length on a Jasco DIP-1000 digital polarimeter. IR spectra were recorded as CHCl3 solutions or 
as thin films between NaCl plates on a Bruker IFS 28. 1H and 13C NMR spectra were recorded in CDCl3 on 
Varian Mercury VX 300 and VX 400 spectrometers using TMS as internal standard. Chemical shifts δ are 
reported in parts per million (ppm), coupling constants J are given in Hertz (Hz). High resolution ESI mass 
spectra were obtained from a Bruker Apex 70e Fourier transform ion cyclotron resonance mass 
spectrometer equipped with a 7.0 Tesla superconducting magnet and an external electrospray ion source 
(Agilent, off axis spray).  
 
 
(2S,6R)-6-tert-Butyldimethylsilyloxymethyl-2-methoxy-5,6-dihydropyran 183: To a mixture of tert-
butyldimethylsilyloxyacetaldehyde (9.10 g, 52.2 mmol), 1-methoxy-1,3-butadiene (4.06 g, 47.9 mmol), and 
crushed molecular sieves 4Å (1.30 g) was added (R,R)-Jacobsen HDA catalyst (116 mg, 0.24 mmol). The 
mixture was stirred for 24 h at rt, after which the starting material was fully consumed as judged by TLC. 
The product was purified by flash chromatography (column dimensions: 30 × 5 cm, EtOAc/PE = 1:10) to 
give 183 (10.90 g, 42.2 mmol, 88%) as a slightly brown oil. 1H NMR (CDCl3, 400 MHz): δ = 0.07 (s, 6H), 
0.90 (s, 9H), 2.06-2.10 (m, 2H), 3.47 (s, 3H), 3.65 (dd, J = 10.15, 6.24 Hz, 1H), 3.75 (dd, J = 10.15, 5.85 
Hz, 1H), 3.85 (m, 1H), 5.02 (m, 1H), 5.64 (dd, J = 10.15, 1.56 Hz, 1H), 5.97 (dtd, J = 10.15, 6.25, 1.56 Hz, 
1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = -5.2, -5.1, 18.4, 26.0, 26.8, 55.2, 65.4, 72.5, 97.5, 126.7, 128.2 
ppm. Rf = 0.64 (EtOAc/n−hexane = 1:6). 
 
 
(2R,6R)-6-tert-Butyldimethylsilyloxymethyl-2-isopropoxy-5,6-dihydropyran 184: To a solution of 183 
(4.58 g, 17.6 mmol) in iPrOH (125 ml) was added PPTS (442 mg, 1.76 mmol). The mixture was stirred at rt 
overnight, diluted with brine (500 ml) and extracted with tBuOMe (3 × 250 ml). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography (column dimensions: 25 × 4 cm, EtOAc/PE = 1:10) to give 184 (4.76 g, 16.6 mmol, 94%) 
as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.07 (s, 6H), 0.90 (s, 9H), 1.17 (d, J = 6.25 Hz, 3H), 
1.25 (d, J = 6.25 Hz, 3H), 1.97 (m, 2H), 3.62 (dd, J = 10.54, 4.68 Hz, 1H), 3.71 (dd, J = 10.54, 5.85 Hz, 
1H), 3.99-4.06 (m, 2H), 5.09 (s, 1H), 5.71 (m, 1H), 6.00 (m, 1H) ppm. Rf = 0.61 (EtOAc/n/hexane = 1:10). 
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(2R,6R)-6-Hydroxymethyl-2-isopropoxy-5,6-dihydropyran 44: To a solution of 184 (4.76 g, 16.6 mmol) 
in anhydrous THF (100 ml) was added TBAF•3H2O (5.51 g, 17.5 mmol) and the mixture was stirred for 1.5 
h at rt. After dilution with sat. aq. NH4Cl (300 ml), the mixture was extracted with tBuOMe (3 × 150 ml). 
The combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was 
purified by flash chromatography (column dimensions: 25 × 4 cm, EtOAc/PE = 1:3) to give 44 (1.85 g, 10.7 
mmol, 65%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 1.18 (d, J = 6.24 Hz, 3H), 1.25 (d, J = 6.25 
Hz, 3H), 1.89 (dddd, J = 17.56, 5.46, 3.51, 1.56 Hz, 1H), 2.14 (dddt, J = 17.56, 11.32, 2.34, 1.95 Hz, 1H), 
2.33 (dd, J = 5.85, 5.46 Hz, 1H, OH), 3.61 (m, 1H), 3.71 (m, 1H), 4.00 (heptet, J = 6.25 Hz, 1H), 4.08 (m, 
1H), 5.11 (s, 1H), 5.72 (dtd, J = 10.15, 2.73, 1.56 Hz, 1H), 6.00 (dd, J = 10.15, 5.85 Hz, 1H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ = 21.97, 23.83, 26.04, 65.14, 66.64, 69.41, 92.64, 125.56, 127.94 ppm. Rf = 0.21 
(EtOAc/n/hexane = 1:4). 
 
 
(2R,6R)-6-Formyl-2-isopropoxy-5,6-dihydropyran 30: To a solution of 44 (86 mg, 0.50 mmol) in 
anhydrous CH2Cl2 (3 ml) was added Dess-Martin periodinane (254 mg, 0.60 mmol) and the mixture was 
stirred for 1 h at rt, after which the starting material was fully consumed as judged by TLC. The reaction 
mixture was transferred to a flash column (column dimensions) and eluted with CH2Cl2/tBuOMe (20:1), 
affording 30 (81.4 mg, 0.48 mmol, 96%) as a colorless, somewhat volatile liquid. 1H NMR (CDCl3, 400 
MHz): δ = 1.21 (d, J = 6.25 Hz, 3H), 1.25 (d, J = 6.25 Hz, 3H), 2.12-2.29 (m, 2H), 4.07 (heptet, J = 6.25 
Hz, 1H), 4.43 (dd, J = 11.31, 4.29 Hz, 1H), 5.21 (d, J = 1.17 Hz, 1H), 5.76 (m, 1H), 6.02 (m, 1H), 9.74 (s, 
1H) ppm. 
 
 
(S)-tert-Butyldimethylsilyl glycidyl ether 186: To a solution of imidazole (1.22 g, 18.0 mmol) and (S)-
glycidol (995 μl, 1.11 g, 15.0 mmol) in CH2Cl2 (15 ml) was added at 0°C tert-butyldimethylsilyl chloride 
(2.49 g, 16.5 mmol). The mixture was stirred for 2 h at rt and quenched by addition of sat. aq. NH4Cl. The 
mixture was extracted three times with CH2Cl2 and the combined organic fractions were dried (Na2SO4), 
filtered, and concentrated in vacuo, affording 186 (2.35 g, 12.5 mmol, 83 %) as a colorless liquid. 1H NMR 
(CDCl3, 200 MHz): δ = 0.06 (s, 3H), 0.07 (s, 3H), 0.89 (s, 9H), 2.62 (dd, J = 5.15, 2.67 Hz, 1H), 2.76 (dd, 
J = 5.08, 4.11 Hz, 1H), 3.07 (dddd, J = 4.76, 4.111, 3.19, 2.76 Hz, 1H), 3.64 (dd, J = 11.92, 4.76 Hz, 1H), 
3.84 (dd, J = 11.92, 3.19 Hz, 1H) ppm. 
 
 
Methyl (R)-6-tert-butyldimethylsilyloxy-5-hydroxyhex-2-ynoate 187: To a solution of methyl propiolate 
(6.23 ml, 5.88 g, 70.0 mmol) in THF (80 ml) was added slowly at -78°C n-BuLi (1.6 M in hexane, 43.8 ml, 
70.0 mmol). (Caution! If the reaction temperature exceeds ~-55°C, decomposition takes place!) The 
solution was stirred for 20 min. at -78°C and a solution of tert-butyldimethylsilyl glycidyl ether (186, 8,74 
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g, 46.4 mmol) in THF (30 ml) was added at -78°C. The mixture was stirred for an additional 20 min. at 
−78°C and BF3•Et2O (8.87 ml, 9.94 g, 70.0 mmol) was added dropwise. The mixture was stirred for 2 h at 
−78°C. The reaction was quenched by addition of sat.aq. NH4Cl (15 ml) and extracted with Et2O (3 × 50 
ml). The combined organic fractions were washed with sat aq. NaHCO3 (2 × 50 ml), dried (Na2SO4), 
filtered, and concentrated in vacuo. Purification by flash chromatography (column dimension: 25 × 4 cm, 
EtOAc/PE = 1:4) yielded 187 (10.7 g, 39.2 mmol, 84%) as a slightly yellow oil. 1H NMR (CDCl3, 200 
MHz): δ = 0.00 (s, 6H), 0.81 (s, 9H), 2.48 (d, J = 7.38 Hz, 2H), 3.49-3.66 (m, 2H), 3.68 (s, 3H), 3.72-3.79 
(m, 1H) ppm. 13C NMR (CDCl3, 50 MHz): δ = <-5.0 18.0, 23.0, 25.6, 52.4, 65.2, 69.4, 74.1, 85.8, 153.8 
ppm. 
 
 
Methyl (R)-6-tert-butyldimethylsilyloxy-5-hydroxyhex-2Z-enoate 188: To a solution of alkyne 187 
(10.32 g, 37.9 mmol) in EtOAc (200 ml) was added Lindlar catalyst (1.2 g). The mixture was stirred for 5 h 
under a 1 bar H2 atmosphere. The mixture was filtered over Celite and the filtrate was washed with sat. aq. 
NaHCO3 (100 ml), dried (MgSO4) and concentrated in vacuo. The crude product contained the desired 
product (E/Z > 1:20) in pure form as judged by 1H NMR, but it was further purified (to remove traces of 
palladium) by flash chromatography (column dimensions: 25 × 5 cm, EtOAc/PE = 1:4) to give 188 (9.63 g, 
35.1 mmol, 93%) as a colorless oil. 1H NMR (CDCl3, 200 MHz): δ = 0.00 (s, 6H), 0.83 (s, 9H), 2.64-2.89 
(m, 2H), 2.93 (bs, 1H, OH), 3.43-3.61 (m, 2H), 3.62 (s, 3H), 3.64-3.72 (m, 1H), 5.81 (dt, J = 11.52, 1.58 
Hz, 1H), 6.26 (dt, J = 11.52, 7.46 Hz, 1H) ppm. 13C NMR (CDCl3, 50 MHz): δ = 18.0, 25.6, 32.4, 66.7, 
71.0, 120.6, 146.2, 166.6 ppm. 
 
 
(R)-6-(tert-butyldimethylsilyloxy)methyl-5,6-dihydro-α-pyrone 189: To a solution of hydroxy ester 188 
(274 mg, 1.00 mmol) in benzene (5 ml) was added PPTS (25 mg, 0.10 mmol) and the mixture was heated to 
reflux for 5.5 h. The mixture was allowed to cool to room temperature, diluted with Et2O (50 ml) and 
washed with H2O (25 ml) and brine (25 ml). The combined organic fractions were dried (MgSO4), filtered, 
concentrated in vacuo, and purified by flash chromatography (column dimension: 25 × 2 cm, EtOAc/PE = 
1:2) to give 189 (206 mg, 0.85 mmol, 85%) as a colorless oil. 1H NMR (CDCl3, 200 MHz): δ = 0.08 (s, 
6H), 0.89 (s, 9H), 2.32-2.63 (m, 2H), 3.81 (d, J = 5.05 Hz, 1H), 4.46 (m, 1H), 6.00 (dt, J = 9.68, 1.21 Hz, 
1H), 6.90 (ddd, J = 9.58, 5.55, 2.95 Hz, 1H) ppm. 
 
 
(R)-6-hydroxymethyl-5,6-dihydro-α-pyrone 190: To a solution of TBS ether 189 (1.21 g, 5.00 mmol) in 
THF (25 ml) was added TBAF•3H2O (1.74 g, 5.50 mmol). The mixture was stirred for 16 h at rt. The 
mixture was concentrated in vacuo, and purified by flash chromatography (column dimension: 25 × 2.5 cm, 
CH2Cl2/MeOH = 10:1) to give 190 (365 mg, 2.85 mmol, 57 %) as a colorless oil that crystallized upon 
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storage. 1H NMR (CDCl3, 300 MHz): δ = 2.32 (m, 1H), 2.62 (m, 1H), 3.75 (dd, J = 12.31, 4.69 Hz, 1H), 
3.90 (dd, J = 12.31, 3.23 Hz, 1H), 4.56 (m, 1H), 6.04 (dd, J = 9.67, 2.05, 1H), 6.94 (ddd, J = 9.67, 6.16, 
2.25 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = <-5.0, 25.1, 63.1, 78.3, 120.1, 145.7, 164.0 ppm. 
 
4.5 References 
 
1. Christmann, M.; Bhatt, U.; Quitschalle, M.; Claus, E.; Kalesse, M. Angew.Chem. 2000, 112, 
4535-4538; Angew. Chem. Int. Ed. 2000, 39, 4364-4366. 
2. Bhatt, U.; Christmann, M.; Quitschalle, M.; Claus, E.; Kalesse, M. J. Org. Chem. 2001, 66, 1885-
1893. 
3. Crimmins, M.T.; King, B.W. J. Am. Chem. Soc. 1998, 120, 9084-9085. 
4. Kalesse, M.; Quitschalle, M.; Khandavalli, C.P.; Saeed, A. Org. Lett. 2001, 3, 3107-3109. 
5. Vicario, J.L.; Job, A.; Wolberg, M.; Mueller, M.; Enders, D. Org. Lett. 2002, 4, 1023-1026. 
6. Kalesse, M.; Chary, K.P.; Quitschalle, M.; Burzlaff, A.; Kasper, C.; Scheper, T. Chem. Eur. J. 
2003, 9, 1129-1136. 
7. Boger, D.L.; Ichikawa, S.; Zhong, W. J. Am. Chem. Soc. 2001, 123, 4161-4167. 
8. Cossy, J.; Pradaux, F.; BouzBouz, S. Org. Lett. 2001, 3, 2233-2235. 
9. Dosseter, A.G.; Jamison, T.F.; Jacobsen, E.N. Angew. Chem. 1999, 111, 2549-2552; Angew. 
Chem. Int. Ed. 1999, 38, 2398-2400. 
10. Mancuso, A.J.; Swern, D. Synthesis 1981, 165-196. 
11. Dess, D.B.; Martin, J.C. J. Org. Chem. 1983, 48, 4155-4156. 
12. Takano, S.; Shimazaki, Y.; Y., I.; Ogasawara, K. Tetrahedron Lett. 1990, 31, 3619-3622. 
13. Tsubuki, M.; Kanai, K.; Honda, T. Heterocycles 1993, 35, 281-288. 
14. Chavez, D.E.; Jacobsen, E.N. Angew. Chem. 2001, 113, 3779-3782; Angew. Chem. Int. Ed. 2001, 
40, 3667-3670. 
 
 
  
 
 
 
5 
Connection of the fragments 
Chapter 5 
 
 108
Connection of the fragments 
 
 
5 Connection of the fragments 
 
5.1 Retrosynthesis 
 
The connection of A, B, and C fragments was envisioned to be achieved through two Wittig 
reactions, the phosphonium salt being present on the terpenoid fragment in both occasions 
and the aldehyde moiety on the A and C fragments. There are, obviously, two approaches 
to construct the full skeleton: (i) B + C → BC → ABC (right to left) and (ii) A + B → AB 
→ ABC (left to right).  
 
Since the synthesis of fragment A requires the highest number of steps, the former route 
can be considered more efficient in terms of convergence. The latter route, however, 
provides a viable alternative, because, at this stage of the synthesis, the available amount of 
A and C building blocks were comparable. 
 
5.2 Right to left route 
 
Aldehyde 30 was reacted with terpene-derived phosphonium salts 176 and 179 (using the 
procedure of the corresponding Wittig reaction in Kalesse's total synthesis of (+)-
ratjadone1,2) to give coupling products 191 and 192 (differing in protective group and 12,13 
double bond geometry (ratjadone numbering)) in reasonable to good yield. However, 
neutralization of the slightly acidic silica with Et3N prior to flash chromatography proved 
essential, and neglecting this resulted in a loss of up to 75% of the product.  
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Figure 5.1. Right to left and left to right strategies 
 
The next task at hand was selective cleavage of the protective group on the terpenoid 
alcohol in the presence of the acetal function on the C ring. This proved impossible for 191, 
which is hardly surprising since a THP ether is also an acetal. The acetate in 192 was 
considered a more suitable protective group at this position. Indeed, formation of the 
desired alcohol was observed by TLC analysis upon treatment with K2CO3 in MeOH. TLC 
analysis of the product solution also indicated presence of the desired alcohol 193, 
uncontaminated with other compounds. After concentration of the product solution, 
Connection of the fragments 
however, no product alcohol could be detected, and a mixture of products was formed. 
After three days, the product mixture converged to a single, unidentified product. A 
possible explanation for this observation is displacement of the isopropoxy group of the 
acetal by the newly formed allylic alcohol function. This instability may also be a reason 
why such intermediates are not found in either Kalesse's1,2 or Williams'3 synthesis of 
ratjadone. 
 
O
O
OiPr
PBu3Cl
PGO
PGO
O OiPr
30
191: 12,13-E, PG = THP
192: 12,13-Z, PG = Ac
O OiPr
HO
193
Decomposition
179: 12,13-E, PG = THP
176: 12,13-Z, PG = Ac
+
192
a
b
 
Scheme 5.1. (a) KOtBu, toluene, 0°C, 89% for 191, 49% for 192; (b) K2CO3, MeOH. 
 
This problem was considered a major reason to abandon this route, since it was inherent to 
the synthesis planning and could hardly be circumvented. However, it still may be useful 
for the synthesis of derivatives lacking the acetal functionality at the C ring. Therefore, it 
was decided to construct a derivative with a 2,5-dihydroxyphenyl C ring. This moiety is 
easily available and has the advantage that it can be e.g. transformed to a quinone, which is 
expected to display a similar electrophilicity as the α,β-unsaturated δ-lactone of ratjadone. 
For this purpose, commercially available 2,5-dihydroxybenzaldehyde (194) was protected 
as a bis-TBS ether and subsequently reacted with terpene-derived phosphonium salt 178, 
giving Wittig product 196 in moderate yield. It is unclear why the yield in this case is much 
lower than in comparable reactions, where the yield is often excellent (90-100%).  
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Scheme 5.2. (a) TBSCl, imidazole, DMF, 81%; (b) 178, KOtBu, toluene, 0°C, 42%; (c) LiAlH4, THF, 0°C, 
95%; (d) NCS, Me2S, CH2Cl2, -78→-10°C, 95%; (e) PBu3; (f) 108, KOtBu, toluene, 0°C, 98% over two 
steps; (g) HF•py, py/THF 1:1, 65%. 
 
The acetate group of the Wittig product 196 was cleaved by reduction (treatment with 
K2CO3 in MeOH led to partial cleavage of the phenolic TBS ethers) and the resulting 
alcohol was converted to tributylphosphonium salt 199 in a two step sequence. 
Subsequently, a second Wittig reaction with A ring aldehyde 108 afforded tetrakis-TBS 
ether 200 in excellent yield. The final cleavage of the four TBS ethers was troublesome. 
Reaction with TBAF in THF led to rapid decomposition of the starting material. When 200 
was reacted with TBAF in THF in the presence of AcOH, the phenolic TBS ethers were 
cleaved smoothly, but cleavage of the remaining two TBS ethers was extremely slow and 
led to partial decomposition. Fortunately, treatment with HF•py in a 1:1 mixture of pyridine 
and THF (under similar conditions as the final desilylation in Kalesse's total synthesis of 
(+)-ratjadone1,2) afforded ratjadone analogue 201 in 65% yield. 
Attempts to oxidize hydroquinone 201 to the corresponding quinone using DDQ resulted in 
the formation of an unstable product, presumably the quinone. Possibly, the electrophilic 
quinone is susceptible to intramolecular attack by the adjacent electron-rich diene, leading 
to a bicylic structure. This could, however, not be confirmed, since the product was not 
obtained in pure form. 
 
Connection of the fragments 
5.3 Left to right route 
 
Due to the problems encountered in the right to left route, we decided to pursue the inverse 
approach. In order to avoid unnecessary wasting of valuable fully functionalized A ring 
fragment, we decided to carry out some preliminary studies to validate the viability of this 
approach. Since Kalesse and co-workers reported that ratjadone derivative 54 with a 
monosubstituted THP ring was still a very active compound (IC50 = 5.0 ng ml-1),4 we 
considered using a simplified A ring fragment of type 202. 
 
O
OPG
O
202  
Figure 5.2. Simplified A ring fragment. 
 
Commercially available (±)-2-(hydroxymethyl)tetrahydropyran was converted to the 
corresponding volatile aldehyde 203 by Swern oxidation.5 Aldehyde 203 was then treated 
with 2-lithio-1,3-dithiane to give 204. The resulting alcohol function was then protected as 
a TBS ether (205) or an acetate (206). Hydrolysis of the thioacetal of 205 under various 
conditions (PhI(O2CCF3)2, CH3CN/H2O; MeI, CaCO3, CH3CN/H2O) was apparently 
accompanied with cleavage of the silyl ether.  
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Scheme 5.3. (a) (COCl)2, DMSO, Et3N, CH2Cl2, -78→0°C, 65% ; (b) 1,3-dithiane, nBuLi, THF, -78°C, 
then 203, -78→25°C, 70%; (c) TBSOTf, 2,6-lutidine, CH2Cl2, -78→0°C, 91% (borsm); (d) AcCl, py, 43%; 
(e) PhI(O2CCF3)2, CH3CN/H2O 9:1; (f) 50 eq. MeI, CaCO3, CH3CN/H2O 2:1, 96% for 202b. 
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Whereas the Stork protocol6 (PhI(O2CCF3)2, CH3CN/H2O) was also unsuccessful with 206, 
treatment with excess MeI and CaCO3 in CH3CN/H2O led to clean conversion to the 
desired aldehyde 202b. 
 
Simplified A ring fragment 202b was then connected to terpenoid fragment 182 and the 
ω−TBS ether was converted to the corresponding tributylphosphonium salt 210 in the 
familiar three step sequence. 
 
O
OAc
O
202b
O
OAc
a
X
207: X = OTBS
208: X = OH
209: X = Cl
210: X = PBu3Cl
b
c
d
O
OR
211: X = OiPr, Y = H, R = Ac
211a: X = OiPr, Y = H, R = H
212: X = OH, Y = H, R = Ac
213: X,Y = O, R = Ac
g
h
O YX
e
f
 
Scheme 5.4. (a) 182, KOtBu, toluene, 0°C, 77%; (b) TBAF•3H2O, AcOH, THF, 0°C→rt, 73%; (c) NCS, 
Me2S, CH2Cl2, -78→-10°C, 86%; (d) PBu3; (e) 30, KOtBu, toluene, 0°C, 77% over two steps; (f) K2CO3, 
MeOH, 77%; (g) PPTS, acetone/H2O 6:1, quant. (h) various conditions, no reaction or decomposition. 
 
Wittig reaction of phosphonium salt 210 and C ring fragment 30 then afforded 211. The 
final steps to a simplified ratjadone analogue were cleavage of the acetal and oxidation of 
the resulting lactol, followed eventually by cleavage of the acetate. It was shown that the 
acetate group could be selectively cleaved at the stage of 211. To proceed to the desired 
ratjadone analogue, the acetal of 211 was smoothly cleaved by treatment with PPTS in an 
acetone/water mixture. However, subsequent oxidation of hemiacetal 212 to the lactone 
was unsuccessful under various conditions, including MnO2 oxidation, TPAP oxidation, 
and Dess-Martin oxidation.7 However, the left to right connection strategy proved valid, 
and since all three fragments were available in sufficient amounts, we decided to move on 
to the next stage. 
 
With a reliable procedure for the elaboration of the three fragments to the target ratjadone 
analogues at hand, we started to construct an analogue with a fully functionalized A ring. 
For this purpose, A ring aldehyde 108 was reacted with terpene-derived phosphonium salts 
182 and 181 to give Wittig products 214 and 215, respectively. Whereas it proved difficult 
Connection of the fragments 
to cleave the primary TBS ether of 214 selectively, the primary TES ether of 215 was 
readily cleaved under slightly acidic conditions in MeOH.  
 
O
OTBS
O
108
O
OTBS
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X
214: X = OTBS
215: X = OTES
216: X = OHb
OTBS OTBS
 
 
Scheme 5.5. (a) 182 or 181, KOtBu, toluene, 0°C,65% with 182, 100% with 181; (b) PPTS, MeOH, 66%. 
 
Thus, for the described strategies, the ω-functionalized terpene fragment with acetate 
protection at the α-position (178) and the α-functionalized terpene fragment with TES 
protection at the ω-position (181) proved the best building blocks with respect to synthesis 
efficiency and orthogonality. The fact that both fragments are derived from the same 
synthesis route (both are derived from 164) is an additional advantage. 
Alcohol 216 was smoothly converted to tributylphosphonium salt 218 by Corey-Kim 
reaction8 and subsequent treatment with PBu3. Wittig reaction with C ring aldehyde 30 then 
afforded coupling product 219 in very good yield. 
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Scheme 5.6. (a) NCS, Me2S, CH2Cl2, -78→-10°C; (b) PBu3; (c) 30, KOtBu, toluene, 0°C, 84% over three 
steps; (d) PPTS, acetone/H2O 6:1, 99%. 
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Although hydrolysis of isopropyl acetal 219 was successful, the resulting lactol 220 
(mixture of anomers) proved to be unstable. It was therefore not fully characterized, but 
only used as an intermediate. The subsequent oxidation to the corresponding lactone 221 
proved a great challenge. In our hands, a variety of oxidation methods (including Dess-
Martin, TPAP, and MnO2 oxidations) failed, and the desired lactone could not be obtained. 
In some cases, the starting material decomposed completely within minutes, whereas in 
other cases, no reaction seemed to take place at all. On some occasions, conversion to a 
slighty less polar product (TLC analysis) was observed, but mild aqueous workup resulted 
in a complex mixture of products. 
 
5.4 Conclusion 
 
In summary, the left to right connection strategy provides a reliable way of connecting the 
three fragments to give the full carbon skeleton of the desired ratjadone analogues. Both a 
simplified A ring and a fully functionalized one were used. Although the final products 
could not be obtained, connection of the fragments was very efficient, providing the 
coupling products in excellent yields. This demonstrates the general validity of the 
employed strategy. 
The right to left strategy could not be used for the synthesis of these compounds because of 
incompatibility of the free allylic alcohol and the acetal functionality. However, this 
method proved successful in the synthesis of analogues lacking the acetal function in the C 
ring. As an example, hydroquinone-containing derivative 201 was synthesized. 
 
5.5 Outlook 
 
Although the connection of the ratjadone analogue fragments proceeded very efficiently, 
the essential oxidation to the lactone failed in our hands, even using literature procedures 
for similar conversions. This troublesome oxidation might, however, be circumvented by 
using aldehyde 185, with the lactone functionality already installed. Although this option 
Connection of the fragments 
was discarded because of the severe instability of aldehyde 185, it might be useful when the 
aldehyde is generated in situ by Swern oxidation5 and the subsequent Wittig reaction is 
performed at low temperature in a one-pot procedure as described by Tsubuki et al.9 
 
By using excess of the lactone fragment 185, a reasonable yield might be achieved. 
Furthermore, the many alternative A and B fragments that are available, may be employed 
in the construction of a small library of ratjadone analogues. 
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Scheme 5.7. Possible alternative route to ratjadone analogue 221. (a) (COCl)2, DMSO, Et3N, CH2Cl2; (b) 
KOtBu, toluene; (c) HF•py, py/THF. 
 
5.6 Experimental section 
 
General. All commercial reagents were purchased from Fluka, Merck or Aldrich and used without further 
purification, unless otherwise stated. All oxygen- and water-sensitive reactions were carried out in oven-
dried glassware under argon. THF was distilled from potassium/benzophenone ketyl, Et2O was distilled 
from sodium/potassium benzophenone ketyl, and CH2Cl2 was distilled from calcium hydride. Other dry 
solvents were purchased from Fluka. Flash chromatography was performed using silica gel 60 (230-400 
mesh, Merck). Thin-layer chromatography (TLC) was performed using silica plates (Merck, silica gel 60 
F254) and developed using Cer-MOP reagent [molybdatophosphoric acid (5.0 g), cerium (IV) sulfate (2.0 g), 
and concentrated H2SO4 (16 ml) in water (200 ml)]. Optical rotations were measured using a 1 ml cell with 
1 dm path length on a Jasco DIP-1000 digital polarimeter. IR spectra were recorded as CHCl3 solutions or 
as thin films between NaCl plates on a Bruker IFS 28. 1H and 13C NMR spectra were recorded in CDCl3 on 
Varian Mercury VX 300 and VX 400 spectrometers using TMS as internal standard. Chemical shifts δ are 
reported in parts per million (ppm), coupling constants J are given in Hertz (Hz). High resolution ESI mass 
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spectra were obtained from a Bruker Apex 70e Fourier transform ion cyclotron resonance mass 
spectrometer equipped with a 7.0 Tesla superconducting magnet and an external electrospray ion source 
(Agilent, off axis spray).  
 
 
THP ether 191: To 10-chlorogeranyl THP ether (172, 136 mg, 0.50 mmol) was added tri-n-butylphosphine 
(123 μl, 101 mg, 0.50 mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 
179 was dissolved in toluene (4 ml) and the mixture was cooled to 0°C. Aldehyde 30 (61 mg, 0.361 mmol) 
was added, followed by KOtBu (1 M solution in THF, 650 μl, 0.650 mmol). The mixture was stirred for 15 
min. at 0°C, then diluted with H2O (20 ml) and extracted with tBuOMe (3 × 30 ml). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography on a Et3N-neutralized column (column dimensions: 25 × 2 cm, EtOAc/PE = 1:8) to give 
191 (126 mg, 0.321 mmol, 89%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 1.18 (d, J = 6.25 Hz, 
3H), 1.24 (d, J = 6.25 Hz, 3H), 1.51-1.83 (m, 6H), 1.68 (s, 3H), 1.75 (s, 3H), 2.05-2.12 (m, 4H), 2.27 (dt, 
J = 7.80, 7.42 Hz, 2H), 3.49-3.52 (m, 1H), 3.86-3.89 (m, 1H), 4.01 (m, 1H), 4.01 (dd, J = 11.71, 6.64 Hz, 
1H), 4.24 (dd, J = 11.71, 6.25 Hz, 1H), 4.47 (m, 1H), 4.62 (dd, J = 3.90, 2.73 Hz, 1H), 5.11 (s, 1H), 5.37 
(td, J = 6.24, 1.17 Hz, 1H), 5.48 (t, J = 6.24 Hz, 1H), 5.59 (dd, J = 15.61, 6.24 Hz, 1H), 5.72 (dd, J = 10.15, 
1.56 Hz, 1H), 5.99 (m, 1H), 6.27 d, J = 15.61 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 12.5, 16.5, 
19.7, 22.1, 24.0, 25.6, 26.6, 30.8, 31.0, 39.2, 62.3, 63.6, 66.9, 69.3, 93.0, 97.7, 120.8, 125.9, 126.2, 128.4, 
132.6, 133.0, 135.8, 139.5 ppm. 
 
 
Acetate 192: To 10-chloroneryl acetate (169, 415 mg, 1.80 mmol) was added tri-n-butylphosphine (444 μl, 
364 mg, 1.80 mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 176 was 
dissolved in toluene (15 ml) and the mixture was cooled to 0°C. Aldehyde 30 (340 mg, 2.00 mmol) was 
added, followed by KOtBu (1 M solution in THF, 2.34 ml, 2.34 mmol). The mixture was stirred for 15 min. 
at 0°C, then diluted with sat. aq. NH4Cl (100 ml) and extracted with tBuOMe (3 × 50 ml). The combined 
organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by 
flash chromatography on a Et3N-neutralized column (column dimensions: 25 × 2 cm, EtOAc/PE = 1:10) to 
give 192 (305 mg, 0.875 mmol, 49%) as a colorless oil. 1H NMR (CDCl3, 300 MHz): δ = 1.18 (d, J = 6.04 
Hz, 3H), 1.24 (d, J = 6.23 Hz, 3H), 1.76 (s, 3H), 1.77 (s, 3H), 2.05 (s, 3H), 2.06-2.26 (m, 6H), 4.02 (heptet, 
J = 6.22 Hz, 1H), 4.48 (m, 1H), 4.55 (d, J = 7.32 Hz, 1H), 5.47 (m, 1H), 5.61 (dd, J = 15.74, 6.41 Hz, 1H), 
5.70-5.75 (m, 1H), 5.99 (m, 1H), 6.27 (d, J = 15.74 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 12.4, 
21.2, 22.1, 23.5, 24.0, 26.9, 31.0, 31.8, 60.9, 66.9, 69.4, 93.0, 107.5, 119.3, 125.9, 126.6, 128.4, 131.8, 
133.5, 135.6, 142.0, 170.8 ppm. Rf = 0.67 (EtOAc/n-hexane = 1:4). 
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2,5-Bis(tert-butyldimethylsilyloxy)benzaldehyde 195: To a solution of 2,5-dihydroxy-benzaldehyde (276 
mg, 2.00 mmol) and imidazole (408 mg, 6.00 mmol) in DMF (10 ml) was added in one portion at 0°C tert-
butyldimethylsilyl chloride (724 mg, 4.80 mmol). The mixture was stirred for 2 h at rt, diluted with H2O (25 
ml) and extracted with PE (3 × 50 ml). The combined organic fractions were washed with H2O (50 ml) and 
brine (50 ml), dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography on a Et3N-neutralized column (column dimensions: 25 × 2.5 cm, EtOAc/PE = 1:20) to give 
195 (591 mg, 1.61 mmol, 81%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.18 (s, 6H), 0.25 (s, 
6H), 0.97 (s, 9H), 1.01 (s, 9H), 6.76 (d, J = 8.98 Hz, 1H), 6.97 (dd, J = 8.98, 3.12 Hz, 1H), 7.23 (d, J = 3.12 
Hz, 1H), 10.39 (s, 1H) ppm. Rf = 0.79 (EtOAc/n-hexane = 1:10). 
 
 
1-Acetoxy-9-(2,5-bis(tert-butyldimethylsilyloxy)phenyl)-3,7-dimethyl-2,6,8-nonatriene 196: To 10-
chlorogeranyl acetate (171, 577 mg, 2.50 mmol) was added tri-n-butylphosphine (595 μl, 506 mg, 2.50 
mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 178 was dissolved in 
toluene (25 ml) and the mixture was cooled to 0°C. Aldehyde 195 (591 mg, 1.61 mmol) was added, 
followed by KOtBu (1 M solution in THF, 2.50 ml, 2.50 mmol). The mixture was stirred for 15 min. at 0°C, 
then diluted with sat. aq. NH4Cl (100 ml) and extracted with tBuOMe (3 × 100 ml). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography on a Et3N-neutralized column (column dimensions: 30 × 2.5 cm, EtOAc/PE = 1:40) to give 
196 (367 mg, 0.674 mmol, 42%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.17 (s, 6H), 0.18 (s, 
6H), 0.98 (s, 9H), 1.02 (s, 9H), 1.73 (s, 3H), 1.85 (s, 3H), 2.06 (s, 3H), 2.15 (m, 2H), 2.32 (m, 2H), 4.60 (d, 
J = 6.95 Hz, 2H), 5.38 (m, 1H), 5.59 (m, 1H), 6.56 (dd, J = 8.60, 2.74 Hz, 1H), 6.61-6.67 (m, 2H), 6.76 (d, 
J = 16.28 Hz, 1H), 6.96 (d, J = 2.74 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = -4.3, -4.2, 12.6, 16.6, 
18.3, 18.3, 21.1, 25.8, 25.9, 26.8, 39.2, 61.3, 116.2, 118.5, 119.1, 112.0, 120.9, 129.6, 132.3, 133.2, 134.5, 
141.6, 147.1, 149.6, 170.9 ppm. Rf = 0.64 (EtOAc/n-hexane = 1:4). HRMS: calcd. for C31H53O4Si2 
(M+Na)+ 567.3296 found 567.3298. 
 
 
9-(2,5-Bis(tert-butyldimethylsilyloxy)phenyl)-3,7-dimethyl-1-hydroxy-2,6,8-nonatriene 197: To a 
solution of 196 (324 mg, 0.595 mmol) in THF (15 ml) was added at 0°C LiAlH4 (23 mg, 0.595 mmol) and 
the mixture was stirred for 10 min. at rt. The mixture was diluted with sat. aq. NH4Cl (25 ml) and brine (25 
ml) and extracted with with tBuOMe (3 × 75 ml). The combined organic fractions were dried (Na2SO4), 
filtered, and concentrated in vacuo. The product was purified by flash chromatography on a Et3N-
neutralized (column dimensions: 25 × 2.5 cm, EtOAc/PE = 1:4) to give 197 (284 mg, 0.564 mmol, 95%) as 
a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.17 (s, 6H), 0.18 (s, 6H), 0.98 (s, 9H), 1.03 (s, 9H), 1.70 
(s, 3H), 1.85 (s, 3H), 2.13 (m, 2H), 2.33 (m, 2H), 4.16 (d, J = 6.63 Hz, 2H), 5.45 (td, J = 6.63, 1.17 Hz, 1H), 
5.60 (t, 7.03 Hz, 1H), 6.56 (dd, J = 8.59, 2.73 Hz, 1H), 6.59-6.67 (m, 2H), 6.76 (d, J = 16.39 Hz, 1H), 6.96 
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(d, J = 3.12 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = -4.5, -4.4, 12.4, 16.3, 18.1, 18.2, 25.7, 25.8, 
26.8, 39.1, 59.3, 116.3, 119.1, 120.0, 120.9, 123.7, 129.7, 132.7, 133.3, 134.5, 139.1, 147.2, 149.7 ppm. 
Rf = 0.32 (EtOAc/n-hexane = 1:4). HRMS :calcd. for C29H50O3Si4 (M+Na)+ 525.3191 found 525.3192. 
 
 
9-(2,5-Bis(tert-butyldimethylsilyloxy)phenyl)-1-chloro-3,7-dimethyl-2,6,8-nonatriene 198: To a solution 
of NCS (90 mg, 0.673 mmol) in CH2Cl2 (10 ml) was added at -10°C Me2S (53 μl, 45 mg, 0.729 mmol). The 
mixture was stirred for 10 min. at -10°C, and the resulting white suspension was cooled to -78°C. Alcohol 
197 (282 mg, 0.561 mmol) was added and the mixture was stirred for 1 h at -10°C. After dilution with sat. 
aq. NH4Cl (50 ml), the mixture was extracted with CH2Cl2 (3 × 50 ml). The combined organic fractions 
were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography (column dimensions: 25 × 2.5 cm, EtOAc/PE = 1:20) to give 198 (281 mg, 0.534 mmol, 
95%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.17 (s, 6H), 0.18, (s, 6H), 0.98 (s, 9H), 1.02 (s, 
9H), 1.75 (s, 3H), 1.85 (s, 3H), 2.16 (m, 2H), 2.33 (m, 2H), 4.11 (d, J = 8.20 Hz, 2H), 5.49 (m, 1H), 5.58 
(m, 1H), 6.56 (dd, J = 8.59, 2.73 Hz, 1H), 6.61-6.69 (m, 2H), 6.76 (d, J = 16.39 Hz, 1H), 6.96 (d, J = 2.73 
Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ = -4.5, -4.3, 12.5, 16.1, 18.1, 18.2, 25.7, 25.8, 26.6, 39.1, 
41.0, 116.3, 119.2, 120.1, 120.6, 121.1, 129.7, 132.2, 133.3, 134.7, 142.2, 147.2, 149.7 ppm. Rf = 0.82 
(EtOAc/n-hexane = 1:4). 
 
 
Tetrakis TBS ether 200: To chloride 198 (278 mg, 0.529 mmol) was added tri-n-butylphosphine (139 μl, 
118 mg, 0.582 mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 199 was 
dissolved in toluene (10 ml) and the mixture was cooled to 0°C. Aldehyde 108 (219 mg, 0.495 mmol) was 
added, followed by KOtBu (1 M solution in THF, 600 μl, 0.600 mmol). The mixture was stirred for 15 min. 
at 0°C, then diluted with sat. aq. NH4Cl (50 ml) and extracted with tBuOMe (3 × 50 ml). The combined 
organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by 
flash chromatography on a Et3N-neutralized column (column dimensions: 25 × 2 cm, EtOAc/PE = 1:40) to 
give 200 (442 mg, 0.483 mmol, 98%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.04 (s, 6H), 0.05 
(s, 3H), 0.09 (s, 3H), 0.14 (s, 3H), 0.17 (s, 3H), 0.19 (s, 6H), 0.86 (d, J = 7.80 Hz, 3H), 0.88 (s, 9H), 0.93 (s, 
9H), 0.98 (s, 9H), 1.02 (s, 9H), 1.54-1.60 (m, 2H), 1.70 (d, J = 6.64 Hz, 3H), 1.77 (s, 3H), 1.85 (s, 3H), 2.15 
(m, 3H), 2.33 (m, 2H); 3.23 (m, 1H), 3.81-3.86 (m, 2H), 4.27 (m, 1H), 5.44 (ddq, J = 15.22, 5.08, 1.57 Hz, 
1H), 5.60-5.67 (m, 3H), 5.89 (d, J = 11.32 Hz, 1H), 6.48 (ddd, J = 15.22, 10.93, 1.17 Hz, 1H), 6.56 (dd, J = 
8.59, 3.12 Hz, 1H), 6.59-6.70 (m, 2H), 6.76 (d, J = 16.39 Hz, 1H), 6.96 (d, J = 2.73 Hz, 1H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ = -4.7, -4.61, -4.55, -4.4 (2C), -4.3 (2C), -4.2, 5.5, 12.5, 16.7, 17.9, 18.11, 18.17, 
18.23, 18.27, 25.7(3C), 25.8 (6C), 25.9 (3C), 27.1, 29.8, 39.6, 40.5, 71.8, 75.1, 79.2, 79.8, 116.3, 119.1, 
120.1, 120.9, 124.4, 125.8, 126.6, 129.8, 130.4, 131.7, 132.9, 133.4, 134.5, 137.9, 147.2, 149.7 ppm. 
Rf = 0.73 (EtOAc/n-hexane = 1:10). HRMS: calcd. for C52H94O5Si4 (M+Na)+ 933.6071 found 933.6077. 
Connection of the fragments 
 
 
Hydroquinone 201: To a solution of tetrakis-TBS ether 200 (46.0 mg, 0.0502 mmol) in pyridine (1.5 ml) 
and THF (1.5 ml) was added HF•py (1.0 ml) and the mixture was stirred for 4 h at rt. The reaction was 
quenched by addition of sat. aq. NaHCO3 (25 ml), the mixture was brought to pH 4 with 1 N aq. HCl and 
extracted with tBuOMe (3 × 25 ml). The combined organic fractions were dried (Na2SO4), filtered, and 
concentrated in vacuo. The product was eluted on a small silica column (CHCl3→CHCl3/MeOH = 10:1) to 
give 201 (14.7 mg, 0.0323 mmol, 65%) as a yellow solid. 1H NMR (acetone-d6, 400 MHz): δ = 0.82 (d, J = 
7.02 Hz, 3H), 1.64 (m, 1H), 1.67 (d, J = 6.24 Hz, 3H), 1.80 (s, 3H), 1.83 (m, 1H), 1.87 (s, 3H), 2.18 (m, 
2H), 2.37 (q, J = 7.41 Hz, 2H), 2.86 (s, 1H) 3.34 (ddd, J = 11.32, 4.30, 2.34 Hz, 1H), 3.81 (t, J = 7.03 Hz, 
1H), 3.87-3.92 (m, 2H), 4.15 (m, 1H), 5.45 (ddq, J = 15.22, 5.07, 1.56 Hz, 1H), 5.61-5.73 (m, 3H), 5.92 (d, 
J = 10.93 Hz, 1H), 6.52 (m, 2H), 6.70 (d, J = 8.58 Hz, 1H), 6.80 (s, 1H), 6.97 (d, J = 2.73 Hz, 1H), 7.69 (s, 
1H), 7.90 (s, 1H) ppm. 13C NMR (acetone-d6, 100 MHz): δ = 5.8, 12.6, 16.6, 18.0, 27.6, 30.6, 40.2, 40.7, 
71.0, 74.9, 79.7, 80.1, 112.5, 115.7, 117.2, 121.6, 125.72, 126.0, 126.3, 127.7, 131.8, 132.4, 133.2, 134.0, 
135.4, 138.1, 148.6, 151.4 ppm. Rf = 0.41 (CH2Cl2/MeOH = 9:1). 
 
 
2-Formyltetrahydropyran 203: To a solution of oxalyl chloride (3.84 ml, 5.59 g, 44.0 mmol) in CH2Cl2 
(400 ml) was added at -78°C DMSO (6.25 ml, 6.88 g, 88.0 mmol). The mixture was stirred for 10 min. at -
78°C and 2-(hydroxymethyl)tetrahydropyran (4.65 g, 40.0 mmol) was added. The mixture was stirred for an 
additional 20 min at -78°C, Et3N (27.7 ml, 20.2 g, 200 mmol) was added and the mixture was allowed to 
warm to room temperature. After dilution with sat. aq. NH4Cl (500 ml), the mixture was extracted with 
CH2Cl2 (3 × 250 ml). The combined organic fractions were dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by flash chromatography (column dimensions: 30 × 3 cm, EtOAc/PE = 1:3) afforded 
203 (2.97 g, 26.0 mmol, 65%) as a volatile colorless liquid. 1H NMR (CDCl3, 400 MHz): δ = 1.48-1.66 (m, 
4H), 1.88-1.97 (m, 2H), 3.58 (ddd, J = 11.32, 10.54, 2.73 Hz, 1H), 3.87 (dd, J = 11.32, 2.34 Hz, 1H), 4.11 
(m, 1H) ppm. Rf = 0.50 (EtOAc/n-hexane = 1:2). 
 
 
(1,3-Dithian-2-yl)-(tetrahydropyran-2-yl)methanol 204: n-BuLi (1.6 M in hexane, 9.38 ml, 15 mmol) 
was added at -78°C to a solution of 1,3-dithiane (1.80 g, 15.0 mmol) in THF (100 ml). The mixture was 
stirred for 30 min. at -30°C, recooled to -50°C and 2-formyltetrahydropyran (203, 1.14 g, 10.0 mmol) was 
added. The mixture was stirred overnight at 0°C. The reaction was quenched by addition of sat. aq. NH4Cl 
(100 ml) and the mixture was extracted with tBuOMe (3 × 100 ml). The combined organic fractions were 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (column 
dimensions: 25 × 3 cm, EtOAc/PE = 1:4→1:2) afforded 204 (1.64 g, 7.01 mmol, 70%) as a colorless solid. 
1H NMR (CDCl3, 400 MHz, minor isomer signals in brackets): δ = 1.24-1.76 (m, 4H), 1.88-2.11 (m, 2H), 
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2.71-2.95 (m, 4H), 3.21-3.84 (m, 3H), 4.22 (4.14) (d, J = 5.86 (6.63) Hz, 1H) ppm. 13C NMR (CDCl3, 100 
MHz, minor isomer signals in brackets): δ = 23.2 (22.9), 25.8 (25.8), 25.9 (25.9), 28.1 (28.2), 28.5 (28.8), 
48.6 (48.3), 68.5 (68.7), 74.8 (75.2), 76.2 (76.9) ppm. Rf = 0.24 (EtOAc/n-hexane = 1:4). 
 
 
tert-Butyldimethylsilyl (1,3-dithian-2-yl)-(tetrahydropyran-2-yl)methyl ether 205: To a solution of 
alcohol 204 (1.64 g, 7.00 mmol) and 2,6-lutidine (975 μl, 900 mg, 8.40 mmol) in CH2Cl2 (20 ml) was added 
dropwise at -78°C TBSOTf (1.77 ml, 2.04 g, 7.70 mmol). The mixture was allowed to warm to room 
temperature and then quenched by addition of sat.aq. NH4Cl (25 ml). The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (2 × 25 ml). The combined organic fractions were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash chromatography (column dimensions: 
25 × 3 cm, EtOAc/PE = 1:15) afforded 205 (1.46 g, 4.17 mmol, 60%) and unreacted alcohol 204 (566 mg, 
2.41 mmol, 34%) as a colorless oil. The yield based on recovered starting material was therefore 91%. 1H 
NMR (CDCl3, 400 MHz): δ =0.07 (s, 3H), 0.15 (s, 3H), 0.91 (s, 9H), 1.34-1.58 (m, 4H), 1.68 (m, 1H), 1.86 
(m, 2H), 2.06 (m, 1H), 2.78-3.00 (m, 4H), 3.33-3.38 (m, 2H), 3.70 (dd, J = 6.25, 2.73 Hz, 1H), 3.96 (m, 
1H), 4.26 (d, J = 2.74 Hz, 1H) ppm. 
 
 
(1,3-Dithian-2-yl)-(tetrahydropyran-2-yl)methyl acetate 206: To a solution of alcohol 204 (2.34 g, 10.0 
mmol) in pyridine (2.0 ml) was added at 0°C acetyl chloride (1.07 ml, 1.18 g, 15.0 mmol). The mixture was 
stirred at 0°C for 2 h. The mixture was diluted with 1N aq. HCl (250 ml) and extracted with tBuOMe (3 × 
150 ml). The combined organic fractions were dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by flash chromatography (column dimensions: 30 × 3 cm, EtOAc/PE = 1:4) afforded 206 (1.26 
g, 4.31 mmol, 43%) as a colorless oil. 1H NMR (CDCl3, 400 MHz, signals for minor isomer in brackets): δ 
= 1.30-1.63 (m, 4H), 1.80-2.10 (m, 2H), 2.17 (2.13) (s, 3H), 2.51-2.99 (m, 4H), 3.38-4.26 (m, 3H), 5.25-
5.30 (m, 1H) ppm. Rf = 0.63 (EtOAc/n-hexane = 1:2). 
 
 
2-Acetoxy-2-(tetrahydropyran-2-yl)acetaldehyde 202b: To a mixture of dithiane 206 (947 mg, 
3.24 mmol), CaCO3 (1.22 g, 12.2 mmol), CH3CN (14 ml) and H2O (7 ml) was added MeI (10.1 ml, 23.0 g, 
162 mmol). The mixture was stirred overnight at rt. The mixture was concentrated in vacuo. The residue 
was diluted with sat. aq. NH4Cl (100 ml) and the mixture was extracted with tBuOMe (3 × 100 ml). The 
combined organic fractions were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash 
chromatography (column dimensions: 25 × 2 cm, EtOAc/PE = 1:2) afforded 202b (582 mg, 3.12 mmol, 
96%) as a colorless oil. 1H NMR (CDCl3, 400 MHz, signals for minor isomer in brackets): δ = 1.47-1.67 
(m, 6H), 2.24 (2.20) (s, 3H), 3.43 (t, J = 11.32 Hz, 1H), (3.74 (td, J = 9.76, 3.90 Hz, 1H)), 3.93-4.02 (m, 
2H), 5.00 (4.93) (d, J = 3.13 (4.30) Hz, 1H), 9.55 (9.60) (s, 1H) ppm. 13C NMR (CDCl3, 100 MHz, signals 
Connection of the fragments 
for minor isomer in brackets): δ = 20.7, 23.0 (22.9), 25.4 (25.6), 27.0 (27.6), 69.1 (68.7), 76.3 (77.1), 79.9 
(80.0), 170.3, 197.3 (196.8) ppm. Rf = 0.41 (EtOAc/n-hexane = 1:2). 
 
 
1-Acetoxy-10-(tert-butyldimethylsilyl)oxy-5,9-dimethyl-1-(tetrahydropyran-2-yl)deca-2,4,8-triene 207: 
To chloride 175 (1.21 g, 4.00 mmol) was added tri-n-butylphosphine (987 μl, 809 mg, 4.00 mmol) and the 
mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 182 was dissolved in toluene (30 ml) 
and the mixture was cooled to 0°C. A solution of aldehyde 202b (634 mg, 3.40 mmol) in toluene (10 ml) 
was added, followed by KOtBu (1 M solution in THF, 4.00 ml, 4.00 mmol). The mixture was stirred for 15 
min. at 0°C, then diluted with sat. aq. NH4Cl (100 ml) and extracted with tBuOMe (3 × 100 ml). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was 
purified by flash chromatography on a Et3N-neutralized column (column dimensions: 30 × 2.5 cm, 
EtOAc/PE = 1:8) to give 207 (1.14 g, 2.62 mmol, 77%) as a colorless oil.  1H NMR (CDCl3, 400 MHz, 
values for minor isomer in brackets): δ = 0.05 (s, 6H), 0.90 (s, 9H), 1.46-1.61 (m, 5H), 1.59 (s, 3H), 1.76 (s, 
3H), 1.83 (m, 1H), 2.05-2.17 (m, 1H), 2.09 (2.08) (s, 3H), 3.37-3.46 (m, 2H), 3.99 (s, 2H), 4.00-4.04 (m, 
1H), 5.28 (5.22) (dd, J = 7.81, 5.46 (8.20, 3.51) Hz, 1H), 5.35 (t, J = 7.03 Hz, 1H), 5.54 (5.60) (dd, J = 
15.22, 7.81 (14.83, 8.19) Hz, 1H), 5.82 (5.85) (d, J = 10.54 (10.93) Hz, 1H), 6.51 (6.50) (dd, J = 15.22, 
10.54 (14.83, 10.93) Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz, values for major isomer): δ = -5.1, 13.5, 
16.9, 18.5, 21.5, 23.1, 23.2, 25.9, 26.0, 26.2, 27.7, 39.6, 68.4, 68.6, 76.8, 78.7, 123.5, 123.8, 125.1, 130.7, 
134.4, 140.5, 170.1 ppm. Rf = 0.76 (EtOAc/n-hexane = 1:2). 
 
 
1-Acetoxy-5,9-dimethyl-10-hydroxy-1-(tetrahydropyran-2-yl)deca-2,4,8-triene 208: To a solution of 
TBS ether 207 (932 mg, 2.13 mmol) and AcOH (306 μl, 320 mg, 5.34 mmol) in THF (35 ml) was added 
TBAF•3H2O (1.01 g, 3.20 mmol). The mixture was stirred for 17 h at rt, then diluted with sat. aq. NH4Cl 
(100 ml) and extracted with tBuOMe (3 × 100 ml). The combined organic fractions were dried (Na2SO4), 
filtered, and concentrated in vacuo. The product was purified by flash chromatography on a Et3N-
neutralized column (column dimensions: 30 × 2.5 cm, EtOAc/PE = 2:3) to give 208 (502 mg, 1.56 mmol, 
73%) as a colorless oil. 1H NMR (CDCl3, 300 MHz, values for minor isomer in brackets): δ = 1.32-1.40 (m, 
1H), 1.41-1.62 (m, 4H), 1.66 (s, 3H), 1.77 (s, 3H), 1.79-1.87 (m, 1H), 2.09 (2.08) (s, 3H), 2.09-2.18 (m, 
4H), 3.37-3.48 (m, 2H), 3.97 (s, 2H), 4.00-4.04 (m, 1H), 5.28 (5.22) (dd, J = 7.86, 5.49 (8.05, 3.84) Hz, 
1H), 5.38 (t, J = 6.22 Hz, 1H), 5.60 (5.55) (dd, J = 14.82, 7.87 (15.00, 8.05) Hz, 1H), 5.82 (5.86) (d, J = 
10.98 Hz, 1H), 6.51 (6.50) (dd, J = 14.82, 10.98 (15.00, 10.98) Hz, 1H) ppm. 13C NMR (CDCl3, 75 MHz, 
values for minor isomer in brackets): δ = 13.6 (13.6), 16.7 (16.5), 21.3 (21.3), 23.2 (23.0), 25.7 (25.7), 25.9, 
27.6 (27.2), 39.4 (39.7), 68.4, 68.5 (68.6), 72.2 (72.1), 76.6 (77.1), 78.6 (78.7), 123.7 (123.7), 124.8 (124.6), 
125.1 (124.9), 130.6 (131.1), 134.9, 140.2 (140.1), 170.1 (170.0) ppm. Rf = 0.26 (EtOAc/n-hexane = 1:2). 
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1-Acetoxy-10-chloro-5,9-dimethyl-1-(tetrahydropyran-2-yl)deca-2,4,8-triene 209: To a solution of NCS 
(73 mg, 0.55 mmol) in CH2Cl2 (5 ml) was added at -10°C Me2S (44 μl, 37 mg, 0.60 mmol). The mixture 
was stirred for 10 min. at -10°C, and the resulting white suspension was cooled to -78°C. Alcohol 208 (161 
mg, 0.50 mmol) was added and the mixture was stirred for 1 h at -10°C. The reaction was quenched by 
addition of sat. aq. NH4Cl (5 ml). After dilution with tBuOMe (30 ml) and H2O (15 ml), the phases were 
separated and the porganic phase was washed with brine (20 ml), dried (Na2SO4), filtered, and concentrated 
in vacuo. The product was purified by flash chromatography (column dimensions: 20 × 2 cm, EtOAc/PE = 
1:6) to give 209 (147 mg, 0.427 mmol, 86%) as a colorless oil. 1H NMR (CDCl3, 400 MHz, values for 
minor isomer in brackets): δ = 1.31-1.40 (m, 1H), 1.42-1.60 (m, 4H), 1.73 (s, 3H), 1.76 (s, 3H), 1.79-1.87 
(m, 1H), 2.09 (2.08) (s, 3H), 2.11-2.20 (m,4H), 3.21-3.48 (m, 2H), 4.01 (s, 2H), 4.01-4.04 (m, 1H), 5.28 
(5.22) (dd, J = 8.19, 5.47 (8.19, 3.90) Hz, 1H), 5.50 (t, J = 6.64 Hz, 1H), 5.56 (5.62) (dd, J = 15.22, 8.20 
(15.22, 8.19) Hz, 1H), 5.82 (5.84) (d, J = 10.93 Hz, 1H), 6.50 (6.49) (dd, J = 15.22, 10.93 Hz, 1H) ppm. 13C 
NMR (CDCl3, 100 MHz, values for minor isomer in brackets): δ = 14.2, 16.9 (16.6), 21.4 (21.5), 23.1 
(23.2), 25.8 (25.9), 26.4, 27.7 (27.4), 39.1, 52.4, 68.6 (68.7), 77.1 (76.7), 78.7 (78.8), 124.0 (124.1), 125.4 
(124.9), 129.9 (129.9), 130.5 (131.1), 131.8, 139.7 (139.6), 170.1 (170.0) ppm. Rf = 0.72 (EtOAc/n-hexane 
= 1:2). 
 
 
11-Acetoxy-1-[(2R,6R)-2-isopropoxy-5,6-dihydro-2H-pyran-6-yl]-3,7-dimethyl-11-(tetra-hydropyran-
2-yl)undeca-1,3,7,9-tetraene 211: To chloride 209 (345 mg, 1.00 mmol) was added tri-n-butylphosphine 
(296 μl, 243 mg, 1.20 mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 
210 was dissolved in toluene (10 ml) and the mixture was cooled to 0°C. Aldehyde 30 (255 mg, 1.50 mmol) 
was added, followed by KOtBu (1 M solution in THF, 1.50 ml, 1.50 mmol). The mixture was stirred for 15 
min. at 0°C, then diluted with sat. aq. NH4Cl (100 ml) and extracted with tBuOMe (3 × 50 ml). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was 
purified by flash chromatography on a Et3N-neutralized column (column dimensions: 25 × 2 cm, EtOAc/PE 
= 1:4) to give 211 (353 mg, 0.770 mmol, 77%) as a colorless oil. 1H NMR (CDCl3, 400 MHz, values for 
minor isomer in brackets): δ = 1.18 (d, J = 6.25 Hz, 3H), 1.24 (d, J = 6.25 Hz, 1H), 1.34-1.52 (m, 5H), 1.75 
(s, 3H), 1.76 (s, 3H), 1.84-1.87 (m, 1H), 2.01-2.17 (m, 4H), 2.10 (2.09) (s, 3H) 2.24-2.28 (m, 4H), 3.40-3.47 
(m, 2H), 3.98-4.05 (m, 3H), 4.47 (m, 1H), 5.12 (s, 1H), 5.28 (5.22) (dd, J = 7.80, 5.46 (8.20, 3.90) Hz, 1H), 
5.47 (t, J = 6.64 Hz, 1H), 5.56 (5.61) (dd, J = 15.22, 7.80 (15.22, 8.20) Hz, 1H), 5.60 (dd, J = 15.61, 6.63 
Hz, 1H), 5.72 (m, 1H), 5.83 (5.86) (d, J = 10.93 Hz, 1H), 5.96-5.6.02 (m, 1H), 6.27 (d, J = 15.61 Hz, 1H), 
6.51 (6.50) (dd, J = 15.22, 10.93 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz, values for major isomer): δ = 
12.4, 16.9, 21.4, 22.1, 23.2, 24.0, 25.8, 26.7, 27.7, 31.0, 39.5, 66.9, 68.7, 69.3, 77.2, 78.7, 93.0, 123.8, 
125.3, 125.9, 126.3, 128.3, 130.6, 132.3, 133.1, 135.7, 140.1, 170.1 ppm. Rf = 0.37 (EtOAc/n-hexane = 
1:4). 
Connection of the fragments 
 
 
11-Hydroxy-1-[(2R,6R)-2-isopropoxy-5,6-dihydro-2H-pyran-6-yl]-3,7-dimethyl-11-(tetra-hydropyran-
2-yl)undeca-1,3,7,9-tetraene 211a: To a solution of acetate 211 (26.8 mg, 0.058 mmol) in MeOH (1 ml) 
was added K2CO3 (7.7 mg, 0.056 mmol) and the mixture was stirred overnight at rt. The mixture was 
diluted with sat. aq. NH4Cl (25 ml) and brine (25 ml), and extracted with tBuOMe (3 × 25 ml). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was 
purified by flash chromatography on a Et3N-neutralized column (column dimensions: 25 × 2 cm, EtOAc/PE 
= 1:4) to give 211a (353 mg, 0.770 mmol, 77%) as a colorless oil. 1H NMR (CDCl3, 400 MHz, values for 
minor isomer in brackets): δ = 1.18 (d, J = 6.25 Hz, 3H), 1.19-1.32 (m, 1H), 1.24 (d, J = 6.25 Hz, 1H), 1.41-
1.60 (m, 4H), 1.75 (s, 3H), 1.76 (s, 3H), 1.82-1.85 (m, 1H), 2.00-2.17 (m, 4H), 2.21-2.28 (m, 2H), 2.29, (bs, 
1H, OH), 3.16 (dd, J = 10.93, 7.42 Hz, 1H), 3.37-3.49 (m, 2H), 3.95-4.06 (m, 2H), 4.42-4.50 (m, 1H), 5.11 
(s, 1H), 5.48 (m, 1H), 5.59 (5.60) (dd, J = 15.61, 6.63 (14.83, 6.63) Hz, 1H), 5.70-5.73 (m, 1H), 5.84 (5.85) 
(d, J = 10.92 Hz, 1H), 5.95-6.02 (m, 1H), 6.27 (d, J = 15.61 Hz, 1H), 6.51 (6.50) (dd, J = 15.22, 10.92 Hz, 
1H) ppm. Rf = 0.56 (EtOAc/n-hexane = 1:2). 
 
 
 
11-Acetoxy-1-[(2R,6R)-2-hydroxy-5,6-dihydro-2H-pyran-6-yl]-3,7-dimethyl-11-(tetrahydropyran-2-
yl)undeca-1,3,7,9-tetraene 212: To a solution of 211 (20.6 mg, 0.045 mmol) in acetone (3 ml) was added a 
solution of PPTS (10.8 mg, 0.043 mmol) in H2O (0.5 ml). The mixture was stirred for 16.5 h at rt. The 
mixture was diluted with sat. aq. NaHCO3 (25 ml) and brine (25 ml) and extracted with tBuOMe (3 × 25 
ml). The combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo to give 212 
(20.2 mg, 0.046 mmol, quant.), which was used in following steps without further purification. 1H NMR 
(CDCl3, 400 MHz, values for minor isomer in brackets): δ = 1.31-1.44 (m, 1H), 1.46-1.57 (m, 4H), 1.75 (s, 
3H), 1.76 (s, 3H), 1.78-1.87 (m, 1H), 2.02-2.20 (m, 4H), 2.22-2.29 (m, 2H), 3.38-3.47 (m, 2H), 4.03 (m, 
1H), 4.52 (ddd, J = 10.54, 6.44, 3.90 Hz, 1H), 5.28 (5.22) (dd, J = 7.80, 4.10 (7.80, 5.66) Hz, 1H), 5.44 (s, 
1H), 5.48 (t, J = 6.44 Hz, 1H), 5.56 (5.64) (dd, J = 15.22, 7.81 (14.83, 8.20) Hz, 1H)), 5.60 (dd, J = 15.80, 
6.44 Hz, 1H), 5.79-5.87 (m, 2H), 6.04-6.07 (m, 1H), 6.31 (d, J = 15.80 Hz, 1H), 6.51 (6.50) (dd, J = 15.41, 
10.73 (14.83, 10.53) Hz, 1H) ppm. Rf = 0.31 (EtOAc/n-hexane = 1:2). 
 
 
Tris TBS ether 214: To chloride 175 (168 mg, 0.555 mmol) was added tri-n-butylphosphine (137 μl, 112 
mg, 0.555 mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 182 was 
dissolved in toluene (5 ml) and the mixture was cooled to 0°C. Aldehyde 108 (108 mg, 0.244 mmol) was 
added, followed by KOtBu (1 M solution in THF, 600 μl, 0.600 mmol). The mixture was stirred for 15 min. 
at 0°C, then diluted with sat. aq. NH4Cl (25 ml) and extracted with tBuOMe (3 × 25 ml). The combined 
 125
Chapter 5 
 
 126
organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by 
flash chromatography on a Et3N-neutralized column (column dimensions: 25 × 2 cm, EtOAc/PE = 1:20) to 
give 215 (111 mg, 0.159 mmol, 65%) as a colorless oil. [α]23D = -10.4° (c = 0.89, CHCl3). 1H NMR (CDCl3, 
400 MHz): δ = 0.04 (s, 6H), 0.05 (s, 6H), 0.06 (s, 3H), 0.09 (s, 3H), 0.84 (d, J = 7.03 Hz, 3H), 0.88 (s, 9H), 
0.90 (s, 9H), 0.92 (s, 9H), 1.52-1.63 (m, 2H), 1.59 (s, 3H), 1.70 (d, J = 6.64 Hz, 3H), 1.70-1.78 (m, 1H), 
1.74 (s, 3H), 2.08 (m, 2H), 2.16 (m, 2H), 3.21 (m, 1H), 3.81-3.84, (m, 2H), 4.00 (s, 2H), (dd, J = 5.47, 5.08 
Hz, 1H), 5.37 (m, 1H), 5.43 (ddq, J = 15.22, 5.47, 1.56 Hz, 1H), 5.58 (dqd, J = 15.22, 6.64, 1.17 Hz, 1H), 
5.62-5.68 (m, 1H), 5.83 (d, J = 10.93 Hz, 1H), 6.46 (ddd, J = 14.83, 10.53, 1.17 Hz, 1H) ppm. 13C NMR 
(CDCl3, 100 MHz): δ = -5.1, -4.5, -4.4, -4.3, -4.2, 5.6, 13.6, 16.7, 18.0, 18.3, 18.4, 18.6, 25.9, 26.0, 26.1, 
29.8, 39.7, 40.6, 68.6, 71.8, 75.1, 79.2, 79.8, 123.8, 124.2, 125.6, 126.5 130.3, 131.3, 134.4, 137.9 ppm. 
Rf = 0.39 (EtOAc/n-hexane = 1:20). 
 
 
TES ether 215: To chloride 174 (1.818 g, 6.00 mmol) was added tri-n-butylphosphine (1.628 ml, 1.335 g, 
6.60 mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 181 was dissolved 
in toluene (60 ml) and the mixture was cooled to 0°C. Aldehyde 108 (1.800 g, 4.07 mmol) was added, 
followed by KOtBu (1 M solution in THF, 6.50 ml, 6.50 mmol). The mixture was stirred for 15 min. at 0°C, 
then diluted with sat. aq. NH4Cl (200 ml) and extracted with tBuOMe (3 × 150 ml). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography on a Et3N-neutralized column (column dimensions: 30 × 4 cm, EtOAc/PE = 1:40) to give 
215 (2.830 g, 4.08 mmol, 100%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.04 (s, 6+3H), 0.09 (s, 
3H), 0.61 (q, J = 7.81 Hz, 6H), 0.84 (d, J = 6.64 Hz, 3H), 0.88 (s, 9H), 0.92 (s, 9H), 0.96 (t, J = 7.81 Hz, 
9H), 1.57 (m, 2H), 1.61 (s, 3H) 1.70 (d, J = 6.25 Hz, 3H), 1.75 (s, 3H), 2.03 (m, 1H), 2.09 (m, 2H), 2.15 (m, 
2H), 3.23 (ddd, J = 10.54, 4.29, 3.51 Hz, 1H), 3.81-3.86 (m, 2H), 4.00 (s, 2H), 4.26 (m, 1H), 5.32-5.47 (m, 
2H), 5.56-5.70 (m, 2H), 5.84 (d, J = 10.93 Hz, 1H), 6.47 (ddd, J = 15.22, 10.93, 1.56 Hz, 1H) ppm. 13C 
NMR (CDCl3, 100 MHz): δ = -4.7, -4.63, -4.57, -4.46, 4.45, 5.5, 13.5, 16.6, 17.9, 18.1, 18.3, 25.8, 25.9, 
26.0, 29.7, 39.5, 40.5, 68.3, 71.8, 75.1, 79.2, 79.9, 124.2, 124.3, 125.7, 126.7, 130.4, 131.4, 134.5, 
138.1 ppm. Rf = 0.47 (EtOAc/n-hexane = 1:20). 
 
 
Alcohol 216: To a solution of TES ether 215 (2.409 g, 3.47 mmol) in MeOH (40 ml) was added PPTS 
(437 mg, 1.74 mmol) and the mixture was stirred for 4 h at rt. The mixture was diluted with sat. aq. 
NaHCO3 (100 ml) and brine (200 ml) and extracted with tBuOMe (3 × 200 ml). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography on a Et3N-neutralized column (column dimensions: 30 × 4 cm, EtOAc/PE = 1:6) to give 
216 (1.375 g, 2.37 mmol, 68%) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.04 (s, 6+3H), 0.09 (s, 
3H), 0.84 (d, J = 7.03 Hz, 3H), 0.88 (s, 9H), 0.92 (s, 9H), 1.54-1.64 (m, 2H), 1.67 (s, 3H) 1.70 (d, J = 6.64 
Connection of the fragments 
Hz, 3H), 1.75 (s, 3H), 2.01 (m, 1H), 2.10 (m, 2H), 2.17 (m, 2H), 3.23 (m, 1H), 3.81-3.86 (m, 2H), 3.99 (s, 
2H), 4.26 (t, J = 4.69 Hz, 1H), 5.38-5.47 (m, 2H), 5.57-5.70 (m, 2H), 5.84 (d, J = 10.92 Hz, 1H), 6.47 (ddd, 
J = 15.22, 10.93, 1.57 Hz, 1H) ppm. 13C NMR (CDCl3, 100 MHz): δ =  −4.8, -4.7, -4.6, -4.5, 5.7, 6.6, 13.6, 
16.5, 17.8, 18.1, 18.2, 25.76, 25.83, 26.0, 26.9, 29.7, 39.4, 40.4, 68.7, 71.8, 75.0, 79.2, 79.8, 124.4, 125.5, 
125.7, 126.6, 130.4, 131.5, 135.0, 137.8 ppm. Rf = 0.33 (EtOAc/n-hexane = 1:4). 
 
 
Chloride 217: To a solution of NCS (413 mg, 3.09 mmol) in CH2Cl2 (30 ml) was added at -10°C Me2S 
(246 μl, 210 mg, 3.38 mmol). The mixture was stirred for 10 min. at -10°C, and the resulting white 
suspension was cooled to -78°C. Alcohol 216 (1.084 g, 1.87 mmol) was added and the mixture was stirred 
for 1 h at -10°C. After dilution with sat. aq. NH4Cl (150 ml), the mixture was extracted with CH2Cl2 (3 × 
100 ml). The combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The 
product, which was estimated >90% pure by 1H NMR, was used in the next step without further 
purification, since flash chromatography under various conditions resulted in significant loss of material. 1H 
NMR (CDCl3, 400 MHz): δ = 0.04 (s, 6+3H), 0.09 (s, 3H), 0.84 (d, J = 7.03 Hz, 3H), 0.88 (s, 9H), 0.92 (s, 
9H), 1.56 (m, 2H), 1.70 (d, J = 6.64 Hz, 3H), 1.74 (bs, 3+3H), 2.10 (m, 2H), 2.17 (m, 2H), 3.22 (m, 1H), 
3.81-3.86 (m, 2H), 4.01 (s, 2H), 4.26 (t, J = 4.69 Hz, 1H), 5.43 (ddq, J = 15.22, 5.46, 1.57 Hz, 1H), 5.51 (t, 
J = 7.03 Hz, 1H), 5.58-5.69 (m, 2H), 5.83 (d, J = 10.93 Hz, 1H), 6.46 (ddd, J = 15.22, 10.93, 1.57 Hz, 1H) 
ppm. Rf = 0.77 (EtOAc/n-hexane = 1:4). 
 
 
Tetraene 219: To chloride 217 (max. 1.87 mmol) was added tri-n-butylphosphine (508 μl, 417 mg, 
2.06 mmol) and the mixture was stirred for 3 h at 70°C. The resulting phosphonium salt 218 was dissolved 
in toluene (20 ml) and the mixture was cooled to 0°C. Aldehyde 30 (426 mg, 2.50 mmol) was added, 
followed by KOtBu (1 M solution in THF, 5.00 ml, 5.00 mmol). The mixture was stirred for 15 min. at 0°C, 
then diluted with sat. aq. NH4Cl (150 ml) and extracted with tBuOMe (3 × 100 ml). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The product was purified by flash 
chromatography on a Et3N-neutralized column (column dimensions: 30 × 3 cm, EtOAc/PE = 1:10) to give 
219 (1.127 g, 1.58 mmol, 84% over three steps) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ = 0.04 (s, 
6+3H), 0.09 (s, 3H), 0.84 (d, J = 6.64 Hz, 3H), 0.88 (s, 9H), 0.92 (s, 9H), 1.18 (d, J = 5.86 Hz, 3H), 1.24 (d, 
J = 6.25 Hz, 3H), 1.56 (m, 2H), 1.70 (d, J = 6.25 Hz, 3H), 1.75 (bs, 3+3H), 2.00-2.31 (m, 6H), 3.22 (m, 
1H), 3.81-3.86 (m, 2H), 4.01 (m, 1H), 4.26 (dd, J = 5.08, 4.68 Hz, 1H), 4.48 (m, 1H), 5.12 (s, 1H), 5.41-
5.53 (m, 2H), 5.57-5.74 (m, 4H), 5.84 (m, 1H), 6.00 (m, 1H), 6.28 (d, J = 15.61 Hz, 1H), 6.47 (m, 1H) ppm. 
13C NMR (CDCl3, 100 MHz): δ = -4.73, -4.65, -4.59, -4.46, 5.4, 12.3, 16.6, 17.9, 18.1, 18.2, 22.0, 23.9, 
25.8, 25.9, 26.7, 29.7, 30.9, 39.4, 40.4, 66.9, 69.3, 71.8, 75.0, 79.2, 79.8, 93.0, 124.4, 125.7, 126.0, 126.4, 
126.6, 128.5, 130.4, 131.6, 132.7, 133.2, 135.9, 137.7 ppm. Rf = 0.65 (EtOAc/n-hexane = 1:4). 
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Hemiacetal 220: To a solution of isopropyl acetal 219 (143 mg, 0.20 mmol) in acetone (18 ml) was added a 
solution of PPTS (50 mg, 0.20 mmol) in H2O (3 ml). The mixture was stirred overnight at rt. The mixture 
was diluted with sat. aq. NaHCO3 (50 ml) and brine (100 ml) and extracted with tBuOMe (3 × 100 ml). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo to give crude 220 (133 
mg, 0.197 mmol, 99%) as a colorless oil, that was used immediately in subsequent oxidation experiments 
without further purification. Rf = 0.30 (EtOAc/n-hexane = 1:4). 
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Summary 
 
This thesis describes the development of a flexible synthesis of analogues of the cytotoxic 
polyketide natural product ratjadone (I). The synthesis features combination of three 
building blocks of comparable size. The retrosynthetic analysis is shown in Scheme I. 
Ratjadone analogues II are to be formed by Wittig connection of two aldehyde fragments 
(tetrahydropyran fragment III and protected lactone fragment V) to a central terpene-
derived fragment IV. 
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Scheme I. Retrosynthetic analysis of ratjadone analogues. 
 
Fragments III were synthesized by a newly developed diene-controlled asymmetric hetero 
Diels-Alder reaction. Aldehyde VI (derived from the sugar mannitol) is the sole source of 
chirality in the synthesis of these compounds. It is used to construct silyloxydienes VII, 
which reacted efficiently with α,β-unsaturated aldehydes to give, after desilylation, 
tetrahydropyran-4-ones VIII (Scheme II). Typically, only the two isomers with all-cis 
configuration on the ring were formed. The yields of the latter two steps varied from 69-
85%, and the diastereoselectivities varied from 1.6:1 to 10:1. 
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Scheme II. Synthesis of compounds VIII via hetero Diels-Alder reaction. 
 
Ketone VIIIa was then converted in five steps to the adequately protected aldehyde X, 
which was to be used in further steps (Scheme III). The absolute stereochemistry is 
different from that in the natural product, but this was considered of minor importance with 
respect to the effiency in rapid diversity generation. 
 
O
O
O
O
VIIIa
O
OH
OHIX
OH O
OTBS
OTBSX
O
 
 
Scheme III. Synthesis of building block X. 
 
α,ω-Bifunctionalized terpene derivatives IV were synthesized from protected geraniol or 
nerol by catalytic SeO2 oxidation. The resulting free alcohol could be activated by 
conversion to the chloride by Corey-Kim reaction. Alternatively, by protective group 
manipulations, C1 could be activated (Scheme IV). 
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Scheme IV. Synthesis of bifunctionalized terpenoid building blocks. 
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Lactone fragment V was synthesized by making use of Jacobsen's catalytic asymmetric 
hetero Diels-Alder methodology. Protective group manipulations followed by oxidation 
afforded desired aldehyde V (Scheme V). 
 
O
O OiPr
V
TBSO
O OMe
XV
TBSO
O OMe
+
 
 
Scheme V. Synthesis of fragment V. 
 
The fragments were successfully combined using a standard reaction sequence 
(deprotection – activation – phosphonium salt formation – Wittig reaction). Although the 
acetal function at C1 could be hydrolyzed, oxidation to the desired lactone was 
unsuccessful under a variety of conditions (Scheme VI). 
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Scheme VI. Connection of fragments X, XIVa, and V. 
 
A (hydro)quinone was considered a reasonable alternative to the lactone ring, and 
hydroquinone-containing ratjadone analogue XX was obtained using a similar strategy as 
above (Scheme VII). 
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Scheme VII. Synthesis of compound XX. 
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Samenvatting 
(Ontwerp en Synthese van Ratjadon-Analoga) 
 
Dit proefschrift beschrijft de ontwikkeling van een flexibele synthese van analoga van de 
cytotoxische polyketide natuurstof ratjadon (I). Uitgangspunt van de synthese is de 
combinatie van drie bouwstenen van vergelijkbare grootte. De retrosynthetische analyse is 
weergegeven in Schema I. Ratjadon-analoga II zullen worden gevormd door Wittig reactie 
van twee aldehyde fragmenten (tetrahydropyran-fragment III en beschermd lacton-
fragment V) met een centraal terpenoïde fragment IV. 
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Schema I. Retrosynthetische analyse van ratjadon-analoga. 
 
Fragmenten III werden gesynthetiseerd door middel van een nieuw ontwikkelde diëen-
gecontrolleerde asymmetrische hetero-Diels-Alder reactie. Aldehyde VI (afgeleid van de 
suiker mannitol) is de enige bron van chiraliteit in de synthese van deze verbindingen. Het 
werd gebruikt voor de bereiding van silyloxydiënen VII, die efficiënt reageerden met α,β-
onverzadigde aldehydes, leidend tot tetrahydropyran-4-onen VIII (Schema II). In het 
algemeen werden alleen de twee isomeren met de allen-cis configuratie op de ring 
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gevormd. De opbrengst van de laatste twee stappen varieerde van 69-85% en de 
diastereoselectiviteit varieerde van 1.6:1 tot 10:1. 
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Schema II. Synthese van verbindingen VIII d.m.v. hetero-Diels-Alder reactie. 
 
Keton VIIIa werd toen in vijf stappen omgezet naar het geschikt beschermde aldehyde X, 
dat verder in de synthese gebruikt zou worden (Schema III). De absolute stereochemie 
verschilt van die in de natuurstof, maar dit werd van ondergeschikt belang geacht met 
betrekking tot de efficiëntie van de snelle diversiteitsontwikkeling. 
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Schema III. Synthese van bouwsteen X. 
 
α,ω-Gebifunctionaliseerde terpeen-derivaten IV werden gesynthetiseerd vanuit beschermd 
geraniol of nerol door catalytische SeO2-oxidatie. De daaruit verkregen vrije alcohol kon 
worden geactiveerd door omzetting in het chloride door Corey-Kim-reactie. Tevens kon 
door beschermgroepmanipulaties C1 worden geactiveerd (Schema IV). 
 
Lacton-fragment V werd gesynthetiseerd door gebruik te maken van Jacobsen's catalytische 
asymmetrische hetero-Diels-Alder methodologie. Beschermgroepmanipulaties gevolgd 
door oxidatie leverden het gewenste aldehyde V op (Schema V). 
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Schema IV. Synthese van gebifunctionaliseerde terpenoïde bouwstenen. 
 
O
O OiPr
V
TBSO
O OMe
XV
TBSO
O OMe
+
 
 
Schema V. Synthese van fragment V. 
 
De fragmenten werden op succesvolle wijze aan elkaar bevestigd door middel van een 
standaard reactie-sequentie (ontscherming – activering – fosfoniumzoutvorming – Wittig 
reactie). Hoewel de acetaal-functie op C1 kon worden gehydrolyseerd, was oxidatie tot het 
gewenste lacton onder verschillende omstandigheden niet succesvol (Schema VI). 
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Schema VI. Verbinding van fragmenten X, XIVa en V. 
 
Een (hydro)quinon werd beschouwd als een redelijk alternatief voor de lactonring en 
hydroquinon-bevattend ratjadon-analogon XX werd verkregen via een soortgelijke strategie 
als hierboven (Schema VII). 
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Schema VII. Synthese van verbinding XX. 
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Zusammenfassung 
(Entwurf und Synthese von Ratjadon-Analoga) 
 
Die vorliegende Dissertationsschrift beschreibt die Entwicklung einer flexiblen Synthese 
von Analoga des cytotoxischen Polyketid-Naturstoffs Ratjadon (I). Ausgangspunkt der 
Synthese ist die Kombination von drie Bausteine vergleichbarer Größe. Die 
retrosynthetische Analyse ist in Schema I dargestellt. Ratjadon-Analoga II sind hierbei 
durch eine Wittig Reaktion von zwei Aldehyd-Fragmente (Tetrahydropyran-Fragment III 
und geschützes Lacton-Fragment V) mit einem zentralen Terpenoid-Fragment IV 
zugänglich. 
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Schema I. Retrosynthetische Analyse von Ratjadon-Analoga. 
 
Fragmente III wurden mittels eine neu entwickelte Dien-kontrollierten asymmetrischen 
hetero-Diels-Alder-Reaktion hergestellt. Aldehyd VI (abgeleitet von D-Mannit) ist die 
einzige chiral-Pool-Quelle in der vorgestellten Synthese von Ratjadon-Analoga. Er dient als 
Ausgangsstoff für die Darstellung der Silyloxydiene VII, die ausgezeichnet mit α,β-
ungesättigten Aldehyden zu Tetrahydropyran-4-onen VIII (Schema II) reagieren. Als 
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Produkte wurden ausschließlich die Isomere mit cis-Konfiguration am Ring gebildet. Die 
Ausbeuten der letzten beiden Schritte variierten von 69-85% und die Diastereoselektivität 
zeigte Verhältnisse von 1.6:1 bis 10:1. 
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Schema II. Synthese von Verbindungen VIII mittels hetero-Diels-Alder-Reaktion. 
 
Keton VIIIa wurde in fünf Schritten in den geschützten Aldehyd X überführt, welcher im 
weiteren Syntheseverlauf eingesetzt wurde (Schema III). Die absolute Stereochemie 
unterscheidet sich zwar von der des Naturstoffs, dieser Aspekt kann jedoch im Hinblick auf 
die Effiziens und Variabilität der Synthese vernachlässigt werden. 
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Schema III. Synthese von Baustein X. 
 
Mittels SeO2-Oxidation  gelangt man ausgehend von Nerol oder Geraniol zum α,ω-
bifunktionalisierten Terpen-Derivat IV. Der daraus erhaltene freie Alkohol wurde in einer 
Corey-Kim-Reaktion in das entsprechende Chlorid überführt. Zusätzlich konnte C1 durch 
Schutzgruppenmanipulationen aktiviert werden (Schema IV). 
 
Das Lacton-Fragment V wurde durch Anwendung der Jacobsen's asymmetrischen hetero-
Diels-Alder-Methodologie synthetisiert. Schutzgruppenoperationen und anschließende 
Oxidation liefern den gewünschten Aldehyd V (Schema V). 
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Schema IV. Synthese von bifunktionalisierten Terpenoid-Bausteinen. 
 
O
O OiPr
V
TBSO
O OMe
XV
TBSO
O OMe
+
 
 
Schema V. Synthese von Fragment V. 
 
Die erhaltenen Fragmente wurden abschließend erfolgreich mittels einer Standard-
Reaktionssequenz (Entschützung – Aktivierung – Phosphoniumsalzbildung – Wittig-
Reaktion) verknüpft. Obwohl die Acetal-Funktion an C1 hydrolysiert werden konnte, war 
die Oxidation zum gewünschten Lacton unter verschiedene Bedingungen nicht erfolgreich 
(Schema VI). 
OTES
Cl
XIVa
O
OTBS
PBu3Cl
OTBS
O
OTBS
O
OTBS
OH
O
OTBS
O
OTBS
X
+ XVI
XVII  
 
Schema VI. Verknüpfung von Fragmenten X, XIVa und V. 
 
(Hydro-)Chinone können weitläufig als Strukturanaloga des Lactonringes betrachtet 
werden. Ein Ratjadon-Analogon (XX) mit einem Chinon anstelle des Lactonringes konnte 
ebenfalls durch eine ähnliche Strategie wie oben (Schema VII) erfolgreich synthetisiert 
werden. 
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O
OTBS
O
OH
OH
OH
AcO
OTBS
TBSO TBSO
HO
AcO
PBu3Cl
XIIIa
XVIII XIX
XX
 
Schema VII. Synthese von Verbindung XX. 
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